TWO-PHOTON IMAGING OF GLIAL ION AND WATER HOMEOSTASIS IN HEALTH AND DISEASE

Alexander S. Thrane & Vinita Rangroo Thrane

Supervisors:
Prof. Erlend A. Nagelhus
Prof. Maiken Nedergaard

Letten Centre, Institute of Basic Medical Sciences & Centre for Molecular Medicine Norway
Faculty of Medicine
University of Oslo
Norway

Center for Translational Neuromedicine
Division of Glial Therapeutics
Department of Neurosurgery
University of Rochester
USA

2013
# TABLE OF CONTENTS

1. ACKNOWLEDGMENTS ................................................................. 4
2. ABSTRACT .................................................................................. 5
3. ABBREVIATIONS ....................................................................... 6
4. LIST OF PAPERS ....................................................................... 7
5. INTRODUCTION .......................................................................... 8
6. HYPOTHESES AND AIMS ........................................................... 37
7. METHODOLOGICAL CONSIDERATIONS ......................................... 38
8. SUMMARY OF RESULTS .............................................................. 57
9. DISCUSSION AND FUTURE DIRECTION .......................................... 63
10. CONCLUSIONS .......................................................................... 79
11. REFERENCES ............................................................................ 80
12. PAPERS I-VI ............................................................................. 99
1. ACKNOWLEDGMENTS

‘In my own view, some advice about what should be known, about what technical education should be acquired, about the intense motivation needed to succeed, and about the carelessness and inclination toward bias that must be avoided is far more useful than all the rules and warnings of theoretical logic.’ Santiago Ramón y Cajal in ‘Advice for a Young Investigator’ (1916).

This thesis is the result of our combined work at the Center for Translational Neuromedicine in Rochester, NY, and at the Letten Centre in Oslo.

We would like to express our deepest gratitude for all those who made this work possible. First, we would like to thank our families for their unwavering support, including Berit, Vijay, Kumud, Per, Bente, Rytik, Camilla and Hannibal. Second, we would like to thank our supervisors Erlend A. Nagelhus and Maiken Nedergaard for their invaluable advice, numerous discussions, and long hours of hard work helping shape this thesis. Third, we would like to thank all the colleagues and collaborators that helped us both in Oslo and Rochester, including Michael J. Chen, Nathan A. Smith, Justin Chang, Maria L. Cotrina, Qiwu Xu (Jim), Ning Kang, Nanhong Lou, Takahiro Takano, Takumi Fujita, Fushun Wang, Lane Bekar, Salvador Pena, Arnulfo Torres, Yonghong Liao, Douglas Zeppenfeld, Benjamin Plogg, Jeffrey Iliff, Thiyagarajan Meenakshisundaram, Rashid Deane, Arthur Cooper, Abdelatif Benraiss, Weiguo Peng, Gry F. Vindedal, Scott Kennedy, Phillip M. Rappold, Nadia N. Haj-Yasein, David Wang, Georg A. Gundersen, Rune Enger, Torgeir Holen, Øyvind Skare, Johannes P. Helm, Anna E. Thoren, Vidar Jensen, Øyvind Hvalby, Arne Klungland and Ole P. Ottersen.

This work was sponsored by PhD stipends from IMB (A.S.T.) and from MLS (V.R.T.), and also Fulbright scholarships for both of the candidates.
2. ABSTRACT

The vital role of glial cells in the nervous system has only been revealed relatively recently as these cells are electrically silent. Technical advances that allow direct visualization of glial activity have therefore been paramount to the recent glial renaissance. One such technique, two-photon laser scanning microscopy (2PLSM), forms the basis of our thesis. 2PLSM offers the necessary spatial and temporal resolution to study glial cells in intact living brain. Exploiting the strengths of 2PLSM, we chose to examine key roles of glial water and ion homeostasis in health and disease. Our first study (Paper I) delineated a novel aquaporin-4 (AQP4) mediated glial signaling pathway that is activated in response to hypo-osmotic brain edema, and which may contribute to the high mortality of this condition. In the second study (Paper II) we showed that AQP4 plays a crucial role in oxygen microdistribution during cortical spreading depression (CSD), a wave of tissue depolarization closely linked to migraine. In the next study (Paper III), we found that general anesthetics directly suppress astrocyte calcium signals, and this effect may explain some of the sedative effects of these drugs. In Paper IV we explored the paravascular circulation of cerebrospinal fluid (CSF) through brain, and found that this compartment served both as a highway for selective lipid transport and signal mediation between astrocytes. In Paper V we used 2PLSM to show a pathological activation of microglia in the advanced stages of hepatic encephalopathy (HE), which may be linked to the development of fatal brain edema in severe cases of this condition. Finally, in Paper VI we use a congenital disorder of ammonia handling to show that the immediate neurotoxicity of ammonia is mediated by a direct short-circuiting of astrocyte potassium buffering. This secondarily causes an impairment of inhibitory neurotransmission, and is not related to astrocyte swelling as was previously hypothesized. Blocking the downstream accumulation of chloride in neurons using Na⁺-K⁺-2Cl⁻ cotransporter subtype-1 (NKCC1) inhibitor bumetanide, we were able to reverse ammonia neurotoxicity and thus develop a clinically relevant therapy. Taken together, using in vivo 2PLSM imaging we were able to elucidate important roles of glial cells in normal brain function and debilitating neurological disorders.
3. ABBREVIATIONS

ΔF/F₀ - change in fluorescence normalized to time 0
1PLSM - one-photon laser scanning microscopy
2PLSM - two-photon laser scanning microscopy
AM - acetoxymethyl
Aqp4 - aquaporin-4 gene
AQP4 - aquaporin-4 protein
ATP – adenosine triphosphate
BAPTA - 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid
BBB - blood-brain barrier
CNS - central nervous system
CSD - cortical spreading depression
CSF - cerebrospinal fluid
DAPC - dystrophin-associated protein complex
EGABA - GABA reversal potential
eGFP - enhanced green fluorescent protein
EPSP - excitatory post-synaptic potential
FITC - fluorescein isothiocyanate
GABA - γ-aminobutyric acid
GFAP - glial fibrillary acidic protein
Gln - glutamine
Glu - glutamate
Glt1 - glutamate transporter 1 gene
GLT1 - glutamate transporter 1 protein
GS - glutamine synthetase
HE - hepatic encephalopathy
ICP - intracranial pressure
ISM - ion-sensitive microelectrode
IP₃ - inositol-1,4,5-triphosphate
IP₃R2 - IP₃ receptor 2
KCC2 - K⁺-2Cl⁻ cotransporter-2
KO – knock-out
[K⁺]₀ - extracellular potassium concentration
mRNA - messenger ribonucleic acid
mGluR5 - metabotropic glutamate receptor 5
MSO - L-methionine sulfoximine
NH₄⁺ - ammonium
NH₃ - ammonia
[NH₄⁺]₀ - extracellular ammonium concentration
NAD⁺ - nicotinamide adenine dinucleotide
NADH - reduced NAD⁺
NKA - Na⁺-K⁺-ATPase
NKCC1 - Na⁺-K⁺-2Cl⁻ cotransporter-1
NMR – nuclear magnetic resonance
Otc<sup>opf-ash</sup> - ornithine transcarbamylase deficient mouse with sparse-fur and abnormal skin and hair
ROI - region of interest
RVD - regulatory volume decrease
shRNA - short hairpin ribonucleic acid
Slc12a2 – NKCC1 gene
V<sub>m</sub> - membrane potential
WT - wild-type
4. LIST OF PAPERS

PAPER I

PAPER II

PAPER III

PAPER IV

PAPER V

PAPER VI
5. INTRODUCTION

“What is the function of glial cells in neural centers? The answer is still not known, and the problem is even more serious because it may remain unsolved for many years to come until physiologists find direct methods to attack it.” Santiago Ramon-y Cajal

These words by Cajal rang very true in both his day and for the century that followed (Ransom et al. 2003). Because scientists did not possess adequate tools to directly explore the functions of glial cells, they were quickly forgotten amidst the vast array of data accumulated on neurons, where electrophysiology provided concrete endpoints to study. Like many other discoveries in science, the realization of the importance of glial cells coincided with the invention and subsequent application of new techniques to the field. One such technique that has gained momentum since the 1990s is two-photon laser scanning microscopy (2PLSM) (Denk et al. 1990), and this is the primary method of investigation used in our thesis. Imaging in live animals has traditionally been dominated by techniques such as functional magnetic resonance imaging and positron emission tomography, which have relatively poor temporal and anatomical (spatial) resolution (Lauritzen 2005; Schafer et al. 2012). High-resolution analyses have, on the other hand, been restricted to light and electron microscopy in fixed tissue sections or slices. Thus, high temporal and anatomical resolution has long been incompatible with analyses of living animals (Misgeld and Kerschensteiner 2006). The introduction of 2PLSM changed this, and now allows anatomical structures as small as dendritic spines to be studied in living brains over days and even weeks (Holtmaat et al. 2009). 2PLSM studies in intact animals thus allow investigators to address important biological questions in clinically relevant manner, significantly shortening the distance from bench to bedside (Dirnagl 2006).

Glial cells are by far the most numerous cell-type in the brain, outnumbering neurons 10:1 (Ransom et al. 2003). However, until around 30 years ago glial cells were only thought to act as a form of glue providing structural support for neurons. Glial involvement in normal brain function and their roles in neurological disorders is therefore a relatively new field of research. Additionally, studies that increase our understanding of glial cells are highly salient for the general field of neuroscience, as they can open up a completely new set of therapeutic targets for brain disorders (Nedergaard et al. 2010; Verkhratsky et al. 2012b). Glial cells have already been
implicated in a number of diseases, including stroke, epilepsy, Alzheimer, Parkinson, spinal cord injury, traumatic brain injury, brain edema, macular edema and migraine (Fuhrmann et al. 2010; Manley et al. 2000; Reichenbach et al. 2007; Takano et al. 2007; Tian et al. 2005; Verkhratsky et al. 2012b). They have also been shown to have key roles in regulating physiological parameters critical for neuronal function, such as extracellular potassium ([K+]o) and other ion homeostasis, volume regulation, neurotransmitter recycling, cerebral blood flow and energy metabolism (Attwell et al. 2010; Caesar et al. 2008; Haj-Yasein et al. 2012; Kirischuk et al. 2012; Mathiesen et al. 2012; Nedergaard and Verkhratsky 2012; Paulsen et al. 1988b; Pellerin et al. 2007; Takano et al. 2006; Wang et al. 2012a). More studies focusing on how glial cells can generate and influence central nervous system (CNS) disorders are therefore clearly needed. Our thesis aims to use the advantages of 2PLSM to help address this ‘glial knowledge gap’ with the hope of elucidating novel therapeutic approaches.

**Two-photon imaging using femtosecond-pulsed lasers**

Before introducing the neurobiological background for our thesis studies, we first want to review the central aspects of 2PLSM imaging. Starting with the basic principles of fluorescence imaging – light is a form of electromagnetic radiation that can be described as both a particle, called a photon, or a wave. The wavelength of light describes its energy content; the shorter the wavelength the higher the energy of individual photons. Fluorescence imaging relies on the interaction of light with a molecule that then absorbs the light energy, raising the molecule to a higher energy (excited) state. The molecule, called a fluorochrome, then loses some energy through mechanical vibration, before emitting the rest of its energy as a new photon and returning to its basal ‘unexcited’ state. The emitted photon is always of lower energy (red-shifted) compared to the exciting photon due to the energy lost in vibration (Christensen and Nedergaard 2011). In a biological setting, relevant fluorochromes are frequently bonded to macromolecules to attain desired chemical properties, such as lipid solubility, and are then called fluorophores (Paredes et al. 2008).

The resolution of traditional light microscopy has been significantly improved with the advent of the laser, which is an acronym for ‘light amplification by stimulated emission of radiation’ (Maiman 1960). In laser scanning microscopy, a collimated (parallel rays) coherent (in phase) beam of monochromatic (only 1 wavelength) photons is scanned across the specimen of interest, usually in a raster
pattern using galvanometric mirrors (Duemani Reddy et al. 2008). However, an early issue with laser scanning microscopy was that extensive light excitation occurred above and below the focal point of the microscope, introducing noise to the collected image. This issue was greatly improved by the introduction of confocal laser scanning microscopy, where a strategically placed pinhole effectively cuts out all light emitted from outside the focal point. The pinhole also gives confocal microscopy its other important feature; the ability to collect optical sections from the specimen. However, the major issue with confocal microscopy that has made it largely incompatible with in vivo studies is the large amount of light energy delivered to the tissue both in and around the focal point (Misgeld and Kerschensteiner 2006). Another aspect of this problem, is that due to light scattering at the wavelength required to excite biologically relevant fluorophores confocal microscopy is unable penetrate tissue much deeper than 50 μm (Christensen and Nedergaard 2011).

![Figure 1. Optical principles of 1PLSM and 2PLSM. Left: Differences between pulsed 2PLSM and continuous wave 1PLSM imaging. Right: Jablonski diagram of two-photon vs. one-photon absorption and emission.](image)

Although theoretically conceived almost a century ago, 2PLSM was only made possible in the 1990s through the development of powerful femtosecond pulsed lasers (Denk et al. 1990). 2PLSM is based on the principle that if a pulsed laser emits a high enough concentration of photons, 2 or more photons may excite the same molecule simultaneously. Denk et al. were the first to successfully apply this concept to laser scanning microscopy (Denk et al. 1990). Since multiple photons are used to excite the target, each individual photon can have a relatively low energy, i.e. long wavelength (Fig. 1). This has several advantages over conventional confocal
microscopy in that the longer wavelengths used, frequently in the infrared band (800-1000 nm), achieve much deeper tissue penetration (500-1000 um) and exert much less photodamage (injury due to light) (Helmchen and Denk 2005). The latter issue becomes even more important when conducting fluorescent imaging, as the fluorophores used can generate free radicals when excessively stimulated by light causing phototoxicity (Bestvater et al. 2002; Christensen and Nedergaard 2011). Finally, the transfer of light energy in 2PLSM is non-linear, and only in the focal point of the beam will a critical concentration of photons be achieved sufficient to excite (or damage) the tissue (Table 1). This means that 2PLSM has inherent optical sectioning and noise reduction properties, and thus does not require a pinhole to block out-of-focus light as with confocal microscopy.

Table 1. Summary of the salient 2PLSM and 1PLSM parameters.

<table>
<thead>
<tr>
<th></th>
<th>2PLSM</th>
<th>1PLSM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laser wave</td>
<td>Pulsed</td>
<td>Continuous</td>
</tr>
<tr>
<td>Wavelength</td>
<td>800-1000 nm</td>
<td>400-600 nm</td>
</tr>
<tr>
<td>Tissue penetration</td>
<td>500-1000 um</td>
<td>20-50 um</td>
</tr>
<tr>
<td>Excitation</td>
<td>Non-linear</td>
<td>Linear</td>
</tr>
<tr>
<td>Phototoxicity</td>
<td>Limited to focal point</td>
<td>Entire cone of light</td>
</tr>
<tr>
<td>Emission</td>
<td>All photons useful</td>
<td>Out-of-focus photons generate noise</td>
</tr>
<tr>
<td>XY resolution</td>
<td>$\frac{1}{2} \lambda$ (e.g. 450 nm)</td>
<td>$\frac{1}{2} \lambda$ (e.g. 250 nm)</td>
</tr>
<tr>
<td>Z resolution</td>
<td>$\lambda$ (e.g. 900 nm)</td>
<td>$\lambda$ (e.g. 500 nm)</td>
</tr>
</tbody>
</table>

Neuroglia – more than just glue

The major difference between glial cells and neurons are that glia lack electrical excitability and therefore cannot fire action potentials. The lack of an easily measurable form of activity in glia is also one of the major reasons for the previously neurocentric focus of brain research (Ransom et al. 2003). The term glia was first coined by Rudolf L. K. Virchow (1821-1902), who thought that glia were a connective tissue ‘glue’ whose function was to provide structural support to neurons. Later, in 1851, Heinrich Müller made the first drawing of a glial cell in the retina, now known as the Müller cell. In the spinal cord, Jakob Henle was the first to describe star-like ‘stellate cells,’ which we now know as astrocytes. These findings were later elaborated upon by numerous eminent histopathologists, including Camillo Golgi (1843-1926) and Santiago Ramón y Cajal (1852-1934) (Verkhratsky and Butt 2007). We now know that glia are a heterogeneous group of cells that can generally
be divided into macro- and micro-glia on the basis of morphology. The latter cell type is of mesenchymal origin and migrates to the brain in embryology, differentiating to become the resident immune-cell of the CNS (Kettenmann et al. 2011). Macrogial cells are of ectodermal origin and the sub-types include oligodendrocytes in the CNS and Schwann cells in PNS, which both provide the myelin sheath to neuronal axons (Barres 2008). However, the most numerous macrogial cell type and the major focus of our thesis are astrocytes. These complex and heterogeneous cells perform many of the essential homeostatic functions that the more specialized neurons cannot perform (Fig. 2) (Matyash and Kettenmann 2010). Astrocytes are capable of complex signaling and recent discoveries have led many to suspect that these cells may play an active role in CNS signal transmission (Agulhon et al. 2008).

**Astrocytes – stars of the brain**

Astrocytes were named because of their star-like appearance, owing primarily to their high expression of cytoskeletal glial-fibrillary acidic protein (GFAP) (Ransom et al. 2003). Astrocytes can be divided up into two main subgroups, stellate and radial (elongated) cells. Stellate astrocytes in the grey matter are called protoplasmic astrocytes, and in the white matter fibrous astrocytes (Matyash and Kettenmann 2010). Radial astrocytes are further divided into Müller cells (in the retina) and Bergmann glia (in the cerebellum) (Nimmerjahn et al. 2009; Reichenbach et al. 2007). Radial astrocytes, apart from those in retina and cerebellum, are commonly present...
during development in the brain and are thought to be involved in neural migration (Regan 2007). Protoplasmic astrocytes are the cell-type seen most frequently in the cerebral cortex of adults, and our thesis focuses primarily on this sub-group (Oberheim et al. 2012). Astrocytes, although named after their star-like appearance in early histological preparations, are in fact more bush-like, and extend a multitude of fine processes that almost entirely fill a 3-dimesional domain (Fig. 3). This astrocyte domain usually encompasses thousands of synapses, multiple blood vessels and usually does not overlap with neighboring astrocyte domains except during pathological conditions such as epilepsy (Oberheim et al. 2008). Astrocyte processes that extend to synapses are termed peri-synaptic and those extending to blood vessels are called perivascular endfoot processes (Simard and Nedergaard 2004). Astrocytes are thus strategically located in a domain-structure that can integrate local synaptic activity with metabolic supply from the blood (Oberheim et al. 2008). Moreover, because the extracellular space is of very limited size in the CNS, astrocytes are also ideally constructed to influence both the content and volume of the extracellular space locally, regulating neurotransmitter and ion concentrations (Thorne and Nicholson 2006).

Finally, astrocytes are extensively coupled to each other via gap-junctions, thus forming a vast syncytium of cells. Recent research has indicated that this may

**Figure 3.** Astrocyte complexity distinguishes advanced nervous systems. Left: GFAP-stained protoplasmic astrocytes from mouse (inset) and human, illustrating the dramatic increase in the complexity of these cells through evolution. Right: Mouse (inset) and human astrocytes labeled with intracellular dye reveals a more ‘bush’ than ‘star’-like structure compared to GFAP staining. Scale bar 20 um. Modified with permission from Oberheim et al. 2009.
help astrocytes act as effective conduits for redistributing metabolites or ions between active and inactive synapses (Giaume et al. 2010; Rouach et al. 2008). All of these anatomic specializations would lead one to suspect that highly developed astrocytes might be a pre-requisite for more complex nervous systems. Interestingly, glial complexity increases much more steeply than neuronal complexity from lower to higher species, perhaps indicating that highly evolved astrocytes are necessary to cope with high synapse densities (Oberheim et al. 2006). Additionally, some disease states in brain and retina are characterized by a reduction in the glia/neuron ratio early in the disease, perhaps indicating that common neurological disorders are primary gliopathies (Verkhratsky et al. 2012b).

There has been a vast increase in our understanding of the subset of channels and receptors expressed by astrocytes in recent years. Notably, astrocytes express abundant channels and transporters for potassium (e.g. inward rectifying K⁺ channel Kir4.1, Na⁺-K⁺-ATPase, NKA), sodium, chloride, water (e.g. aquaporin-4, AQP4), metabolites (e.g. monocarboxylate transporters), amino acids (e.g. system N transporter 1, SN1) and neurotransmitters (e.g. glutamate transporter 1, GLT1) (Kirischuk et al. 2012; Lovatt et al. 2007; Paulsen et al. 1988b). These membrane proteins are principally involved in what we now believe to be key astrocyte functions, including [K⁺]o buffering, neurotransmitter clearance and recycling at the synapse (especially glutamate and γ-aminobutyric acid, GABA), cerebral blood flow regulation, water transport and feeding neurons with lactate via the glucose-lactate shuttle (Bak et al. 2006; Haj-Yasein et al. 2012; Iliff et al. 2012; Paulsen et al. 1988a; Pellerin et al. 2007; Takano et al. 2006). Additionally, immunogold and in situ studies have indicated that astrocytes might be capable of directly influencing synaptic processing via vesicular or non-vesicular (e.g. connexin hemichannel) neurotransmitter release, or so-called ‘gliotransmission’ (Bezzi et al. 2004; Hamilton and Attwell 2010; Jourdain et al. 2007; Zhang et al. 2004). In conclusion, several lines of evidence indicate that astrocytes can actively modulate neuronal function and thus regulate information transmission in the CNS, perhaps coupling this to local metabolic factors (Attwell et al. 2010). These seminal observations have led to a revision of the classical neurocentric view of the synapse, and prompted the inclusion of astrocytes into a ‘tripartite synapse’ (Araque et al. 1999). Our thesis seeks to extend this work and use 2PLSM to address two related ways that astrocytes can influence synaptic function: the control of extracellular ion and volume homeostasis.
Astrocyte water homeostasis and AQP4

A tightly regulated water homeostasis is essential for normal brain function (Amiry-Moghaddam and Ottersen 2003). An excessive influx of water into the brain parenchyma will cause swelling, called brain edema. Because the brain is enclosed in a rigid cranium this swelling will raise intracranial pressure, which can then set up a vicious cycle where venous drainage from the brain is compressed and pressure rises further until the brain herniates through the base of the skull. Brain edema is therefore associated with significant mortality and morbidity, and current treatments are unfortunately limited to only partially effective and quite old approaches such as hyperosmotic infusions or corticosteroids (Grande and Romner 2012).

Water can be transported through biological membranes via several mechanisms. Initially, water transport was thought to occur exclusively through passive diffusion directly through the lipid bilayer. However, this assumption was dispelled through Nobel Prize winning work by Peter Agre and co-authors, who isolated an ancient family of membrane channels in erythrocytes that are highly permeable to water (Preston and Agre 1991; Preston et al. 1992). Subsequent work has shown that almost all animals and plants express a family of water channels, called aquaporins, and to date no less than 12 isoforms have been identified in mammals (Agre et al. 2004). More recently, it has also been shown that membrane transporters (e.g. EEAT) and ion channels can contribute to active and passive water flux (MacAulay and Zeuthen 2010), and these critical observations also need to be incorporated to generate a comprehensive model of transmembrane water transport (Fig. 4).

Figure 4. Multiple pathways for water transport across the lipid bilayer. Aquaporins and several types of ion channels can increase plasma membrane H$_2$O permeability. Most cotransporters also move H$_2$O with every cycle of substrate transport.
Aquaporins are a family of transmembrane proteins that selectively permeate water, and can thus increase water flux across cell membranes manifold (King et al. 2004). Water transport across aquaporins is mediated by osmotic gradients, and hence diffusion is passive and bi-directional. A sub-group of aquaporins also permeate other substances in addition to water, such as urea, ammonia or glycerol, but the physiological role of this metabolite permeability is incompletely understood (King et al. 2004). Aquaporins are expressed in a range of tissues including blood (erythrocytes), kidney (renal tubules), lens, retina and brain. The principal types of aquaporins expressed in brain are AQP1 (choroid plexus epithelial cells), and AQP4 (astrocytes and ependymocytes) (Agre et al. 2004). Some aquaporins appear capable of gating the degree of water permeability (e.g. AQP2 via vasopressin in kidney) (Moeller et al. 2011). However, it is somewhat controversial whether AQP4 is capable of gating. Several studies have indicated that phosphorylation of different sites on the AQP4 molecule can increase or decrease water permeability (e.g. in response to glutamate, erythropoietin, vasopressin and potassium) (Gunnarson et al. 2009; Gunnarson et al. 2008; Illarionova et al. 2010; Moeller et al. 2009; Niermann et al. 2001; Song and Gunnarson 2012). However, subsequent structural determinations have contradicted these observations (Mitsuma et al. 2010).

**Figure 5.** AQP4 expression in astrocytes is polarized to endfeet and peri-synaptic processes. Left: Immunogold labeling for AQP4 (black dots) showing sub-pial endfeet and peri-synaptic enrichment. Modified with permission from Nielsen et al. 1997. Right: Individual AQP4 channels permeate water. 4 AQP4 channels can assemble into tetramers, which have central pore that may permeate other molecules. Numerous AQP4 tetramers join together into orthogonal arrays of particles that almost completely cover astrocyte endfoot membranes.
AQP4, which is the main aquaporin explored in our thesis, is expressed to such a large extent by astrocytes that formations of AQP4 proteins clustered in so-called orthogonal arrays of particles can be seen by freeze fracture EM to cover almost the entire surface of astrocyte processes (Fig. 5) (Rash et al. 2004). AQP4 is thought to be permeable primarily to water, and no other solutes, although there is some debate whether the central pore formed between tetramers can act as a gas-channel (Fang et al. 2002; Wang et al. 2007; Wang and Tajkhorshid 2010). Additionally, AQP4 is selectively enriched in distinct subcellular domains, including perivascular endfeet and peri-synaptic processes, indicating that AQP4 may have a role in dissipating osmotic gradients generated near the synapses to the vasculature (Fig. 6) (Amiry-Moghaddam et al. 2003a; Binder et al. 2006; Frydenlund et al. 2006; Nagelhus et al. 1999; Nielsen et al. 1997). The peri-vascular localization of AQP4 in brain is controlled by the dystrophin-associated protein complex (DAPC), and disruption of this complex in a mouse model of myotonic dystrophy is associated with a loss of the perivascular enrichment (Amiry-Moghaddam et al. 2004; Frigeri et al. 2001; Vajda et al. 2004). However, a recent study that AQP4 anchoring mechanism may differ between macroglial cell types (Enger et al. 2012).

![Figure 6](image.png)

**Figure 6.** The subcellular localization of AQP4 is ensured by the DAPC-complex. Left: Illustration showing the expression pattern of AQP1 (blue) and AQP4 (red) in the human brain. Right: AQP4 is anchored to distinct membrane domains in astrocytes via the DAPC-complex. Adapted with permission from Amiry-Moghaddam and Ottersen 2003.
AQP4 has been implicated in the pathophysiology of a range of CNS disorders, including hypo-osmotic brain edema, stroke, epilepsy, hydrocephalus, migraine, and meningitis (Amiry-Moghaddam et al. 2003b; Binder et al. 2004; Binder et al. 2006; Manley et al. 2000; Padmawar et al. 2005; Papadopoulos et al. 2004; Papadopoulos and Verkman 2005). Constitutive Aqp4 knock-out (KO) mice have for instance been shown to have reduced hypo-osmotic brain edema and reduced stroke infarct size, which is hypothesized to be related to decreased astrocyte swelling and secondary dysfunction (Manley et al. 2000). A glia-specific Aqp4 KO has also recently been created, and observations from these animals are strikingly similar to constitutive KO, indicating that most of the functional AQP4 is expressed in astrocytes and not e.g. endothelial cells (Haj-Yasein et al. 2011c). Although there is an expanding literature exploring AQP4 functions in the CNS, several critical questions remain unanswered, including: 1) Are all forms of astrocyte swelling AQP4-dependent, or is this phenotype only evident in cell culture or acute brain slices from young animals? 2) Does AQP4 play a role in astroglial signaling through sensitizing these cells to small volume changes near the synapse or blood vessels? 3) Does AQP4 mediate astrocyte volume changes at the level of the individual cell or is the role of AQP4 instead to facilitate more global water and cerebrospinal fluid (CSF) flux (Iliff et al. 2012)? 4) Does AQP4 only permeate water or can it also act as a gas channel to for instance O2? Because this is a rapidly evolving field, the current thesis has restricted itself to addressing only a subset of these questions.

Astrocyte regulation of \([K^+]_o\) homeostasis in the brain

Rapid and efficient potassium homeostasis is vital in maintaining normal neuronal function, and is thought to be one of the primary functions of astrocytes (Kofuji and Newman 2004). Interestingly, the blood-brain barrier (BBB) is highly impermeable to potassium ions, ensuring that \([K^+]_o\) in the CNS is regulated internally and is minimally affected by systemic fluctuations (Hansen et al. 1977). Astrocytes have multiple passive and active potassium transport mechanisms, and similar to most mammalian cells the potassium gradient is largely responsible for their negative (more so than neurons, \sim 85\, mV) membrane potential (Kofuji and Newman 2004). Moreover, astroglia including Müller cells likely have a much greater permeability to and capacity for buffering \([K^+]_o\) than neurons, although this permeability may be
restricted to functional micro-domains (Newman et al. 1984; Walz 2000). Astrocyte potassium buffering is thought to be divided into two main mechanisms: local potassium uptake and spatial buffering (Fig. 7) (Kimelberg and Nedergaard 2010; Kofuji and Newman 2004).

Figure 7. Two proposed mechanisms for astrocyte potassium homeostasis. Top: Potassium spatial buffering involves astrocyte uptake of increased potassium from the synaptic cleft down its electrochemical gradient to the vasculature. This mechanism is thought to involve potassium channel Kir4.1 and potentially AQP4. Bottom: Local potassium accumulation coupled with sodium pumping and sodium/chloride cotransport to remove excess K+ released from neuronal activity. This mechanism is thought to involve NKCC1 / KCC2 and the NKA. Modified with permission from Kimelberg and Nedergaard 2010.

Ion pumps, cotransporters or potassium channels can all mediate local potassium uptake. This mechanism is thought to be temporary and the influxed potassium ions are eventually released back into the extracellular space, restoring the ionic composition of the various cellular compartments. Cotransporters and ion pumps usually couple K+ influx to anion (e.g. Cl-) influx or cation (e.g. Na+) efflux, to maintain electroneutrality. The NKA pump and (Na+)K+-Cl- cotransporters are thought to be the main proteins responsible for short-term buffering of increases in [K+]o following neuronal activity (Andersson et al. 2004; Kofuji and Newman 2004; Miyakawa-Naito et al. 2003; Olson et al. 1986; Xiong and Stringer 2000). The NKA exports 3Na+ and imports 2K+ causing it to be mildly electrogenic (hyperpolarizing the membrane potential, Vm) and is sensitive to inhibition by several drugs, such as the plant-toxins ouabain and digitalis. Previous studies have indicated that the astroglial isoform of NKA is more effective in buffering [K+]o than the neuronal isoform (Grisar et al. 1983; Reichenbach et al. 1987). (Na+)K+-Cl- cotransporters move all relevant ions in an electroneutral manner, and are highly expressed in secretory epithelia and ependymal cells, and to a lesser extent in both neurons and astrocytes (Delpire et al. 1999; Rivera et al. 2005). There are several important types
of (Na⁺)-K⁺-Cl⁻ cotransporters, including Na⁺-K⁺-Cl⁻ cotransporter-1 (NKCC1) expressed at a high level in early development when it imports Cl⁻, and K⁺-2Cl⁻ cotransporter-2 (KCC2) expressed later in development when it exports Cl⁻. The ontogenic expression patterns of these two cotransporters are thought to represent a developmental switch in the action of GABA, from depolarizing in early development to hyperpolarizing in adulthood (Rivera et al. 2005; Rivera et al. 1999). NKCC1 but not KCC2 is highly sensitive to low doses of the clinically used diuretic bumetanide, whilst both transporters are inhibited by the diuretic furosemide (Kimelberg 1987; Kofuji and Newman 2004).

The second mechanism for astroglial potassium clearance is spatial buffering (Chen and Nicholson 2000; Xiong and Stringer 2000). This mechanism entails astrocytes redistributing local increases in [K⁺]₀ from areas of high neuronal activity through the gap junction-coupled astrocyte syncytium to areas of less activity with lower [K⁺]₀. The driving force for the potassium current is the difference between the local potassium equilibrium potential (E_K) and the glial syncytium membrane potential (V_m) (Chever et al. 2010; Djukic et al. 2007; Haj-Yasein et al. 2011a; Heuser et al. 2012; Karowski and Proenza 1977; Nagelhus et al. 2004; Newman et al. 1984). Potassium siphoning is a variant of spatial buffering that involves redistribution of increased [K⁺]₀ to specific subcellular compartments due to polarized potassium channel expression, such as in retinal Müller cells (Newman 1985; Newman et al. 1984). One of the main advantages of this mechanism is that it allows the redistribution of potassium ions with little increases in potassium inside individual astrocytes. However, though this model provides an astrocyte-specific mechanism for buffering [K⁺]₀, there are many faults with the theory including the lack of a sufficiently strong electrochemical gradient to push a potassium current between astrocytes (Meeks and Mennerick 2007). In the brain the potassium channel subtype Kir4.1 is highly enriched in astrocytes, where it has a polarized expression similar to AQP4, principally being present in endfeet and peri-synaptic membranes. It therefore seems likely that there is some functional coupling between potassium and water homeostasis in these specialized astrocyte membrane domains (Amiry-Moghaddam et al. 2003b; Chever et al. 2010; Djukic et al. 2007; Nagelhus et al. 1999; Strohschein et al. 2011). Any spillover or siphoning of excess potassium beyond the local uptake at the individual synapse is thought to be a hallmark of pathology or an artifact of experimental preparations (e.g. epilepsy or spreading depression) (Kofuji
and Newman 2004). Potassium homeostasis in the brain is a controversial topic and further studies are clearly warranted to help ascertain the relative importance of the various mechanisms involved in \([K^+]_o\) buffering.

**Cortical spreading depression (CSD) and migraine**

CSD is a self-propagating wave of depolarization and neurodepression that spreads through cortical grey matter at a slow rate of 2-5 mm min\(^{-1}\) (Lauritzen 2001; Leao 1947). Waves of CSD can be evoked in experimental animals by intense neuronal stimulation, local application of potassium or tissue injury (Takano and Nedergaard 2009).

![Figure 8](image.png)

**Figure 8.** Model of migraine pathophysiology. The illustration shows a human cortex with a wave of CSD spreading across it. The CSD wave itself (yellow) is accompanied by neurodepression (decreased electrocorticogram amplitude), depolarization (increased \([K^+]_o\)), hyperemia, hypoxia and will typically manifest as visual phenomena called an *aura*. This period is followed by prolonged oligemia, slow restoration of neuronal activity and activation of trigeminal nociceptive afferents causing the characteristic headache (green). Modified with permission from Takano et al. 2009.

CSD has been closely linked to the pathophysiology of migraine headaches, where sufferers often experience a phenomenon called *aura* that manifests as sensory phenomena (e.g. scintillation-scotoma). These phenomena show a slow somato- or retino-topic spread across the cortex that is of an equivalent velocity to CSD.
As the ‘aura wave’ subsides, the patient typically begins to experience throbbing headaches, which is thought to be related to secondary meningeal vasodilation with activation of trigeminal nociceptive afferents (Fig. 8) (Takano and Nedergaard 2009). However, the characteristic wave of depressed neuronal (electrocorticogram) activity seen during CSD is present in a very narrow zone of cortex, and thus cannot be detected non-invasively with external electroencephalogram electrodes in humans (Lauritzen et al. 2011). When functional imaging is used to measure cerebral blood flow during migraine attacks investigators again observe a brief and variable hyperemia (more prominent in anesthetized animals) followed by a characteristically slow wave of cortical oligemia (Lauritzen 1994; Tfelt-Hansen and Koehler 2011). Finally, using more invasive recordings investigators have shown that human cortex is capable of generating and sustaining CSD waves following injury or experimental stimulation (Lauritzen 1994). Taken together, CSD is therefore likely to be a fundamental property of all densely packed nervous tissue, both animal and human.

CSD is characterized by an increase in \([K^+]_o\) of more than 50 mM, and re-establishing the transmembrane potassium gradient thus presents a unique metabolic challenge for the brain parenchyma (Takano et al. 2007). Additionally, other electrolyte gradients are critically altered, with \([Ca^{2+}]_o\) decreasing from 1.2 to 0.1 mM, \([Cl^-]_o\) decreasing from 120 to 70 mM and \([Na^+]_o\) decreasing from 150 to 60 mM (Lauritzen et al. 2011). CSD waves are usually self-terminating and do not cause permanent brain injury (Takano et al. 2007). However, in the context of severe cortical injury (e.g. traumatic brain injury or stroke), so-called peri-infarct or anoxic depolarizations can be observed that persist and increase the area of brain that is permanently damaged (Lauritzen et al. 2011). Interestingly, when fluorocitrate is used to selectively injure astroglial by inhibiting the Krebs cycle this also causes CSD to induce irreversible neuronal dysfunction (Largo et al. 1997; Paulsen et al. 1987). The predilection for migraine attacks to originate in the striate (V1) cortex in humans may therefore relate directly to the relatively lower astrocyte-to-neuron ratio in this area (Lauritzen et al. 2011).

To study this metabolic strain we chose to employ reduced nicotinamide adenine dinucleotide (NADH) imaging, which relies on the natural auto-fluorescence of NADH but not NAD\(^+\) (Fig. 9). NADH is critical co-enzyme in cellular metabolism, which is generated from NAD\(^+\) (reduction) during glycolysis, and to a larger extent
from Krebs cycle, and is used by the mitochondrial respiratory chain (oxidation). When used in conjunction with 2PLSM, NADH imaging can thus be used to generate detailed maps of local tissue red-ox state, where increased NADH signal intensity is a sensitive proxy of tissue hypoxia (Kasischke et al. 2011). Interestingly, NADH fluorescence in neuropil is highest in astrocytes, almost precisely outlining the entire cells (including processes), whilst showing little overlap with mitochondrial staining (Kasischke et al. 2004). NADH imaging during CSD or hypoxemia reveals sharply defined cylindrical perivascular regions of high oxygen tension (low NADH signal) and irregularly shaped interspersed watershed regions of low oxygen tension (high NADH signal) (Kasischke et al. 2011; Takano et al. 2007). The steep sigmoidal NADH-pO₂ curve with a p50 for O₂ of 3.4 mmHg explains the sharp border between high and low NADH signal intensity in perivascular and watershed regions, respectively (Kasischke et al. 2011).

Using in vivo 2PLSM NADH imaging Takano et al. in 2007 made a set of key observations regarding the micro-distribution of oxygen in CSD. The authors observed that in watershed areas tissue hypoxia causes and coincides with CSD, and critical hypoxia in these regions causes swelling along with dendritic spine distortion in neurons, but not astrocytes (Takano et al. 2007). The extent of astrocyte swelling is still somewhat more debated, but the much clearer swelling in neurons shown in this and other studies at least indicates that astrocyte volume regulation is much tighter (from unpublished observations in situ) (Risher et al. 2012) (Takano et al. 2007; Zhou
et al. 2010). More importantly, the NADH observations made by Takano et al. indicate that the self-propagating nature of the CSD wave might stem from a primary energy failure (i.e. NKA failure). This energy failure seems most likely to stem from excess energy consumption than from inadequate supply, as blood flow actually increases during the early phase of CSD. However, what sets up the CSD wave in the first place is a bit more uncertain. The wave itself is preceded by propagating field oscillations in glial and neuronal $V_m$, indicating that CSD might be initiated by neuronal hyperexcitability similar to seizures (Larrosa et al. 2006). Additionally, genetic analysis of patients with familial hemiplegic migraine has revealed mutations in genes encoding calcium channels (e.g. Ca$_{v}$2.1), the astrocytic Na$^+-$K$^+$-ATPase and sodium channels (e.g. SCN1) linked to maintaining $V_m$ (Leo et al. 2011; Takano and Nedergaard 2009). In conclusion, CSD presents a unique metabolic challenge for astrocytes and neurons alike, and the self-sustaining slow propagation of the CSD wave appears to be caused by a vicious cycle of excess oxygen consumption, watershed hypoxia and a secondary failure of potassium homeostasis (Takano et al. 2007).

**Calcium signaling in astrocytes**

The advent of calcium imaging using chemical calcium indicators (e.g. Fluo-3) was one of the major breakthroughs that alerted investigators to the active role of glia in brain information processing. It was known through histological studies since the 1980s that astrocytes express a subset of glutamate receptors (Bowman and Kimelberg 1984; Kettenmann et al. 1984). However, it was not until 1990 that Cornell-Bell et al. observed that cultured astrocytes are able to respond to locally applied glutamate by generating wide-spreading waves of elevated intracellular calcium (Cornell-Bell et al. 1990). This observation was critical to subsequent glial research because it showed that astrocytes have the ability to directly sense synaptic activity. Subsequently, co-cultures of astrocytes and neurons were used to show that astrocytes are not just able to respond, but also to alter neuronal signaling through intracellular calcium signals (Nedergaard 1994; Parpura et al. 1994). Finally, these observations of bidirectional astrocyte communication with neurons were validated in more intact preparations (acute hippocampal slices and retinal preparations) (Kang et al. 1998; Newman and Zahs 1998). More recent work has also indicated that in response to the activation of glutamatergic and purinergic receptors or alterations of
local ion concentrations astrocytes may be able to release neurotransmitters into the synaptic cleft, either via vesicular or non-vesicular mechanisms (e.g. connexin hemichannels) (Hamilton and Attwell 2010; Kang et al. 1998; Simard et al. 2003; Torres et al. 2012; Wang et al. 2012a; Wang et al. 2012b). This extensive astroglial signaling at the level of the individual synapse led to the development of the ‘tripartite synapse’ model, which incorporates an astrocytic process into the basic unit of information processing (Araque et al. 1999).

Figure 10. Illustration of the molecular mechanisms governing intracellular calcium in astrocytes and neurons. Abbreviations: CBP: Ca2+-binding protein; ER: endoplasmic reticulum; GLT: glutamate transporter; GPCR: G-protein coupled receptor; InsP3R: inositol-1,4,5-trisphosphate receptor; LGCC: ligand-gated Ca2+ channel; NCX: sodium–calcium exchanger; PMCA: plasmalemmal Ca2+ ATP-ase; RyR: ryanodine receptor; SERCA: sarco(endo)plasmic reticulum Ca2+ ATP-ase; SOC: store-operated Ca2+ channel; VGCC: voltage-gated Ca2+ channel; ‘Maxi’ channel: high-permeability plasmalemmal channels (such as connexins or pannexins or P2X7 receptors or volume-regulated anion channels) that can act as a pathway for non-exocytotic gliotransmitter release. Modified with permission from Nedergaard et al. 2010.

Intracellular transients of free ionized calcium (Ca\(^{2+}\)) are an old form of cellular signaling that is present even in bacteria, and likely co-evolved with the use of adenosine triphosphate (ATP) as the primary intracellular energy source (Dominguez 2004). Intracellular calcium is tightly regulated in all mammalian cell types, and a rapid increase in this ion is used to among other things to mediate programmed cell-death (apoptosis) (Parpura and Verkhratsky 2012). Astrocytic calcium signals appear to derive primarily from endoplasmic reticulum (ER), where
the concentration of calcium is ~1000x higher than in the cytoplasm. Upon activation of metabotropic G\textsubscript{q}-coupled G-protein coupled receptors, phospholipase C cleaves phosphatidylinositol-4,5-bisphosphate in plasmalemma, releasing inositol-1,4,5-trisphosphate (IP\textsubscript{3}) to the cytosol and diacylglycerol in the membrane. IP\textsubscript{3}-dependent calcium release from the ER via the IP\textsubscript{3} receptor type 2 (IP\textsubscript{3}R2) is thought to be the major pathway of calcium signaling in astrocytes; as opposed to neurons where voltage gated calcium channels mediate vesicular neurotransmitter release (Fig. 10) (Nedergaard et al. 2010). However, it is possible that smaller IP\textsubscript{3}-independent calcium signals in the small processes trigger IP\textsubscript{3} signaling in so-called calcium-induced calcium release (Arcuino et al. 2002). IP\textsubscript{3}-independent mechanisms for calcium influx in astrocytes include plasmalemmal calcium channels (e.g. Cav1) and/or transporters (e.g. Na\textsuperscript{+}-Ca\textsuperscript{2+}-exchanger) (Nedergaard et al. 2010).

Intracellular calcium transients are known to propagate as waves throughout a network of astrocytes joined by gap junctions (composed of two connexons), which is termed the astrocytic syncytium (Rouach et al. 2008). There are a number of mechanisms thought to be involved in calcium wave propagation, including the diffusion of Ca\textsuperscript{2+} or IP\textsubscript{3} through gap junctions and paracrine ATP release activating neighboring metabotropic P2Y receptors (Verkhratsky et al. 2012a). Astrocytic calcium waves as observed in vitro and in situ propagate relatively slowly compared to axonal signals (4-20 \textmu m s\textsuperscript{-1} vs. 10-100 m s\textsuperscript{-1}) (Hartline and Colman 2007). For this reason, some authors would argue that astrocytic calcium waves may be too slow or could generate noise if they were to modulate individual synaptic events (Agulhon et al. 2008). Conversely, this temporal difference may indicate that astrocyte calcium transients are responsible for the integration of neuronal activity over a larger temporal (seconds) and spatial (thousands of synapses) scale, which is more relevant for neurovascular coupling (Iadecola and Nedergaard 2007).

Through the application of 2PLSM to calcium imaging, investigators have recently been able to explore astrocyte calcium signals in intact living brains. In one of the seminal \textit{in vivo} studies Wang et al. showed that physiological sensory stimulation (in the form of air-puffing whiskers) is able to elicit a coordinated calcium response that followed neuronal firing in the stimulated area of somatosensory cortex (Wang et al. 2006). The magnitude of this sensory-evoked astrocytic calcium response was directly correlated with the neuronal response and depended on
activation of Gq-coupled metabotropic glutamate receptor 5 (mGluR5). Subsequent in vivo studies have elaborated on this observation, and shown that other forms of sensory stimulation (e.g. hindlimb electroshock), as well as local agonist application or stimulated neuromodulator release (e.g. acetylcholine and norepinephrine) can also elicit calcium activity in cortical astrocytes (Bekar et al. 2008; Navarrete et al. 2012; Takata et al. 2011; Winship et al. 2007). Astrocytes thus appear able to respond to several types of physiologically relevant signals in vivo.

Figure 11. Astrocytic regulation of blood flow via calcium signals. Left: Illustration of the hypothetical role of astrocytes in connecting neuronal demand with blood flow supply via calcium signaling. Adapted with permission from Iadecola and Nedergaard, 2007. Right: Serial 2PLSM images taken at 3 s intervals of a cerebral arteriole showing functional hyperemia and associated calcium activity (pseudocolored rhod-2 intensity) in the awake mouse cortex (unpublished).

Since in vitro and in situ work showed astrocyte-neuronal signaling is inherently bidirectional, the next question would be what neuronal changes do astrocyte calcium signals elicit in vivo. Unfortunately, on this critical issue the literature is quite divided. The previously discussed ‘tripartite synapse’ model states that astrocyte calcium activity triggers gliotransmitter release, which may in turn modulate neuronal activity (Araque et al. 1999). However, data that directly questions some of the key observations underpinning this model has emerged more recently (Agulhon et al. 2010; Agulhon et al. 2008; Nedergaard and Verkhratsky 2012; Sun et al. 2013). Another critical function for astroglial calcium transients is mediating neurovascular coupling (functional hyperemia) (Fig. 11). Stimulating astrocyte calcium transients or experimentally increasing intracellular calcium using uncaging triggers brisk vascular responses. However, both the type of response (vasodilation or constriction) and the mechanisms implicated are currently under intense debate, as
different experimental paradigms have generated divergent results (e.g. pre-constricted blood vessels in brain slice vs. in vivo) (Attwell et al. 2010; Iadecola and Nedergaard 2007; Lauritzen et al. 2012; Takano et al. 2006).

There are several important questions regarding astrocyte calcium signaling that remain unanswered. First, can we trust the data from in situ studies of young animals or are hippocampal slices not as good a model study astrocytes as it has been for neurons (Sun et al. 2013)? Second, in vivo imaging has a much higher signal-to-noise ratio for calcium recordings and is often acquired at a lower temporal resolution (e.g. 1-10 Hz frame rate). This raises the question of whether we are in fact detecting all the relevant calcium signals or looking in the right places (e.g. soma v.s. processes). Two in situ studies have recently shown that short lasting low amplitude calcium transients in the processes occur even in response to individual synaptic events (Di Castro et al. 2011; Panatier et al. 2011). More recently, high-speed 2PLSM set-ups developed primarily for neuronal calcium imaging are breaching this barrier, allowing frame rates of up to 1000 Hz (Chen et al. 2011). Third, does neuronal activity generate multiple astrocytic calcium waves, and if so do these have different kinetics and functions (Torres et al. 2012)? Fourth, are we imaging deep enough in the cortex? Whisker activation principally stimulates layer IV, and we may be simply observing an axially propagated response in the more superficial layers. Finally, one major problem with the in vivo literature to date is that, with the exception of two studies, it has been carried out using anaesthetized animals, where neuronal activity is known to be significantly depressed (Greenberg et al. 2008). These two preliminary studies of calcium signaling in awake animals revealed profoundly different spontaneous and evoked activity patterns. These included synchronized ‘bursts’ (instead of waves) across hundreds of astrocytes and a much higher level of spontaneous activity (Dombeck et al. 2007; Nimmerjahn et al. 2009). Exploring calcium signaling in astrocytes in awake animals would no doubt give a more physiological view of how astrocytes signal and perhaps provide some more definitive answers to whether or how astrocytes can sense and modulate synaptic transmission.

Cerebrospinal fluid microcirculation in the brain
In most tissues of the body, a parallel lymphatic circulation accompanies blood vessels and supports normal hemodynamic function by resorbing interstitial fluid,
carrying immune cells and transporting lipids (Schmid-Schonbein 1990). The brain, however, is one of the few organs to be entirely devoid of an anatomically distinct lymphatic system. Through the selective barrier properties of the BBB, the composition of the CNS microenvironment is regulated very separately from the rest of the body (Abbott 2004). It has long been thought that CSF might serve the role of peripheral lymph in the CNS. Macroscopically, CSF circulates rapidly from the choroid plexi in the ventricles where it is produced and diffuses through the brain parenchyma by convective bulk flow, before being resorbed by the arachnoid granulations into venous sinuses (Figure 12) (Abbott 2004; Aukland and Reed 1993; Sakka et al. 2011). However, the extracellular space in the brain is extremely narrow and very tortuous, meaning that any bulk flow through this anatomical space should be much slower than the interstitial fluid diffusion rates we observe (0.1-0.3 µL min⁻¹ g⁻¹) (Thorne and Nicholson 2006).

Figure 12: Paravascular CSF circulation in neuropil. Left: Macroscopic CSF circulation, illustrating para-arterial (Art., red) and para-venous (Ven., purple) PVS (blue) ensheathed by astrocyte endfoot (e.f.) processes. Paravascular CSF flow mediates convective bulk flow of interstitial fluid through the narrow and tortuous extracellular space. Right: Microscopic view of paravascular circulation of interstitial fluid (ISF) and lipids through putative transporters in glial endfeet.

These observations have led investigators to suggest that ‘highways’ for more rapid CSF flow through the parenchyma must exist, and the two most likely candidates are the para-axonal and paravascular pathways. The former is more highly developed in species with bigger axons, but diffusion-weighted MRI has also revealed that water flux along axons is a major pathway in the human brain (Abbott 2004;
Mori et al. 2009). Several groups have illustrated the latter pathway since the 1800s by injecting various tracer molecules (e.g. horseradish peroxidase) injected into the brain parenchyma, ventricles or subarachnoid CSF and performing serial histological sectioning. This method causes the tracer to strikingly outline a paravascular space (PVS) ensheathing the cerebral vasculature, although the choice of tracer determines how completely the vasculature will be outlined (Abbott 2004; Cserr et al. 1981; Cserr et al. 1986; Rennels et al. 1990; Szentistvanyi et al. 1984). Interestingly, a recent 3D EM reconstruction has revealed that astrocyte endfeet provide a complete ensheathment of cerebral blood vessels, ensuring the patency of this paravascular compartment (Mathiisen et al. 2010).

The paravascular CSF pathway was recently revisited by Iliff et al., who used 2PLSM to demonstrate that a range of water-soluble tracers and deuterated water (\(^2\text{H}_2\text{O}\)) itself pass rapidly along the separate anatomical space between astrocyte endfeet and the blood vessel wall \textit{in vivo} (Iliff et al. 2012). The PVS is largest near the pial surface, where it is called the Virchow-Robin space, and becomes progressively narrower before almost disappearing at the capillary level (Abbott 2004). Interestingly, Iliff et al. also showed that water flow through this pathway was 70% slowed by deletion of \textit{Aqp4}, indicating that one of the major roles of this protein could be facilitating CSF microcirculation (Fig. 13). It therefore appears that the brain has a distinct pathway for the microcirculation of water and water-soluble compounds. However, another major function of peripheral lymph is the transport of lipids from the gut to the liver and peripheral organs. Despite grey and white matter being composed of 38 and 58 % lipid, respectively (O'Brien and Sampson 1965a; O'Brien and Sampson 1965b), the BBB is largely impermeable to peripheral lipids and lipoproteins (Leoni et al. 2010). The essential lipids needed for myelin or synaptic membranes therefore need to be produced within the CNS (Mauch et al. 2001). Interestingly, astrocytes have been shown to orchestrate this vital process, by producing cholesterol and high-density lipoprotein-like molecules (Fagan and Holtzman 2000). The addition of fatty acid residues (palmitoylation) has important functions during neurodevelopment and synaptic plasticity (Fukata and Fukata 2010). Astrocyte lipid clearance to the blood is also likely to be important, and for instance cholesterol is cleared by conversion to 24S-OH-cholesterol (cerebrosterol), making it BBB permeable (Bjorkhem 2007). CSF is rich in astrocyte-produced lipoproteins, and mutations in genes related to this process (e.g. ApoE) have been linked to
neurodegenerative conditions such as Alzheimer disease (Leoni and Caccia 2011; Leoni et al. 2010; Riddell et al. 2008). Taken together, observations regarding lipid metabolism in the CNS indicate the existence of astrocyte-neuronal lipid (or cholesterol) shuttle, where astrocytes feed neurons with the necessary lipid for synaptic membranes (Nieweg et al. 2009). An important question that is unanswered in current literature is therefore whether the PVS serves as a conduit for rapid lipid as well as water microcirculation through the brain parenchyma.

Figure 13. Immunofluorescence micrograph of AQP4 and GFAP expression in the mouse cortex. Modified from Simard et al. 2003.

**Microglia - the double-edged sword of CNS immunity**

Microglia are a cell type that has come into focus relatively recently. They are the innate immune cells of the CNS and are of mesenchymal origin. Microglia are derived from peripheral macrophages and migrate to the brain during early development (Chan et al. 2007; Verkhratsky and Butt 2007). The function of microglia has been described as a ‘double-edged sword,’ as they have the capability of being both protective and harmful in health and disease. Under physiological conditions, microglia exist in the ‘resting state,’ which is morphologically characterized by the cells extending multiple thin processes from a small central cell body. However, *in vivo* 2PLSM recently showed that ‘resting’ microglial processes are in fact constantly moving, screening their territories, seeking out any signals that may indicate injury or inflammation (Davalos et al. 2005; Nimmerjahn et al. 2005). Like astrocytes, microglia show very little overlap between cells and seem to survey their own domain with their processes (Kettenmann et al. 2011).
Figure 14. The changing states of microglia. Illustration showing resting microglia (left), microglial activation and BBB opening after a small injury (middle), and severe microglial activation (right) associated with amoeboid morphological appearance and phagocytic behavior in the context of a large injury. Note the surveillance capability of fine processes in resting microglia, thought to constantly scan for foreign antigens.

In response to brain injury, infection or inflammation, microglia are known to change their morphology by transforming through an ‘alerted state’ to an ‘amoeboid state’ (Fig. 14). This morphological transition involves retraction of processes, which become fewer but thicker, increase in cell body size and production various cytokines along with other signals (Block et al. 2007; Davalos et al. 2005; Hanisch and Kettenmann 2007; Verkhratsky and Butt 2007). When activated, their morphological change aids phagocytosis and allows the removal of unwanted pathogens or dead host cells. The exact mechanism of how microglial activation is initially triggered is not fully understood, but we do know that microglia possess a number of neurotransmitter (including glutamate, GABA, adenosine and purine) and immune (including complement, cytokine and chemokine) receptors. Many of these receptors are involved in activating microglia during brain injury, but ATP in particular is thought to play a central role (Davalos et al. 2005; Kettenmann et al. 2011; Ohsawa et al. 2007). Brain injury is thought to result in the release of vast amounts of ATP, which microglia respond swiftly to through activation of mainly P2X7 receptors (Burnstock and Verkhratsky 2010; Kettenmann et al. 2011; Verkhratsky and Butt 2007). Activation of these receptors promotes extension of microglial processes towards the perceived site of injury and the release of various cytokines and pro-inflammatory proteins. In addition to releasing pro-inflammatory markers (such as interleukins, tumor necrosis factor-α and transforming growth factor-β), microglia are thought to aid neurons in regeneration post-injury (Kettenmann et al. 2011). For example, they release a number of growth factors, including brain-derived neurotrophic factor and
nerve growth factor, which are thought to aid neurons in overcoming injury (Kettenmann et al. 2011).

In their activated state, microglia have been shown to be effective in phagocytosing unwanted debris, but what happens if this immune response starts targeting host cells? In Alzheimer disease, microglia have been shown to phagocyte neurons, perhaps contributing to loss of cognitive function. Interestingly, knocking out Cx3Cr1 prevented neuronal loss in mice with Alzheimer (Fuhrmann et al. 2010). Additionally, the Alzheimer disease plaque is formed by amyloid-β deposits, astroglial processes, degenerated neurons and activated microglia. It is therefore poorly understood whether microglial activation is protective in various neurodegenerative diseases or whether they present a target for therapy. Activated microglia are known to be able to trigger robust calcium activity in astrocytes, an observation that may explain some of the neurotoxicity of activated microglia (Agulhon et al. 2012). Activated microglia have been observed following stroke, and it is unclear whether the immune response generated might in fact increase the necrotic infarcted area of brain tissue (Verkhratsky and Butt 2007; Wang et al. 2012c). Interestingly, microglia have also recently been implicated in the role of chronic neuropathic pain. Peripheral nerve damage is known to cause activation of microglia in the spinal cord, which then leads to the activation of purinoreceptors, in particular P2X4 and P2Y12. These receptors have been shown to be necessary in producing allodynia and purinergic inhibition results in reversal of this chronic pain symptom (Inoue et al. 2007; Kobayashi et al. 2008; Tsuda et al. 2003). Additionally, microglia are thought to release brain-derived neurotrophic factor in response to peripheral nerve damage as a signaling molecule to neurons, and inhibiting this release may reverse the symptoms of neuropathic pain (Coull JA 2005). Finally, microglial activation has been shown during the final coma stage in hepatic encephalopathy (HE), coinciding with brain edema and BBB opening. However, these data have been collected using ex vivo methods and further investigation using in vivo methods to establish the timescale of these changes is warranted (Butterworth 2011; Jiang et al. 2009; Rodrigo et al. 2010). Taken together, these divergent observations regarding the role of microglia in disease may reflect the double role of help and harm that microglia have in the CNS.
Astrocyte ammonia handling in health and disease

Ammonia is a ubiquitous waste product and vital building block in the body that is intimately linked to protein metabolism (Butterworth 2002a). At physiological pH and temperature ammonia exists as 99% NH$_4^+$ (ammonium) and 1% NH$_3$ (ammonia) and has an acid dissociation constant ($pK_a$) of 9.02 (Ott and Larsen 2004). In the brain, ammonia detoxification has a central role as it is necessary for the recycling of the principle excitatory neurotransmitter glutamate, and hence indirectly the generation of the principle inhibitory transmitter, GABA (Bak et al. 2006; Hertz and Kala 2007; Paulsen et al. 1987). The key step of this glutamine-glutamate-GABA cycle happens in astrocytes, which possess glutamine synthetase (GS), the only enzyme capable of detoxifying ammonia in the brain through condensation with glutamate (Hertz and Zielke 2004; Martinez-Hernandez et al. 1977).

One of the major problems with studying ammonia directly is its volatility and the lack of specific tools to detect the molecule (e.g. ammonia-sensitive dyes or electrodes). Consequently, several investigators have used pH as proxy for ammonia movement, as NH$_4^+$ is a weak acid and NH$_3$ is a volatile base. For instance, when astrocytes or neurons in vitro or in situ are exposed to elevated ammonia this causes a rapid intracellular alkalinization, thought to represent volatile NH$_3$ crossing the lipid bilayer and reaching equilibrium, followed by a prolonged intracellular acidification caused by NH$_4^+$ entry through ion-channels (Boyarsky et al. 1993; Nagaraja and Brookes 1998). Reciprocal pH changes are usually recorded in the extracellular space, as we found in our study. In a set of very interesting experiments Coles et al. used this pH phenomenon in combination with ammonia ion-sensitive microelectrodes to show that light-stimulated neuronal firing in retina is associated with increased aerobic metabolism and a rapid rise in extracellular ammonia, which is then swiftly taken up by glial cells (Coles et al. 1996; Marcaggi and Coles 2000; Marcaggi et al. 2004). Thus, taken together with related data from cultured astrocytes and acute brain slices it is clear that physiological neuronal firing is associated with a significant release of ammonia along with glutamate into the extracellular space (Alger and Nicoll 1983; Waniewski 1992). Interestingly, glial GS has a higher affinity for ammonia than glutamate, suggesting that astrocytes prioritize the removal of ammonia over the potentially excitotoxic neurotransmitter (Ciani et al. 1996; Waniewski 1992).

Ammonia was relatively widely studied in the 1960s - 80s, as in excess it was found to cause gross brain dysfunction, including encephalopathy and seizures.
(Cooper et al. 1979; Lux and Schubert 1969; Martinez-Hernandez et al. 1977; Raabe and Gummit 1975). The epileptogenic effect of GS inhibitor methionine sulfoximine (MSO) was also observed at this time in dogs accidentally fed MSO via biscuits with bleached flour (dogs are 100-times more sensitive to MSO than rodents and primates) (Paulsen et al. 1988b; Proler and Kellaway 1962). Since the realization that liver failure is characterized by an accumulation of ammonia in the blood (hyperammonemia), the brain dysfunction in this condition, termed hepatic encephalopathy (HE), has also been thought to be largely ammonia-related (Butterworth 2002a). Several different hypotheses have been suggested to explain the neurological effects of ammonia, and these include (Fig. 15): ammonia driving an accumulation of glutamine with secondary osmotic damage to astrocytes (glutamine hypothesis), impaired functional hyperemia or decreased overall blood flow, BBB opening with consequent edema, lactic acidosis or impaired pH homeostasis, a failure of energy (glucose/ATP) metabolism, altered ion homeostasis (intracellular accumulation of Na⁺ and Cl⁻, and extracellular increase of K⁺), microglial activation, glutamate excitotoxicity (although nuclear magnetic resonance, NMR, studies have subsequently shown that there is no net glutamate increase in the brain) and an impairment of GABA function (Alger and Nicoll 1983; Butterworth 2002b; Cooper et al. 1979; Folbergrova et al. 1969; Ganz et al. 1989; Gregorios et al. 1985; Jayakumar et al. 2006; Lux 1971; Norenberg 1977; Raabe 1981; Ratnakumari et al. 1994; Rodrigo et al. 2010).

However, rather surprisingly none of these hypotheses have resulted in viable new therapies, and the current therapy for hyperammonemia still relies on older strategies such as increasing gut elimination with lactulose (Butterworth 2002a). We would suggest that part of the shortcoming in these studies is a failure to appreciate the limitations of reduced experimental preparations when used in isolation. Although most of these studies likely hold important clues to the cause of ammonia neurotoxicity, putting the whole story together may require the use of several methodologies spanning different areas of neuroscience, glial-science, electrophysiology, optical imaging and biochemistry.
Figure 15. Diagram summarizing the potential mechanisms for acute hyperammonemic encephalopathy based on a systematic review of the literature. Key: Red - blood vessel, blue - astrocyte and pink - neuron (pre- and post-synaptic processes). Excess blood ammonia crosses the BBB and principally enters astrocytes, where it is detoxified by enzyme glutamine synthetase.
6. HYPOTHESES AND AIMS

Two-photon imaging is a technique that has only recently been applied to the study of glial cells in vivo. We used this technique to examine the glial regulation of ion and water homeostasis in the brain. Glia are thought to be the principle cell type responsible for regulating these processes. Tight regulation of ion and volume changes is essential for normal neuronal function. We therefore hypothesized that by sensing and regulating local ion and water movement, glial cells can detect and alter physiological neuronal activity. Additionally, we propose that CNS disorders involving an imbalance of water and/or ion regulation might be directly caused by glial dysfunction. Utilizing the strengths of 2PLSM, we aimed to examine these homeostatic mechanisms in vivo, at a subcellular level and in real-time. Our ultimate goal was of extending the observations from previous studies to develop new therapies for the neurological disorders studied in our thesis.

Our specific aims were as follows:

I. What is the role of AQP4 in astrocyte calcium signaling elicited by volume changes during brain edema?

II. Does AQP4 affect oxygen micro-distribution during cortical spreading depression?

III. What is the effect of general anesthesia on astrocyte calcium signaling in the cortex of awake behaving animals?

IV. How are lipid molecules transported in the paravascular space and could this specialized gliovascular compartment play a role in astrocyte signaling?

V. Is microglial activation an early feature of HE that can be directly associated with excess ammonia?

VI. What is the role of astrocytes in acute ammonia neurotoxicity and can we identify an early step in this disease pathway that may be targeted for therapy?
7. METHODOLOGICAL CONSIDERATIONS

The goal of our project was to study glial regulation of volume and ion homeostasis in normal and disease settings. To ensure our findings were relevant and translatable to normal adult physiology and pathophysiology we chose to employ largely in vivo mouse models. Several recent papers have highlighted the profound difference between cellular dynamics in vivo as compared to in situ, in vitro or histological specimens (Sun et al. 2013; Takano et al. 2006; Wang et al. 2006). For a subset of the experiments we also adapted recently published techniques for awake imaging to avoid the masking effect of anesthesia on endpoints such as seizures, astrocyte calcium activity and cognitive phenotype (Dombeck et al. 2007; Greenberg et al. 2008; Nimmerjahn et al. 2009). To achieve sufficient temporal and spatial resolution in vivo without damaging the brain we took advantage of the aforementioned benefits offered by 2PLSM. This type of optical imaging employs a pulsed femtosecond laser to achieve specimen excitation with much longer wavelengths than conventional 1PLSM. However, 2PLSM has some theoretical and practical drawbacks as a consequence of the optics employed, which we will outline below (Christensen and Nedergaard 2011). To achieve a more complete picture of the biology, several adjunct techniques were also used in our studies to complement the 2PLSM findings. The relative merits and shortcomings of these techniques will also be addressed.

Limitations of two-photon imaging

There are three main issues with 2PLSM. First, 2PLSM has a theoretical resolution limit that is close to one-half the wavelength of the exciting light (i.e. diffraction limit = \lambda / 2 \times \text{numerical aperture}) (Christensen and Nedergaard 2011). Therefore, 2PLSM theoretically cannot resolve structures smaller than ~ 0.35-45 \, \mu m. Practically, 2PLSM imaging of living brain has further limitations due to aberrations along the optic pathway (e.g. optically dense neuropil). The effective resolution can therefore be approximated from the point spread function of an individual 2PLSM set-up, and usually has a radial resolution of ~ 0.6-1.0 and an axial resolution of ~ 3-5 (due to greater dispersion in this axis) (Dong et al. 2003; Drew et al. 2010). This resolution is still not sufficient to address ultrastructural questions, which for instance conventional transmission electron microscopy can address (resolution 0.2 nm) (Denk et al. 2012; Helmstaedter et al. 2008; Mikula et al. 2012). Additionally, new optical techniques
such as stimulated emission depletion (resolution 70-90 nm) microscopy have breached the diffraction limit of light and are currently allowing optical imaging of subcellular protein localization in cultured cells (Blom et al. 2012; Blom et al. 2011; Hell 2003; Willig et al. 2006). However, due to technical limitations such techniques have to our knowledge not yet been applied *in vivo*. The resolution limit of 2PLSM therefore imposes limitations on the questions that can be addressed using this technique, and for instance comparing the subcellular localization or trafficking of proteins between two closely apposed cell membranes is currently beyond the reach of 2PLSM.

Second, 2PLSM has a technical limit on its temporal resolution; as it usually relies on the movement of galvanometric mirrors to raster scan the laser beam across the specimen (similar to confocal microscopy). These mirrors have too much inertia to allow imaging with a temporal resolution < 80-100 ms. Many important processes happen on a timescale that is orders of magnitude faster than the scan rate of most 2PLSM set-ups, including neuronal signaling (Christensen and Nedergaard 2011). Most of the experiments used in this thesis were conducted using galvanometric mirrors, but the recent advent of random access multiphoton microscopy using acousto-optical deflectors is rapidly breaching this temporal resolution barrier (Chen et al. 2011; Duemani Reddy et al. 2008).

Third, due to the optically dense nature of biological material such as brain, 2PLSM is usually unable to image much deeper than 500 μm below the tissue surface. Maximum imaging depth is again a property of the wavelength used to excite the specimen, and recently the use of ultra-long wavelength lasers (e.g. 1280 nm) facilitated imaging as deep as 1 mm below the cortical surface (Kobat et al. 2009). Deeper imaging will undoubtedly open new avenues for discoveries, as most labs are currently limited to imaging down to layer IV of mouse brain cortex. White matter, subcortical nuclei, hippocampus and deeper cortical layers are thus rarely examined *in vivo* due to the technical limitations of imaging (e.g. 2PLSM).

**Surgical preparations for *in vivo* imaging**

Another critical consideration for imaging involving live animals is the surgical preparation. The typical surgical protocol we employed in our studies involved anesthetizing the animal, sterilizing the skin, fixing the skull to a metal mini-frame, creating a small cranial window (0.5-3 mm diameter), and sealing this window with a
cover glass ± agarose or saline (Fig. 16) (Dombeck et al. 2007; Drew et al. 2010; Holtmaat et al. 2009; Wang et al. 2006).

Figure 16. Neurosurgical preparation for in vivo 2PLSM imaging. Left: Photograph of a cranial window preparation. Kindly provided by Prof. M. Nedergaard. Middle: Immunofluorescence micrograph showing the layers of the mouse cortex and outlining the microvasculature (white - AQP4, blue - DAPI). Right: Collapsed XYZ stack (25-175 μm depth) of fluorescein isothiocyanate (FITC)-dextran labeled cortical blood vessels imaged using 2PLSM.

Generally, we found two steps to be pivotal in this procedure. First, the cranial window had to be created with extreme caution to avoid injuring the underlying brain. Injuries might not be readily apparent during the surgery, but when we subsequently imaged the animal even minor injuries could significantly confound the processes we wished to study (e.g. calcium signaling) (Xu et al. 2007). One method to circumvent this problem and allow more chronic imaging is to thin the skull instead of generating a full thickness cranial window. This approach may cause more limited resolution, and requires a great amount of technical skill, but can potentially generate less microglial activity, reactive astrogliosis and dendritic spine loss (Drew et al. 2010; Holtmaat et al. 2009). Second, the overall physiological state of the animal strongly influenced many of the endpoints we wished to measure, and we therefore excluded all animals displaying problems with e.g. breathing, hypoxia and hypercapnia (Duffy and MacVicar 1996; Thompson et al. 2006). The latter issue was most critical when experimenting with anesthetized mice, as these small rodents easily develop complications from the anesthesia (e.g. inadequate ventilation).

To address some of the issues mentioned above, we adapted a model to image brain cells in awake behaving mice (Dombeck et al. 2007; Nimmerjahn et al. 2009). Extreme care needed to be taken not to cause pain and stress to the animal, and this model had some issues of its own. Our main concern was to avoid causing any harm to the animal and the experiments were therefore planned and executed with great
care. To address the more specific issue of movement artifacts in awake mice, we developed a method of normalizing fluorescence signals (outlined in more detail in paper II). Related papers that imaged awake mice have also reported alternative methods of circumventing this issue, including post hoc algorithm corrections (Dombeck et al. 2009; Dombeck et al. 2010; Harvey et al. 2009; Ozden et al. 2012).

In conclusion, a careful surgical preparation is critical for validity of the results obtained from *in vivo* 2PLSM imaging.

**Ethical considerations for *in vivo* imaging**

Several key agreements including Nuremberg (1947) and Helsinki (1974) have highlighted the need for an ethical framework to regulate the conduct of medical research. The following is an account of the ethical issues that we encountered during our doctoral research and how we addressed them. We chose to use a mouse experimental model because of the similarity of the brain pathophysiology for the conditions we wished to study between mice and humans (translational potential) and the availability of transgenic mice and the. When designing our experiments we have used the three Rs outlined by Russel and Burch (1959) to minimize both the use of animals and any potential distress inflicted (Wolfensohn and Lloyd 2003). We strongly feel this should be a key priority to emphasize to junior researchers at an early stage. In addition, the ethical treatment of experimental animals is pivotal for both obtaining trustworthy results and the continued existence of basic research. With regards to our thesis work, we encountered the most ethical and practical challenges when it came to designing and implementing the *in vivo* experiments.

Firstly, animal experiments should never be performed if other means exist that will adequately address the research question. Unfortunately, our scientific questions could not be addressed without animal experimentation (*replacement*). Modeling of the glial homeostatic system would for instance not help us test our hypotheses, as the basic properties of this system are still not delineated clearly and clinical outcomes cannot be measured in certain reduced preparations. Secondly, we wished to minimize the number of mice needed to challenge our hypotheses (*reduction*). An important part of achieving this goal was careful planning, including an exhaustive literature search to avoid unnecessary duplication of previous results and statistical power calculations to exactly plan the numbers of animals needed.
Finally, and perhaps most importantly, we spent a long time refining our experimental methods. Whenever possible we performed experiments on fully anesthetized animals, which has the benefit that the animal has full analgesia, anesthesia and amnesia. However, for a subset of experiments the use of anesthesia would mask the end-points we wished to examine, and we were forced to adapt a relatively new technique for awake imaging in habituated animals (Dombeck et al. 2007). As awake experiments have the potential of causing significant stress to the animal, they should never be performed without careful consideration of whether the research questions can be addressed in any other way. We found this to be a major ethical burden as well as a practical challenge, also when interpreting the experimental results. We therefore spent extensive efforts when designing these experiments to minimize any pain or distress the animal might experience. Challenges included ensuring adequate anesthesia for the surgical implantation of a cranial window, whilst ensuring the animal could recover completely from the anesthetic. Moreover, adequate postoperative analgesia had to be achieved, and the mice that were imaged multiple times over longer periods had to be carefully assessed for signs of discomfort or distress (Cooper et al. 2000; Langford et al. 2010; Richardson and Flecknell 2005). Finally, during the imaging experiments themselves we had to ensure absolute silence, darkness, adequate warmth and hydration, without the mice getting wet from any of the solutions used (1994). Throughout the design and implementation of these methods we were continuously in contact with the veterinarians at the department of animal health to optimize the animals’ well being. We also relied heavily on advice from researchers with previous experience from similar experiments, and previously published protocols on in vivo experimentation (Dombeck et al. 2007; Nimmerjahn et al. 2009).

**Fluorescent imaging using chemical dyes and transgenic animals**

Fluorescent molecules are generally either chemicals (e.g. tetramethylrhodamine derivatives) or proteins (e.g. fluorescent eGFP isolated from jellyfish). The former can frequently be toxic to living cells at high doses, while the latter are better tolerated as they are frequently derived from living animals (Paredes et al. 2008; Regan et al. 2007). The efficiency of two-photon fluorophore excitation and optimal excitation wavelength cannot be directly extrapolated from one-photon spectra, and likely depends on other factors such as the local electric field (Bestvater et al. 2002;
We used a combination of transgenic mice expressing fluorescent proteins under cell-specific promoters and loading of fluorescent dyes that label cells of interest. The former technique is largely limited by the selectivity and strength of the gene promoter used. *Glt1* is the promoter for the astrocyte specific glutamate transporter GLT1 (mouse ortholog of excitatory amino acid transporter 2), and eGFP expressed by this promoter labels astrocyte soma, principal processes and endfeet sufficiently well (Fig. 17) (Regan et al. 2007). However, the finer peri-synaptic processes were less well resolved and this limited our ability to examine these subcellular microdomains in more detail.

Several hydrophobic dyes were used to selectively label astrocytes (e.g. SR101 and Texas red hydrazide) or monitor intracellular calcium fluctuations (e.g. rhod-2, fluo-4, Oregon green BAPTA, 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid) (Table 2) (Paredes et al. 2008). The former dyes serve as excellent morphological markers (Nimmerjahn et al. 2004), but have relatively recently been shown to trigger epileptiform activity in hippocampal brain slices (Kang et al. 2010). The aforementioned calcium sensitive dyes are acetoxyethyl (AM)-ester linked, allowing the molecule to cross cell membranes by virtue of their lipid solubility. AM-dyes are then trapped inside the cell through the activity of intracellular esterases, which cleave the AM group and render the dye hydrophilic (Paredes et al. 2008). The mechanism for the selective loading of these dyes mainly into astrocytes is still largely a mystery, and one cannot exclude that the dyes themselves have some biological effects on the cells they label (Reeves et al. 2011). The calcium indicators employed in our studies are for instance all BAPTA-based calcium chelators, and
might therefore dampen fluctuations of free Ca\textsuperscript{2+} inside the cell (Paredes et al. 2008; Reeves et al. 2011). Our own experience was therefore to try and minimize the amount of calcium dye loaded, to avoid cell saturation with the dye as this effectively abolished spontaneous calcium transients. Additionally, all chemical calcium indicators need to be loaded over a period of 30 - 45 min into astrocytes either through application on exposed cortex or via pressure injection into the parenchyma. This loading process may itself generate a mild inflammatory response in the brain, adversely effecting recordings (Agulhon et al. 2012). Finally, different calcium indicators have different dissociation constants that determine how long they bind free Ca\textsuperscript{2+} ions, and setting a practical limit on the temporal resolution of imaging. Several investigators have recently found a way to circumvent dye use by generating transgenic mice expressing calcium indicators (e.g. genetically-encoded calcium modulated protein) under astrocyte specific promoters (e.g. GFAP) (Mao et al. 2008; Shigetomi et al. 2010; Tong et al. 2012). In conclusion, both chemical and transgenic fluorescent proteins have inherent limitations that need to be considered when interpreting imaging results.

### Table 2. 1PLSM and 2PLSM excitation/emission spectra of relevant fluorophores.

<table>
<thead>
<tr>
<th>Fluorophore</th>
<th>2P excitation</th>
<th>1P excitation</th>
<th>Emission</th>
</tr>
</thead>
<tbody>
<tr>
<td>eGFP</td>
<td>927 nm</td>
<td>488 nm</td>
<td>509 nm</td>
</tr>
<tr>
<td>Texas red</td>
<td>780 nm</td>
<td>582 nm</td>
<td>602 nm</td>
</tr>
<tr>
<td>SR101</td>
<td>905 nm</td>
<td>586 nm</td>
<td>605 nm</td>
</tr>
<tr>
<td>Fluorescein</td>
<td>800 nm</td>
<td>508 nm</td>
<td>519 nm</td>
</tr>
<tr>
<td>Rhod-2</td>
<td>810 nm</td>
<td>553 nm</td>
<td>576 nm</td>
</tr>
<tr>
<td>Fluo-3,4,5</td>
<td>810 nm</td>
<td>493 nm</td>
<td>520 nm</td>
</tr>
<tr>
<td>Oregon green</td>
<td>810 nm</td>
<td>492 nm</td>
<td>523 nm</td>
</tr>
<tr>
<td>BAPTA</td>
<td>810 nm</td>
<td>559 nm</td>
<td>640 nm</td>
</tr>
<tr>
<td>Nile red</td>
<td>810 nm</td>
<td>559 nm</td>
<td>640 nm</td>
</tr>
</tbody>
</table>

### Data sampling and analysis for 2PLSM

To ensure that all the 2PLSM imaging data we collected were comparable we paid strict attention to maintaining consistent imaging parameters. All 2PLSM images were collected >70 \( \mu \)m below the pial surface in layer I-II of the cerebral cortex. Within individual experiments the depth of imaging, laser power and photomultiplier tube settings were kept within a narrow range. Laser power was generally kept below 40 mW to avoid phototoxicity to the tissue. This is especially important for calcium imaging, as transients can be artificially induced by high laser power (Wang et al.)
All the data was analyzed using either ImageJ (National Institute of Health) or custom-made MatLab software (NedLabAnalysis). For calcium imaging, the software allowed simultaneous quantification of fluorescence intensity in multiple regions of interest (ROIs) from an XYT scan with a tracking function (i.e. ROI tracking to correct for XY displacement). To further reduce confounding due to XY or Z displacement (e.g. movement artifact) most calcium indicator intensity traces were also normalized to Glit1-eGFP intensity. For volumetric analysis the software used XYZT scans, and quantified the number of pixels over a semi-automated threshold value within a manually defined ROI. The pixels were then added up for each XYZ scan and multiplied by the scale factor to get an estimate of cell volume. The principal limitation of this volumetric analysis was the resolution of 2PLSM, to allow accurate thresholding of the cell. We optimized the resolution by using a high magnification and high numerical aperture lens, adequate laser power, and maximally clear optical media (e.g. thin layer of agarose) in the cranial window.

**Electrocorticograms, ion-sensitive microelectrodes (ISMs) and patch clamp**

Neuronal activity causes distinct changes in local voltage due to the ion currents associated with action potentials and post-synaptic potentials (Vanderwolf 1992). In most of our 2PLSM experiments we used electrophysiology to monitor neuronal activity in parallel with the astrocyte imaging. However, it is also possible to image both neuronal and astrocyte activity simultaneously with 2PLSM using dyes like Oregon green BAPTA (Dombeck et al. 2007). We largely obtained our recordings by placing a glass microelectrode into the cerebral cortex and completing the circuit with a ground placed in the fluid bathing the brain. The resultant signals were filtered to yield either local field potential or electrocorticogram recordings (Wang et al. 2006). Additionally, electrocorticogram traces can be analyzed both in terms of morphology (e.g. amplitude of whisker electrocorticogram response) and the relative activity in different frequency bands (usually represented as power spectra). Electrocorticogram activity largely represents the sum of pyramidal neuronal activity in the region where the electrode is placed, and increased activity in different frequency bands can represent either wakeful, asleep or anesthetized patterns of neuronal firing (Table 3) (Schwilden 2006). These techniques have excellent temporal resolution, and for instance allowed us to record individual EPSPs, but not unexpectedly lack spatial resolution. The accurate placement of electrodes is therefore paramount, as
inconsistent electrode placement between experiments can introduce significant bias. To aid and monitor the placement of these microelectrodes we relied on 2PLSM, which allowed us to visualize the FITC-dextran containing electrodes. It was thus possible to accurately place microelectrodes within a consistent distance of the imaged field.

For a subset of experiments we used ISMs to record changes in extracellular ion homeostasis. ISMs are based on the principle that some hydrophobic resins are selective for certain ion currents (e.g. $K^+$), and if these resins are placed in the tip of a microelectrode one can record currents that are principally due to the movement of this ion (Nicholson 1993). As with the field electrodes, the ISMs lack spatial resolution and their placement within the brain needs to be accurate. ISMs also have a number of technical issues. For example, over time the resin from the electrode tip leaks, thus reducing sensitivity. It is therefore important to calibrate ISMs before and after each experiment with regard to sensitivity, and discard all recordings where the after-calibration deviates >5%. Moreover, changes in field recordings need to be subtracted from ISM traces to avoid confounding due to local changes in voltage. A field electrode therefore needs to be placed close to, or ideally in the same location as the ISM, which is most frequently achieved by making double-barreled electrodes (Borrelli et al. 1985). Unfortunately, these electrodes have a much higher failure rate than using two single barreled electrodes, as they are more complex to make and the resin can leak out more easily. Finally, ISM resins are never completely selective for the ion they are meant to measure, and can respond to a lesser extent to other ions. This last issue is especially relevant if the ions have a similar hydrated radius and charge. It is therefore important to check the selectivity coefficient for each resin used, and calculate the interference due to the predicted change of other interfering ions so they may be subtracted from the ISM recording (Nicholson 1993). Due to all these pitfalls and limitations we also piloted alternative techniques for measuring extracellular ion changes, including ion- and pH-sensitive dyes (e.g. BCECF, SNARF-4, TAC-Red) (Boyarsky et al. 1993; Mariot et al. 1991; Padmawar et al. 2005). These dyes have the benefit of granting spatial resolution, albeit at the cost of reduced temporal resolution. Although several dyes are commercially available, we were unable to make these chemicals load brain cells sufficiently in vivo to allow accurate recordings of ion changes.
Table 3. Characteristics of the different waveforms seen in the electrocorticogram.

<table>
<thead>
<tr>
<th>Type</th>
<th>Frequency</th>
<th>Physiology</th>
<th>Pathology</th>
</tr>
</thead>
<tbody>
<tr>
<td>δ (delta)</td>
<td>0-4 Hz</td>
<td>Slow wave sleep</td>
<td>Encephalopathy</td>
</tr>
<tr>
<td>θ (theta)</td>
<td>4-8 Hz</td>
<td>Drowsiness</td>
<td>Encephalopathy</td>
</tr>
<tr>
<td>α (alpha)</td>
<td>8-13 Hz</td>
<td>Relaxed awake</td>
<td>Coma</td>
</tr>
<tr>
<td>β (beta)</td>
<td>13-30</td>
<td>Active awake</td>
<td>Sedatives</td>
</tr>
<tr>
<td>γ (gamma)</td>
<td>30-100+</td>
<td>Memory</td>
<td>Dementia</td>
</tr>
</tbody>
</table>

For a subset of the experiments experienced electrophysiologists in our lab (Fushun Wang, Qiwu Xu and Ning Kang) performed patch clamp analyses. Briefly, this method that gained its developers Erwin Neher and Bert Sakmann a Nobel Prize in 1991 is based on placing a ~1μm tip glass microelectrode on the cell membrane of e.g. a neuron and applying suction so that a $10^9$ (giga) Ω (ohm) resistance seal is formed between the membrane and the electrode (Neher et al. 1978). The high-resistance seal allows the investigator to monitor electrical activity from just a few ion-channels in the little patch of membrane covered by the electrode without interference (noise) from the rest of the cell (Fig. 18). Investigators can either control the membrane potential (voltage clamp) or the movement of ions (current clamp) to measure what changes this induces in the non-clamped parameter, e.g. in voltage-clamp mode you can vary the membrane potential across a range and see what current flow this induces, thus generating an I-V (current-voltage) curve for a particular ion channel (Sakmann and Neher 1984).

There are several variations of patch clamping; including whole-cell where the membrane patch is ruptured allowing the electrode to measure the electrical activity of the whole cell. This method has several advantages over sharp microelectrode recordings used previously (where a very small diameter tip electrode is used to impale the cell); including better electrical access to the cell due to the larger electrode tip diameter. However, the large tip diameter also implies that the whole-cell patch electrode will over a period of >10 min dialyze the contents of the cell (Verkhratsky et al. 2006). Another variation of patch clamping also used in our study is a perforated patch. This is where the electrode is placed on the cell membrane and a giga-Ohm seal is formed, but the membrane patch is not ruptured. Usually agents such as nystatin and gramicidin are used to perforate the membrane patch (as opposed
to antimicrobial agents like amphotericin B), giving the investigator electrical access to the cell that is more selective (depending on what the perforations are permeable to) than with a whole-cell patch (Akaike 1996). A gramicidin patch is for instance very well suited to studying chloride currents, because the perforations are mainly permeable to monovalent cations and uncharged molecules (Kyrozis and Reichling 1995). The drawbacks of a perforated patch are its technical difficulty (the perforated membrane is weakened and a bit unstable), the amount of time it takes for the antibiotics to form adequate perforations (10 - 30 min) and the greater access resistance \(= R_{\text{electrode}} + R_{\text{electrode-cell junction}} \) that causes less signal-to-noise.

![Figure 18. Patch clamp recording. Left: Illustration of various patch clamp techniques outlined in the text. Right: 2PLSM image of a whole-cell patched Purkinje cell outlined with Alexa fluor 488 from the patch micropipette, kindly provided by Qiwu Xu.](image)

**Supporting techniques**

*Gene knock-out or knock-down.* Several of the studies in our thesis use gene deletion (KO) or silencing (knock-down) to explore the molecular mechanisms of disease. Generally speaking gene deletion (KO) is accomplished through a sequence of steps, including (Gaveriaux-Ruff and Kieffer 2007): 1) Sequencing and cloning the gene of interest. 2) Altering the sequence of the gene to make it inoperable (that can produce splice variants) or flanking the important exons with sequences (e.g. LoxP) that promote site-specific recombination (e.g. excision or translocation of the flanked exons). 3) Embryonic stem cells are isolated from the mouse blastocyst, grown in vitro, and the altered gene is inserted by homologous recombination using electroporation. At this stage only embryonic stem cells that have taken up the altered gene can be selected if a gene conferring antimicrobial resistance (e.g. to neomycin) has been included in the inserted construct. 4) Embryonic stem cells with the altered gene are then inserted into a recipient mouse blastocyst, generating chimeric offspring, which when bred with wild-type (WT) mice in the next generation will
generate some offspring heterozygous for the deleted or dysfunctional gene. In the case of gene excision using gene floxing (flanked by LoxP sites), a mouse expressing the floxed gene is bred with a mouse expressing Cre-recombinase (potentially under a tissue or cell specific promoter), so that only cells expressing Cre will excise the floxed gene. In contrast to the previous gene deletion strategies where the KO is permanent from birth (called constitutive), it is also possible to make the final recombination step inducible by a drug of choice (e.g. tamoxifen or tetracycline), for instance by using a modified form of Cre-recombinase that requires a drug to activate the enzyme (van der Weyden et al. 2002). The inducible (or conditional) KO strategy has the benefit of allowing deletion of genes that is incompatible with mouse survival into adulthood (Pascual et al. 2005). Additionally, inducible KO avoids the unknown confounding factors associated with developmental adaptation to the constitutive gene deletion.

As an alternative to conventional gene KO, it is also possible to knockdown or silence genes by expressing e.g. short-inhibitory or short-hairpin ribonucleic acid (shRNA), which contain a complimentary sequence to the messenger RNA (mRNA) from the gene of interest (Haas and Sontheimer 2010). There are several benefits to this strategy, including no need to go through multiple generations of mouse breeding, the ability to induce gene knock-down at any stage of development, and gene knock-down often has less cost associated with it than developing and maintaining a separate KO mouse colony. Conversely, the limitations of gene silencing include a much lower and more variable efficiency of ‘knock-down’ (e.g. 10-70%), challenges with delivery and expression of the silencing RNA construct in the cells of interest (e.g. requires strong highly cell-specific promoter), and relatively high percentage of silencing constructs that work in situ not working in vivo (Ge et al. 2006; Haas and Sontheimer 2010; Jayakumar et al. 2011a; Koyama et al. 2012). For in vivo gene silencing investigators often employ viral vectors that are relatively specific to the cells of interest (e.g. pyramidal neurons), and packaged these with a construct that includes the silencing RNA, a reporter gene (e.g. eGFP), and a sequence recognized by a cell specific promoter (e.g. GFAP). In one of our studies (unpublished), we for instance attempted to use commercially available shRNA to Slc12a2 (coding NKCC1) that has previously been successfully used in glioma cultures. The strategy was to inject mouse pups (e.g. P20) intracortically with high-titer lentivirus (targeting pyramidal cells) expressing Slc12a2 shRNA and eGFP under the pGIPZ promoter (Haas and
Sontheimer 2010). However, eGFP expression was too week to detect, likely due to weak pGIPZ promoter activity in vivo. Some authors have circumvented this problem by illustrating not direct eGFP expression in confocal micrographs, but rather antibody against eGFP (Haas and Sontheimer 2010). However, we needed to be able to visualize the eGFP on our electrophysiology set-up so as to patch affected cells, and were thus unsuccessful in this project. Moreover, there is no assurance that reporter gene expression (i.e. eGFP) means effective gene silencing or vice versa, therefore these types of experiments usually require a lot of controls to ensure that observed changes are a result of gene silencing, and e.g. not simply an effect the viral vector. Taken together, although gene silencing is popular in high tier journals as a supplement to pharmacology (to show molecular specificity), this strategy has several pitfalls ensuring that results need to be interpreted with caution.

Whisker stimulation. Unlike humans, mice devote a large proportion of their brain to process information from their whiskers (also called mystifacial vibrissae) (Schubert et al. 2007; Wang et al. 2006). The part of the cerebral cortex in mice that received whisker information has a columnar organization similar to the primate visual cortex, with whisker ‘barrels’ receiving input from individual whiskers in a 1:1 ratio (Borgdorff et al. 2007). To examine the response of glial cells to physiological sensory stimulation in vivo, we therefore adapted a protocol developed by Wang et al. that uses small air puff stimulate the whiskers whilst simultaneously imaging the relevant whisker barrel with 2PLSM (Wang et al. 2006). The benefit of air puff whisker stimulation over for instance electrical stimulation is that it is non-painful, and can thus be used in awake mice. However, other methods such as electromagnetic movement of microbeads or electrical nerve stimulation may be superior overall (Borgdorff et al. 2007). The benefit of whisker stimulation compared to other forms of sensory stimulation (e.g. hindlimb electroshock) is that whisker sensation in mice is a highly developed sensory modality that takes up a large part of the cortex (Winship et al. 2007). Somatotopic mapping of individual whiskers to their respective whisker barrels is also highly specific (Fig. 19). The difficulty with this form of stimulation is to avoid stimulating other whiskers than the one of interest (usually accomplished by trimming them) and to avoid stimulating the face (accomplished by puffing parallel to the snout) (Wang et al. 2006). In conclusion, we found that whisker
LH stimulation was a good non-invasive way of generating neuronal activation in the sensory cortex.

**Figure 19.** The somatotopic mapping of whiskers to cortical whisker barrels in rodents. **A.** Diagram illustrating the convention for labeling individual whiskers and their projection via trigeminal ganglion cells in the brain stem and thalamic projection neurons to whisker barrels in layer IV of the somatosensory cortex. **B.** Cytochrome oxidase stained tangential section of layer IV barrel cortex. **C.** Dodt gradient contrasted acute coronal section through rodent barrel cortex showing the cortical layers (I-VI) and individual whisker barrels (star). Adapted with permission from Schubert et al. 2007.

**Immunohistochemistry.** In several of our studies, we used immunohistochemistry to allow the accurate anatomical and cellular localization of putative molecular targets. This technique is based on the principle that when one cuts thin specially preserved slices of brain tissue; these slices can be stained with a primary antibody specific for the molecule of interest. A secondary antibody that binds the primary antibody and is cross-linked to for instance a fluorescent molecule then visualizes the primary antibody (Saper and Sawchenko 2003). Immunohistochemistry has several limitations, including a complete lack of temporal resolution (unless serial immunohistochemistry is performed at different time points). Moreover, the spatial resolution depends directly on the method used to visualize the immunohistochemistry. Confocal immunofluorescence microscopy is, for instance, limited by the aforementioned theoretical limit of resolution for the wavelength of light used. Transmission electron microscopy is, on the other hand, usually only limited by the size of the primary and secondary antibody complex employed for e.g. immunogold labeling (Ottersen et al. 1996). Finally, immunohistochemistry is
primarily limited by the sensitivity and specificity of the antibodies used. Unfortunately, many of antibodies that are commercially available are of poor quality. Several steps are routinely run to control for unspecific labeling, e.g. adding human/bovine serum albumin or milk powder to the antibody solution, omitting primary antibody and reabsorbing the primary antibody solution with the peptide used for immunization (Fritschy 2008). However, many investigators feel one cannot truly know the antibody specificity until tissue from mice where the molecule of interest is knocked out is stained and the staining found to be entirely negative (see paper I).

**Laser Doppler Flowmetry.** This is an optical technique where a collimated laser beam is split, and the two coherent laser beams are focused on red blood cells passing through blood vessels (Carter 1991). Because the laser scattered from the red blood cells will be Doppler shifted proportionate to the velocity of the cells, it will not be coherent with the incident light and generate interference. This causes the intensity of the reflected light that the device detects to fluctuate with a frequency that is proportional to the Doppler shift and thus the velocity of the red blood cells. The name of this technique is thus a misnomer, as the device actually measures velocity and not flow. Laser Doppler flowmetry as a measure of cerebral blood flow has several sources of error. Most importantly, the optics is dependent on the incident laser light being at right angles to the blood flow that one wishes to measure. Additionally, it is not possible to get an absolute measure of blood flow, but only record changes in blood velocity. Finally, laser Doppler flowmetry is heavily influenced by blood flow in meningeal vessels superficial to the brain, and these vessels may not necessarily directly reflect cerebrovascular changes.

**Evans blue extravasation.** Evans blue is a chemical dye that has a high affinity for blood albumin, and which fluoresces at 680 nm when excited between 470-540 nm (Vise et al. 1975). The BBB is largely impermeable to macromolecules such as albumin. Systemic administration of Evans blue is therefore frequently used as an assay of BBB opening in disease states (Kaya and Ahishali 2011). The principal limitation of this technique for studying BBB permeability is that not all BBB opening may be characterized by increased permeability to macromolecules such as albumin. A more extensive characterization of BBB permeability thus often involves using other chemicals of different sizes. Finally, it can be beneficial to use Evans blue
pre-bound to albumin as in our study, since some of the chemical may remain unbound to albumin and can cross the BBB.

**Brain water content.** To obtain a measure of overall brain water content we used the extensively published wet/dry-brain weight method. The method is based on the comparison of brain weight immediately after removal from the animal (wet weight) with the brain weight after all water content has been evaporated in an 80°C oven for 24 hours (dry weight). Percent brain water content can then be computed by: wet weight-dry weight/wet weight. The main issue with this method is the reproducibility depends heavily on brain extraction, drying and weighing having been conducted in the exact same way. Delays in brain extraction can for instance rapidly reduce brain water content through evaporation (Haj-Yasein et al. 2011b).

**Intracranial pressure (ICP).** When significant brain edema is allowed to accumulate, pressure will begin to build up inside the rigid confines of the skull. This increase in ICP can be monitored clinically in neurosurgical patients by the implantation of pressure probe through a small craniotomy. We employed a similar approach in our mice, and implanted a pressure probe in the cerebral hemisphere to monitor ICP changes during conditions thought to elicit brain edema (Statler et al. 2001). ICP has a characteristic waveform pattern reflecting the pressure fluctuations in the cardiac cycle. The sources for error when using ICP probe include failure to calibrate the probe properly (cannot get absolute reading), failure to allow the ICP recording to stabilize (results in drift) and manipulation of the transducer wire (causes false ICP fluctuations). Finally, to accurately interpret ICP recordings it is essential to also record mean arterial pressure. We did this by implanting a catheter in the femoral artery connected to an external pressure probe. Using ABP it is possible to calculate cerebral perfusion pressure, using the formula: cerebral perfusion pressure = mean arterial pressure – ICP. Normally, cerebral blood flow stays within a narrow range despite variation in blood pressure due to cerebrovascular autoregulation. However, when ICP reaches critical levels cerebral perfusion pressure can become insufficient to supply adequate blood to the brain.

**NMR spectroscopy.** Atomic isotopes that contain an odd number of protons and neutrons act as small magnets (e.g. ¹H). When these isotopes are placed in a strong
externally applied magnetic field, their magnetic poles will tend to align with the field. NMR spectroscopy exploits the principle that if a radiofrequency pulse of a specific frequency is applied to this magnetic field it will tend to disturb the alignment of the isotopes (Behar et al. 1993). The frequency required is the resonance frequency of the isotope, and this will typically bring the isotope to a higher energy state. The isotope will after a time emit the energy in the form of electromagnetic radiation to return to its alignment in the magnetic field. The resonance frequency not only varies from isotope to isotope, but each individual isotope will also have different resonance frequencies depending on their atomic microenvironment. The latter is termed a chemical shift, and can be referenced to a ‘standard’ where there is little distortion from nearby atoms. In our study, we used $^1$H-isotope that is abundantly present in biological tissue and water. When the $^1$H-NMR signal intensity is plotted against chemical shift (‘NMR spectrum’), several peaks representing $^1$H present in different molecules (e.g. lactate, glutamate). A major issue with $^1$H-NMR is that biological tissues are largely made up of water, generating a large $^1$H-NMR signal. This is usually addressed by dehydrating tissues and reconstituting them with deuterized ($^2$H) water. Standard $^1$H-NMR is therefore incompatible with in vivo analyses, and is performed on homogenated tissue. Because it uses homogenates, however, care needs to be taken to stop enzymatic reactions immediately after extracting the tissue. This is usually achieved by freezing the tissue, followed by denaturing enzymes with a strong acid. Another source of error is that $^1$H-NMR spectra are very sensitive pH or free protons, and changes in pH can cause some $^1$H-NMR peaks to overlap. It is therefore essential to ensure consistent pH between specimens, and use the pH ideal for resolving the peaks of interest without overlaps. Finally, $^1$H-NMR results are frequently reported as concentrations of molecules of interest per unit brain volume. However, NMR can only detect relative amounts of molecules from the signal intensities, and concentrations need to be inferred e.g. by using a standard. This latter step can also introduce some variability to the results (Zwingmann et al. 2003).

**Disease models**

**Acute hyponatremic brain edema:** Hyponatremia is a reduction in the concentration of sodium in the blood. When this occurs acutely it leads to the accumulation of water in the brain; termed osmotic brain edema (Manley et al. 2000; Verbalis 2010). Common causes of hyponatremia in a clinical setting include salt loss in marathon runners,
aggressive intravenous fluid therapy in hospitalized patients and endocrine disorders such as syndrome of inappropriate anti-diuretic hormone (Verbalis 2010). We adapted a method to induce hyponatremic brain edema in mice by acutely injecting 20% (200 mL kg\(^{-1}\)) of the mouse body weight as distilled ion-free water i.p. This model generates robust brain edema, and has previously been used by several other groups as a model of osmotic brain edema (Nase et al. 2008). Previous groups have also added anti-diuretic hormone (vasopressin) analogue desmopressin (DDAVP) to the infused water, but in our hands this was unnecessary and might unintentionally alter AQP4 function (Manley et al. 2000; Moeller et al. 2009; Niermann et al. 2001). Our \textit{in vivo} model of hyponatremic brain edema in mice closely resembles related conditions in humans except for one key aspect. Clinical cases of hyponatremia frequently have a more protracted time-course, with more potential for CNS and extra-CNS (e.g. renal) compensation. Unfortunately a longer time course might be more difficult to image accurately, as calcium indicators are internalized and metabolized in the course of 2-3 hours. These sets of experiments therefore represent a compromise between a more ideal model of hyponatremia, and a model that progresses rapidly enough to allow study by 2PLSM.

\textit{Hepatic encephalopathy (HE)}: HE is brain impairment, ranging from confusion to coma, caused by the accumulation of waste products including ammonia in liver failure (Butterworth et al. 2009). In a clinical setting, hepatic encephalopathy is most frequently seen as a complication of alcoholic liver disease or as acute drug-induced liver failure (e.g. paracetamol overdose). We used the liver toxin azoxymethane to induce acute liver failure and consequent hepatic encephalopathy in mice. Azoxymethane was first discovered in 1960 in Guam, and was isolated as the active ingredient that causes ingested cycad palm nuts to be carcinogenic and hepatotoxic (Bélanger et al. 2006; Matkowskyj et al. 1999). This chemical model of HE has several benefits, in that it is very reproducible and encompasses all the relevant clinical and biochemical features of human HE. Azoxymethane is also one of the few models of HE that can be used in mice, which was an important prerequisite for our study that intended to use transgenic animals (Fig. 20) (i.e. \textit{Cx3Cr1-eGFP}) (Bélanger et al. 2006). Conversely, surgical models of HE (e.g. portocaval anastomosis) usually require the use of larger animals (Butterworth et al. 2009). However, in all chemical models of HE one cannot exclude that the drug itself has some CNS effects.
Moreover, most human HE is due to entirely different liver toxins (e.g. alcohol, paracetamol), and different toxic substances can generate quite disparate phenotypes. Finally, alcohol related HE frequently occurs in the context of acute-on-chronic liver failure, which again this model does not adequately depict (Butterworth et al. 2009).

![Figure 20](image.png)

**Figure 20.** The phenotype of azoxymethane-induced hepatic encephalopathy. Photographs of Evans blue injected mouse brains illustrating the increased BBB permeability in azoxymethane-induced HE; left (control) and middle (hepatic encephalopathy). Right: Hyperbilirubinemia in hepatic encephalopathy causes autofluorescent labeling of brain cells that can be imaged by 2PLSM *in vivo* (unpublished observation).

*Acute hyperammonemia encephalopathy:* Hyperammonemic encephalopathy is neurological dysfunction that results from elevated blood ammonia levels, and in a clinical setting this is most frequently seen in patients with liver disease (Cagnon and Braissant 2007). However, patients with liver failure also have a plethora of other biochemical disturbances, which likely contribute to the neurological phenotype and make it difficult to dissect out the role of ammonia. We therefore chose to examine a model of isolated acute hyperammonemia using a X-linked recessive condition called ornithine transcarbamylase (*Otc*) deficiency (Ratnakumari et al. 1992). Because the enzymatic detoxification of ammonia in the liver via the urea cycle is compromised, both mice and humans with this condition are prone to developing rapid rises in plasma ammonia. Although these *Otc* mice can develop spontaneous hyperammonemic episodes, or dietary-induced episodes (e.g. protein load), we chose to induce acute hyperammonemic encephalopathy by giving a parenteral ammonia load (Moscioni et al. 2006; Ye et al. 1997). This ensured both reproducibility and a short time course ideal for 2PLSM imaging. The plasma ammonia concentrations we recorded using this model was within the range reported for clinical cases (Cagnon and Braissant 2007). However, a major limitation of this model is that time course ammonia intoxication may be more hyperacute than that seen in human cases.
8. SUMMARY OF RESULTS

I. Critical role of aquaporin-4 (AQP4) in astrocytic Ca\(^{2+}\) signaling events elicited by cerebral edema

Hypo-osmotic brain edema is a potentially fatal condition where swelling occurs as a result of a decreased concentration of osmolytes such as sodium. We used 2PLSM to explore the role of astrocyte swelling and volume related calcium signaling in this condition.

First, we showed that acute hypo-osmotic stress causes brief (5-10 min) astrocyte swelling \textit{in situ}, followed by a prolonged regulatory volume decrease. The initial swelling, but not the volume decrease, was AQP4-dependent. Additionally, severe osmotic stress led to irreversible astrocyte swelling and cell lysis. Second, we demonstrated that hypo-osmotic brain edema increased the frequency and prolonged the duration of astrocyte calcium transients, which was also AQP4-dependent. We therefore hypothesized that \textit{Aqp4} deletion suppressed the calcium response by limiting water influx and thus volume changes associated with hypo-osmotic stress. Third, we found that applying purinergic P2 receptor antagonists suppressed calcium transients evoked by astrocyte swelling. Finally, we showed that cultured \textit{Aqp4}\(^{+/+}\) but not \textit{Aqp4}\(^{-/-}\) astrocytes exposed to hypo-osmotic stress released significant amounts of ATP.

We concluded that during hypo-osmotic brain edema AQP4 is necessary for astrocytes to sense osmotic changes and generate volume related signals. These included calcium transients evoked by ATP release that would contribute to a worse clinical outcome by triggering the release of excitotoxic neurotransmitters.
II. NADH fluorescence imaging indicates effect of aquaporin-4 deletion on oxygen microdistribution in cortical spreading depression

CSD is a wave of tissue depolarization linked to migraine, which is accompanied by tissue hypoxia in regions furthest away from the vasculature (microwatershed areas). We used 2PLSM imaging of intrinsic NADH fluorescence during CSD to reveal a previously unrecognized role of AQP4 in cortical oxygen distribution.

We found that deletion of the astrocyte water channel \textit{Aqp4} causes a selective increase of NADH fluorescence in microwatershed areas, indicating greater hypoxia in these regions. Using laser Doppler flowmetry and oxygen sensitive microelectrodes we demonstrated that this hypoxia is not a result of decreased overall oxygen or blood supply. Next, we tested whether \textit{Aqp4} deletion worsens oxygenation through increasing the metabolic demand. The profound increase in [K$^+$]$_o$ that is the hallmark of CSD is believed to cause a unique strain on ion and volume homeostasis in the brain. Using potassium ion sensitive microelectrodes we show that \textit{Aqp4} deletion slows [K$^+$]$_o$ recovery, which might cause oxygen overuse. Alternatively, our data could indicate that AQP4 acts as a gas channel, facilitating oxygen diffusion from the vasculature to microwatershed regions.

In conclusion, our results suggest a novel role for AQP4 in oxygen microdistribution during CSD. Our data indicate that this AQP4 related hypoxia is either a result of AQP4 mediated gas diffusion or AQP4 facilitated potassium ion transport.
III. General anesthesia selectively disrupts astrocyte calcium signaling in the awake mouse cortex

General anesthesia is thought to induce sedation and unconsciousness by exclusively interfering with neuronal signaling. However, the effects of anesthesia on glial cells have not previously been systematically explored. We therefore proceeded to use 2PLSM to explore the effect of several commonly used anesthetics on astrocyte calcium signals in awake behaving mice.

We found that all three anesthetics tested in our study potently suppressed spontaneous calcium signals both in the soma and processes of neocortical astrocytes. The anesthetics also altered the pattern of astrocyte calcium signaling; from highly synchronized in the awake state to largely unsynchronized with anesthesia. Additionally, we demonstrated that calcium signals evoked by physiological sensory (whisker) stimulation were also strongly suppressed by anesthesia. Several lines of evidence indicate that our observations were not secondary effects of the anesthetics silencing neuronal activity: a) Astrocyte signals were suppressed by lower doses of anesthesia than those required to block neuronal activity. b) A local blockade of neuronal activity using TTX or CNQX/AP5 completely suppressed neuronal but not glial signals. c) Similar to previous studies we observed a delay of 0.5-5s between cortical neuronal activation and the astrocyte calcium transients. This delay suggests that astrocyte signaling may be mediated by extra-synaptic events. Finally, we show that the anesthetic effect on astrocytes could be explained by a direct impairment of calcium mobilization via IP₃R2-dependent mechanisms, as astrocyte calcium signaling in response to local agonist (ATP) was also selectively reduced by anesthesia.

In conclusion, anesthetics appear to selectively suppress astrocyte calcium signals. It is therefore possible that some of the sedative effects of these drugs may be mediated via glial targets that are not fully exploited by current pharmacology.
IV. Paravascular microcirculation facilitates rapid lipid transport and astrocyte signaling in the brain

Unlike peripheral organs, the brain is entirely devoid of a separate lymphatic system to resorb interstitial fluid and transport lipids. A recent study identified a paravascular circulation of hydrophilic molecules in the anatomically distinct PVS. However, the paravascular transport of lipophilic substances has not been explored in vivo. Our study aimed to address two related unanswered questions: does the PVS mediate rapid lipid transport and can the PVS act as a separate signaling compartment to coordinate glial communication?

We administered lipid tracers into subarachnoid CSF via the cisterna magna and demonstrated that they move rapidly through the brain parallel to blood vessels. We found that the circulation of lipid tracer was highly restricted to the PVS, indicating that the PVS may serve as a dynamic barrier to lipid diffusion into the brain parenchyma. The lipid tracer entered the brain via a para-arterial and exited via a para-venous route. We were able to enhance the intra-cellular delivery of lipophilic tracer molecules by surgically depressurizing the subarachnoid space. Finally, depressurizing the PVS caused an impairment of desynchronized calcium signaling. To further test this hypothesis of the PVS acting as signaling compartment, we took advantage of one of the most widely used astrocytic calcium wave agonists - ATP. ATP was injected into both the PVS and surrounding parenchyma. Interestingly, the propagation of the calcium wave in astrocytes elicited by PVS ATP administration was much faster and covered a larger diameter than intraparenchymal administration.

Taken together, we demonstrated a novel pathway for the rapid and highly selective microcirculation of lipophilic molecules through paravascular CSF. We show that the PVS acts as a signaling highway between astrocytes, and when knocked causes a pathological pattern of glial communication.
V. **Real-time analysis of microglial activation and motility in hepatic and hyperammonemic encephalopathy**

The role of microglial activation and/or dysfunction in hepatic encephalopathy is incompletely understood and has only been studied *ex vivo*. We used 2PLSM in Cx3cr1-eGFP mice to image dynamic changes in microglial morphology and surveillance behavior in real-time.

We used a model of isolated hyperammonemia that generated robust but reversible encephalopathy (lethargy, ataxia and myoclonic seizures). Contrary to some previous reports, we found no BBB opening or brain edema in this condition. Additionally, we were unable to detect any microglial activation or change in surveillance behavior. Next, we adapted a chemical mouse model of hepatic encephalopathy using azoxymethane, characterized by a slower plasma ammonia increase. Phenotypically the mice progressed through successive stages of encephalopathy including lethargy, ataxia and finally coma, but no seizures. Contrary to the acute hyperammonemia model, we found both increased BBB permeability (leakage) and brain edema at the coma stage. Using 2PLSM imaging, we demonstrated microglial activation and decreased microglial surveillance during the coma stage, but not prior to the onset of neurological dysfunction.

In conclusion, our data suggest that microglial activation does not contribute to the initial neurological dysfunction seen in isolated hyperammonemia. Conversely microglial activation is present during the coma stage of hepatic encephalopathy, where it coincides with BBB opening and brain edema. Microglial activation may therefore contribute to overall mortality in hepatic encephalopathy by accelerating the progression to brain edema and coma.
VI. Ammonia compromises astrocyte potassium buffering and impairs neuronal inhibition without causing swelling in vivo

Ammonia is both a vital building block and a lethally neurotoxic compound if allowed to accumulate. To explore the molecular mechanisms underlying the acute neurotoxicity of ammonia we employed a combination of biochemical, electrophysiological, genetic and optical imaging methods in vivo.

We chose to use a mouse model of congenital Otc deficiency, a childhood condition in which liver ammonia detoxification is dysfunctional, causing elevated plasma ammonia. Otc<sup>enp-ash</sup> mice have cognitive and motor deficits at baseline that significantly worsened following an ammonia challenge and were accompanied by generalized seizures. We showed that ammonia induced seizures originate in the cortex, and are associated with a dysfunction of inhibitory neurotransmission. Using in vivo 2PLSM we demonstrated that this neuronal dysfunction was secondary to an impairment of astrocyte calcium signaling, [K<sup>+</sup>]<sub>e</sub> handling, but not astrocyte swelling (as previously hypothesized). This severe dysfunction of astrocyte potassium buffering was likely due to the competition of ammonium with potassium for membrane transport. Finally, we showed that the elevated [K<sup>+</sup>]<sub>e</sub> and/or [NH<sub>4</sub>]<sup>+</sup> increase the electrochemical gradient Cl<sup>-</sup> import via NKCC1, depolarizing the reversal potential of GABA<sub>A</sub> receptor (E<sub>GABA</sub>). Using either the highly selective NKCC1 antagonist bumetanide or Slc12a2 KO, we were able to rescue the shift in E<sub>GABA</sub> and reverse the disease phenotype.

In conclusion, we demonstrate a novel molecular mechanism for the acutely neurotoxic effects of ammonia, which are primarily results of a profound dysfunction astrocyte ion homeostasis. By specifically targeting this disease mechanism we were able to treat this fatal childhood neurological disorder.
9. DISCUSSION AND FUTURE DIRECTION

In the last 20 years the application of new experimental tools such as calcium imaging and 2PLSM has revealed that normal brain function requires both neuronal and glial cells acting in concert (Nedergaard and Verkhratsky 2012). The late realization that glial cells play an active role in brain function likely reflects the unique challenges faced when studying glial neurobiology. For instance, glial research requires techniques offering both high temporal and spatial resolution, as well as being sensitive to tissue distortion or injury (Agulhon et al. 2012). Although several new techniques such as 2PLSM have been applied to glial research in recent years, many of the basic disease models that have been studied are adaptations of neurocentric research paradigms. Such models, including acute hippocampal slices and primary cell culture, may not be equally representative of glial physiology (Sun et al. 2013). In an attempt to overcome these obstacles and increase the translational potential of our research, we primarily employed \textit{in vivo} animal models. The following is a discussion of what our studies add to current understanding of glial neurobiology, the critical limitations of the data and the important questions that remain open for future study.

\textbf{AQP4 and astrocyte volume homeostasis.} Since the Nobel-prize winning set of first experiments, it has been known that cells expressing aquaporins undergo rapid volume change in response to osmotic stress (Preston et al. 1992). Several prominent studies have subsequently suggested that by virtue of their high AQP4 expression, astrocytes are more likely to swell than other brain cells. AQP4 has therefore been suggested as a novel therapeutic target in brain edema (Amiry-Moghaddam and Ottersen 2003; Manley et al. 2000). However, the data supporting this hypothesis have several limitations, including using reduced preparations (e.g. cultured astrocytes) and post-mortem studies of cell volume (e.g. electron microscopy). Additionally, studies of \textit{Aqp4} KO mice have revealed that the water channel may be either beneficial or detrimental depending on the type of brain edema elicited (Papadopoulos and Verkman 2007). Finally, imaging studies that have attempted to show astrocyte swelling in living tissue have either had technical limitations (Nase et al. 2008) (did not assess tissue perfusion) or have not found significant volume change (Risher et al. 2012; Takano et al. 2007; Zhou et al. 2010). Could there more to the story than AQP4 rendering astrocytes prone to passive swelling? Since the 1980s
it has been known that primary cultured astrocytes respond dynamically to hypo-osmotic stress, first swelling and then undergoing regulatory volume decrease (RVD) (Kimelberg 1987; Olson et al. 1986). The latter process is incompletely understood, but believed to involve the activation of volume-regulated channels, leading to the efflux of amino acids, ATP, glutamate, K\(^+\) and Cl\(^-\). Although volume-regulated anion channels can be inferred using electrophysiology, their actual molecular identity is still unknown (Okada et al. 2009; Takano et al. 2005).

In an attempt to address the role of AQP4 in astrocyte volume regulation, we developed a method for high-resolution astrocyte volumetry in acute cortical slices using 2PLSM. Similar to the original in vitro studies, we found that the response of astrocytes to hypo-osmotic stress is dynamic. We observed a very brief AQP4-dependent initial swelling, followed by robust RVD that was nominally AQP4-independent. The volume dynamics we observed in situ were even faster and smaller than those previously reported in vitro. Thus at least in the context of healthy brain slices, astrocytes are capable of very tight volume control that is AQP4-dependent. Conversely, when the degree of osmotic stress was increased, astrocytes underwent passive AQP4-dependent swelling before inevitable cell lysis.

However, our study has several limitations. First, we employed an in situ and not in vivo model to achieve higher-resolution volume measurements in a setting where we could control osmotic stress precisely. Conversely, the astrocytes were exposed to trauma in the cutting process, had depressurized blood circulation and were derived from young mice that express a different subset of proteins (Sun et al. 2013). Our results also showed that the type of astrocyte response depended on the degree of osmotic stress and the health of the tissue. All of these factors may contribute to altered astrocyte volume dynamics, perhaps resulting in a slower RVD than in vivo. We suggest that the lack of direct evidence of astrocyte swelling and RVD in vivo may reflect the high speed at which these events occur in intact perfused brain (Takano et al. 2007; Zhou et al. 2010).

Our results raise several new questions. First, do astrocytes swell and/or undergo RVD in vivo? As the temporal and spatial resolution of imaging improves, we may be able to better address this question, and also examine volume changes in microdomains (i.e. individual processes) (Haj-Yasein et al. 2012). The polarized AQP4 distribution in endfeet could indicate that this microdomain senses or modulates volume changes associated with fluctuations in blood flow. Additionally,
the high AQP4 expression in astrocytes but not neurons could imply a specialized function in rapid and tight volume regulation, instead of the aforementioned interpretation that astrocytes swell easily. Hence, if astrocyte swelling is not responsible for the brain edema observed in hypo-osmotic conditions, could the increase in tissue water content reflect neuronal swelling? It is conceivable that in the evolutionary division of labor between astrocytes and neurons, that the latter have sacrificed tight volume regulation to attain more specialized signaling functions. Astrocytic RVD may represent a compensatory mechanism for this and avoid detrimental extracellular space shrinkage (with increased ion and neurotransmitter concentrations)? If AQP4 does not solely mediate increased brain edema through facilitating astrocyte swelling, then why is *Aqp4* deletion beneficial in these conditions? Could the increased and pathological astrocyte calcium activity observed in our study, with associated release of excitotoxic transmitters, explain some of this phenotype? The answers to these questions will be essential when designing new therapies for brain edema targeting AQP4 (Amiry-Moghaddam and Ottersen 2003). Finally, what is the molecular identity of volume-regulated anion channels in astrocytes? The answer to this question may be closely related to current contention around the notion of gliotransmission and connexin hemichannels, as neuronal firing causes brisk extracellular space shrinkage and several of the molecules released by volume-regulated anion channels have direct actions on neurons (Okada et al. 2009).

**AQP4 and cerebral oxygen microdistribution.** CSD is a curious and highly reproducible phenomenon where a self-sustaining cortical wave of neurodepression and depolarization can be elicited by focal cortical application of concentrated KCl (Leao 1947). Although the relationship is not clear, CSD has been linked the initiation of migraine headaches, often being cited as an electrochemical correlate of the migraine aura (Lauritzen et al. 2011). Similar self-sustaining waves of spreading depolarization can also be elicited in a range of other neurological conditions, including stroke (anoxic depolarization), traumatic brain injury, intracerebral and subarachnoid hemorrhage (Lauritzen et al. 2011). Additionally, CSD pathophysiology shares several features with epilepsy. Both are episodic disorders that have been linked to mutations in ion channels or transporters that alter neuronal excitability (Takano and Nedergaard 2009). Experimentally, it is possible to trigger either seizures or CSD *in vivo* with intermediate (10-20 mM) or high (>50 mM) potassium.
concentrations, respectively (unpublished observations). CSD therefore appears to occur only when local \([K^+]_o\) reaches a threshold that is such a large strain on ion homeostasis that all neurons in an area remain depolarized and refractory for a sufficient time to prevent recurrent excitatory loops arising.

Several studies have suggested that vasoconstriction and impaired neurovascular coupling may explain parts of the hypoxia and potassium dyshomeostasis seen in CSD (Chuquet et al. 2007; Piilgaard and Lauritzen 2009). However, CSD is initially characterized by significant global and capillary-level hyperemia when the tissue is most hypoxic in animal studies (Lauritzen and Fabricius 1995; Takano et al. 2007). The almost therapeutic effects of anesthesia in CSD might explain part of this inconsistency between awake human and anesthetized animal studies. General anesthesia reduces neuronal exciteability, decreases cerebral metabolic rate and likely as a consequence reduces baseline blood flow so that the initial hyperemia response to CSD becomes more obvious (Lauritzen et al. 2011; Sonn and Mayevsky 2006). Taken together, insufficient blood supply does not appear to cause the initial hypoxia seen in CSD.

As tissue depolarization precedes the hypoxia this in turn suggests that the inadequate oxygenation is a result of the large the metabolic strain of potassium re-uptake (presumably via the NKA). NADH imaging demonstrates that this excess metabolic activity occurs primarily close to blood vessels, effectively depriving areas far from the circulation of oxygen (i.e. microwatersheds). Conversely in anoxia, tissue hypoxia precedes the wave of depolarization and there is no characteristic biphasic pattern of NADH signals, such as that seen in CSD (Takano et al. 2007). Subsequent NADH studies have also shown that mild hypoxemia or increased neuronal activity can also be used to reveal these geometrically shaped biphasic NADH responses. These fundamental observations are likely a biochemical (NADH) correlate of the theoretical Krogh oxygen diffusion cylinders that surround oxygen-rich vessels (i.e. arterioles). Moreover, these limits of oxygen tissue diffusion likely explain key aspects of microvascular anatomy, such the ‘cylinder’ of low capillary density surrounding oxygen rich arterioles in brain and retina (Kasischke et al. 2011). Since the physical limitations of oxygen diffusion and potassium re-uptake are so fundamental to the vascular microanatomy of nervous tissue, we therefore asked whether any molecular adaptations exist to improve microwatershed oxygenation.
Using *in vivo* NADH imaging we showed that during the unique metabolic strain elicited by CSD, AQP4 is necessary for efficient oxygenation of watershed areas. Our observations have several limitations and potential explanations. First, this study was carried out in anesthetized animals, where neuronal excitability would be strongly affected by the choice of anesthetic (i.e. urethane in this case), which might confound the results (Sonn and Mayevsky 2006). However, CSD is arguably such an overwhelming phenomenon that it should be less biased by anesthetics than for instance seizures (Sonn and Mayevsky 2006). Second, ours and other recent NADH-studies have unfortunately lacked cellular resolution, so we are unable to say what cell types become most metabolically compromised. Conversely, the morphological data from Takano et al. seem to indicate that neurons, which show swelling and loss of dendritic spines, are more severely affected than astrocytes (Takano et al. 2007). Third, our study was conducted in constitutive Aqp4 KO mice, and AQP4 expression in other cells or organs could hypothetically explain the excess hypoxia. On the other hand, recent work on glial conditional Aqp4 KO has revealed that these mice have an almost identical phenotype (although CSD has not been explored) (Haj-Yasein et al. 2011c).

Finally, given that we detected a hyperemic response similar to Takano et al. (i.e. adequate blood supply), there are two competing hypothesis that could explain our results. 1) AQP4 may be necessary for the energy efficient function of potassium transporters, such as NKA, by rapidly dissipating any osmotic gradients that are built up. Other forms of AQP4-facilitated potassium transport (e.g. Kir4.1 mediated spatial buffering) are likely to play a lesser role, as the [K⁺]o increase is so global that redistribution would be ineffective (Padmawar et al. 2005). 2) Alternatively, the central pore formed by AQP4 tetramers may enhance the O₂ permeability of astrocyte membranes. Aquaporin-assisted gas diffusion is a controversial hypothesis, but one that may be particularly relevant in a subset of membrane microdomains such as the astrocytic endfeet. The protein density in endfoot membranes is extremely high, mainly due to AQP4 orthogonal arrays, and this may decrease the rate of O₂ diffusion across the lipid bilayer (Wang et al. 2007). Per unit weight brain and retinal tissue have the highest oxygen consumption in the body (Kur et al. 2012). The AQP4 central pore could therefore represent an evolutionary adaptation to enhance oxygen diffusion across protein-enriched membranes such as astrocytic endfeet. Hypothetically AQP4-
assisted O₂ diffusion would increase the size of arterial Krogh cylinders, and improve watershed oxygenation (Fig. 21). However, the hypothesis that aquaporins increase gas diffusion across the lipid bilayer is still very contentious, and unfortunately our data cannot conclusively differentiate this hypothesis from the alternative ion-transport model (Fang et al. 2002; Musa-Aziz et al. 2009; Wang and Tajkhorshid 2010).

Fig 21. Effect of AQP4 deletion on cortical oxygenation. Left 2 panels: Representative false color images of NADH signal intensity in cortex of WT and AQP4 KO mice during CSD. FITC-dextran labeled vasculature is shown in white. Key: red represents +60% and green -60% NADH signal intensity normalized to baseline. Right 2 panels: Illustration of the hypothetical interplay between AQP4, potassium buffering and microwatershed oxygenation in CSD.

**Astrocyte calcium signaling in wakefulness and anesthesia.** In 1990 Cornell-Bell et al. showed that astrocytes respond to glutamate by generating waves of increased intracellular calcium (Cornell-Bell et al. 1990). This seminal study opened the possibility that astrocytes might contribute to synaptic signaling on an equal footing to neurons, leading to the tripartite synapse hypothesis (Araque et al. 1999). Using 2PLSM imaging this hypothesis has subsequently been tested in *in vivo*, where it was demonstrated that astrocytes respond to physiological sensory stimulation in a glutamate-dependent fashion (Wang et al. 2006; Winship et al. 2007). However, most of our current understanding of astrocyte calcium signaling still derives from cultured astrocytes, brain slices or anesthetized whole animals. Because of inherent limitations in each of these methods, several investigators have recently begun to question the fundamental tenets of the tripartite synapse model (Agulhon et al. 2008; Nedergaard and Verkhratsky 2012). The main receptor (mGluR5) implicated in astrocyte-neuronal signaling is, for instance, only expressed in young mice used for acute brain slices (Sun et al. 2013). More recently, two groups have independently developed methods to image glial calcium signals in the cerebellum and motor cortex of awake head-restrained mice (Dombeck et al. 2007; Nimmerjahn et al. 2009). Both these studies found greater spontaneous calcium activity that was highly synchronized, in
stark contrast to the individual infrequent calcium signals seen in anesthetized mice. We therefore proceeded to image astrocyte calcium activity in the sensory cortex of awake and anesthetized mice, to see if this would provide further clues as to 1) the direct effects of anesthetics on astrocytes and 2) the nature and mediators of physiological astrocyte calcium signals.

To start with the first question, we asked whether anesthetics might mediate some of their sedative effects via astrocytes, instead of neurons. General anesthetics are a class of sedative drugs used to induce a reversible sleep-like loss of consciousness (hypnosis), amnesia, immobility and insensitivity to painful stimuli (analgesia). The principal targets for the sedative effects of these drugs are thought to be neuronal receptors or channels, but recently some anesthetics have also been reported to affect astrocyte signaling ex vivo (Mantz et al. 1993; Miyazaki et al. 1997; Tian et al. 2005; Yang et al. 2008). Our data demonstrate that: 1) Three commonly used anesthetics with putatively different neuronal targets all cause a similar global suppression and desynchronization of astrocyte calcium signals. 2) Anesthesia begins to affect astrocyte before neuronal signaling, although this result should be interpreted a bit more cautiously as we are comparing astrocyte calcium imaging with electrical neuronal activity. 3) Anesthesia also suppresses astrocyte calcium signals elicited by sensory stimulation and direct agonist (ATP) application.

The biggest challenge with interpreting our data is distinguishing the direct effects of anesthesia on astrocytes from those that occur secondary to neuronal changes. Perhaps the strongest argument supporting a direct effect of anesthesia on astrocytes, was the marked suppression of agonist-evoked calcium responses. ATP application is known to trigger astrocyte calcium transients without requiring neuronal firing (Cotrina et al. 1998). Our results are also supported by previous in vitro work that has demonstrated anesthesia can directly impair astrocyte calcium mobilization and signal propagation (Mantz et al. 1993; Miyazaki et al. 1997; Yang et al. 2008). Thus, in conclusion, our findings have two important implications with regards to future research: 1) Further study on the effects of anesthesia on astrocyte signaling is needed, as this could lead to a better understanding of current anesthetic agents and more important reveal novel glial pharmacological targets. 2) We also strongly suggest that future studies of astrocyte calcium signaling approach the use of anesthesia cautiously, as they can fundamentally confound results.
Another question we addressed in our study is what characterizes physiological calcium signaling in the awake cortex. Our study revealed a more than 10-fold greater frequency of spontaneous calcium transients in awake than anesthetized animals, which were highly synchronized, and appeared more like sudden bursts than the typical waves described \textit{in vitro}. The pattern of calcium activity we observed in the somatosensory cortex was very consistent with what the two previous awake imaging studies from motor cortex and cerebellum (Dombeck et al. 2007; Nimmerjahn et al. 2009). Moreover, similar synchronized bursts across hundreds of astrocytes can also be elicited in lightly anesthetized animals with whisker stimulation (Wang et al. 2006). In our study we expand on these observations, and showed that sensory-evoked astrocyte calcium signals disappear altogether with increasing doses of anesthesia (Schummers et al. 2008). Additionally, we found that sensory-evoked calcium signals occur at a delay of 1-5 s relative to the firing of cortical neurons, and that these responses are entirely dependent on IP$_{3}$R2 signaling (Dombeck et al. 2007; Nimmerjahn et al. 2009; Wang et al. 2006). Conversely, spontaneous and evoked astrocyte calcium signals were highly resistant to a blockade of local purinergic or glutamatergic activity (using TTX, PPADS/suramin or CNQX/AP5), as has also been reported in cerebellar Bergman glia (Nimmerjahn et al. 2009). At first glance these observations appear to challenge several key elements of the tripartite synapse model, which predict that a local neuronal or purinergic blockade abrogates astrocyte signals.

However, there are several important considerations with ours and the previous two awake imaging studies, which may help explain these results. First, our imaging was conducted only in layers 1 and 2 of the cortex, and our electrophysiology suggested that surface drug application primarily affected these layers. It is therefore possible that astrocyte calcium signals originating deeper in the cortex can propagate radially via mediators that act on IP$_{3}$R2 receptors, but are not dependent on axonal transmission, glutamate or ATP (Nimmerjahn et al. 2009). This form of radial propagation could also explain the faster bursts observed in awake cortex, as compared to the slower waves seen \textit{ex vivo}. Second, several diffuse neuromodulatory systems exist that are activated concurrently with salient stimuli (e.g. whisker stimulation) and release neurotransmitters diffusely and synchronously via varicosities throughout the cortex. Stimulation of brain stem nuclei for noradrenergic and cholinergic systems have, for instance, both been shown to elicit robust cortical
astrocyte calcium responses in anesthetized animals (Bekar et al. 2008; Navarrete et al. 2012; Takata et al. 2011). Third, the puzzling 1-5 s astrocyte-neuronal delay could imply either a very slow response to local neuronal firing (e.g. slow neurotransmitter spillover from the synaptic cleft) or that a slower indirect pathway (e.g. noradrenergic system) triggers the calcium responses. The delay could for instance also serve a purpose if it reflects the time it takes for neuronal firing to deplete ATP stores, when astrocyte calcium signals might be required promote neurovascular or neuro-metabolic coupling (Takano et al. 2006). Fourth, our first study (Paper I) revealed that astrocyte volume changes evoke calcium signals in vivo. Since astrocyte endfeet have the highest AQP4 expression and thus would be the most volume sensitive, it is possible that astrocyte calcium signals occur in response to the mechanical distortion caused by functional hyperemia, which occurs on a 1-5 s timescale (Takano et al. 2006). Finally, two recent in situ studies that used high-resolution 2PLSM have revisited the interesting idea that calcium signals in individual processes may be more relevant to brain or synaptic function the signals in the cell body (Di Castro et al. 2011; Wang et al. 2006). Although the conclusions of these studies need to be interpreted cautiously due to the ontogenic changes in mGluR5 expression (Sun et al. 2013), the general idea of processes signaling independent of the soma is potentially important. We therefore also examined calcium signals in the processes in the awake mouse cortex, and found that although all processes were generally involved in the synchronized bursts, individual processes would also display more frequent isolated signals (Wang et al. 2006). Further exploration of the kinetics and function(s) of these localized calcium signals in awake cortex will be an important next step for our understanding of astrocyte signaling.

In conclusion, our study demonstrates that anesthesia can directly suppress astrocyte signaling. More importantly, we show that calcium signals in the awake cortex are faster, more frequent and synchronized than those observed in situ and in vitro. Our observations highlight important questions regarding the tripartite synapse model, as it is based on studies carried out primarily in reduced preparations or anesthetized mice. We would therefore suggest that the fundamental question of how astrocytes and neurons communicate at the level of the individual synapse still remains unanswered (Nedergaard and Verkhratsky 2012; Perea and Araque 2007). Do astrocytes contribute to synaptic transmission by vesicular or non-vesicular neurotransmitter release (Hamilton and Attwell 2010)? How can astrocytes contribute
to signal transmission if their response time is so slow? Could some of the previous observations of astrocyte-neuronal signaling be artifacts of the experimental preparations (e.g. pup brain slices, traumatic cranial windows) (Agulhon et al. 2012; Sun et al. 2013)? Are synaptic signals somehow integrated within astrocytic microdomains, individual astrocytes or do we need to consider whole astrocytic syncytia (Rouach et al. 2008)?

**Rapid microcirculation of water and lipids through the PVS.** The brain is one of the few organs entirely devoid of a lymphatic system parallel to the blood circulation (Abbott 2004). Macroskopically, the circulation of CSF through the subarachnoid space and ventricles is known to serve many of the functions of peripheral lymphatics. However, the microcirculation within the brain parenchyma is incompletely understood. It is unclear how excess interstitial fluid, waste products and signaling molecules are circulated (Abbott 2004). A recent study by Iliff et al. has shown that water and hydrophilic compounds circulate rapidly through the brain parenchyma via the PVS (Iliff et al. 2012; Rennels et al. 1990). In our study, we address two essential functions of peripheral lymphatics – the transport of lipids and signal molecules. We found that lipophilic tracers injected into subarachnoid CSF were rapidly transported via the PVS with very little diffusion out of this space into the brain parenchyma. This observation was surprising given the small size (<1 kDa) and cell permeability of these tracers. It is possible that the restricted lipid transport is a consequence of lipoprotein binding within the PVS. Indeed, the lipophilic tracers behaved more like large molecular weight hydrophilic tracers, similar in size to lipoproteins (Fagan and Holtzman 2000; Koch et al. 2001). Unlike the results of Iliff et al. we did not find that this lipid transport pathway was affected by AQP4-deletion, indicating that other mechanisms may govern lipid bulk-flow (Iliff et al. 2012).

Moreover, we found that compromising the hydraulic integrity of the PVS enhanced the intracellular accumulation of lipophilic tracers and caused an abnormal pattern of astrocyte calcium signaling. Temporarily knocking out the PVS using a cisterna magna puncture, caused a desynchronization and increased frequency of calcium transients in astrocytes that may represent pathology. The second aim of our study was to examine whether the PVS can act as a separate astrocyte-astrocyte signaling compartment. The PVS is tightly ensheathed by astrocyte endfeet not more than 20 nm apart (Mathiisen et al. 2010). It has previously been shown that a large
proportion of calcium transients initiate and propagate along the vasculature (Simard et al. 2003). When we injected ATP agonist into the PVS \textit{in situ}, we similarly observed a propagation of astrocyte calcium transients along the vasculature before spreading outwards. Interestingly, these paravascular calcium waves were faster and spread over a larger area than when ATP was injected directly into the parenchyma.

Our data indicate that the PVS may act as an efficient highway for astrocyte-astrocyte signaling. However, there are several limitations of our findings. First, the lipophilic molecules used, with the exception of palmitic acid, are chemical tracers and we can only infer that similar sized endogenous lipids circulate in the same manner. It is therefore possible that unknown chemical properties of these tracers interfere with their transport. On the other hand, we tested a range of chemical lipophilic tracers along with a biologically relevant lipid (palmitic acid) and received reproducible results. Second, in our model to assess intracellular delivery we had to apply tracers directly on the cortex or inject them intraparenchymally via a cranial window. As discussed previously, the surgical creation of a cranial window is associated with molecular, cellular and mechanical changes that may confound the results (e.g. inflammation, brain herniation, depressurized local subarachnoid CSF flow) (Holtmaat et al. 2009). Third, in our attempt to look at global movement of tracers through the brain we were forced to use serial slicing of perfusion fixed tissue. The data from these sets of experiments reveal some of the inherent issues with this technique, such as the post-perfusion diffusion of lipid soluble compounds. Having acknowledged these limitations, our observations could still have important implications for current understanding of paravascular lipid circulation, membrane lipid metabolism (e.g. cholesterol and palmitoylation) and diseases involving lipoprotein mutations (e.g. Alzheimer disease). Further studies are clearly warranted to explore the effects of lipid transport in the PVS (Leoni et al. 2010; Takano et al. 2006). Although we demonstrated that the PVS is likely involved in astrocyte-astrocyte signaling, an important question that remains unanswered in our study is whether this lipid microcirculation facilitates astrocyte-vascular communication. Additionally, it is possible that defining the molecular mechanisms responsible for the putatively AQP4-independent restricted lipid microcirculation might open new avenues for intracellular drug delivery across the BBB (Merian et al. 2012).
Microglial activation in hepatic encephalopathy. Microglia are innate immune cells that clear unwanted debris and mediate inflammatory responses in the brain. Microglia transition from a resting to an active state, and finally become phagocytic (amoeboid) when they detect brain injury or infection (Kettenmann et al. 2011). Microglial involvement in HE is incompletely understood. Different HE models have generated conflicting data, and almost all previous studies have been conducted in vitro, in situ or histologically (Bruck et al. 2011; Jover et al. 2006; Rodrigo et al. 2010; Zemtsova et al. 2011). When microglial cells become activated by a perceived pathogen they alter morphology to aid migration and phagocytosis, expressing fewer and thicker processes. This microglial activation is correlated with increased secretion of pro-inflammatory cytokines (e.g. TNF-α), proteolytic enzymes (e.g. matrix metalloproteinase-9) in addition to displaying phagocytic behavior (Kettenmann et al. 2011).

Microglial activation has been identified histologically in bile duct ligation and hepatic devascularization models of HE (Jover et al. 2006; Rodrigo et al. 2010; Zemtsova et al. 2011). However, microglia did not become activated in a study of portal vein ligation, despite the mice experiencing severe encephalopathy (Bruck et al. 2011). Furthermore, activation of microglia in HE has not previously been explored in vivo or in the azoxymethane induced model, which has the added benefit of being one of the most reliable and reproducible models also useable in transgenic mice. We therefore chose to investigate and compare microglial activation and motility in real-time using 2PLSM imaging of Cx3cr1-eGFP mice in azoxymethane-induced HE with acute isolated hyperammonemia. Contrary to some previous reports, we found that microglia only become activated in the later stage of HE, after the onset of symptoms, but coincident with the onset of BBB opening and brain edema. Additionally, we found no change in microglia morphology or motility during isolated hyperammonemia. Thus, our study indicates that microglial activity may be involved in the onset of potentially fatal brain edema late in HE, but that it is not necessary for the neurological dysfunction seen in early HE or acute hyperammonemic encephalopathy.

Our study has several limitations that one needs to consider when interpreting the results. Since in vivo 2PLSM of microglial activation has only been performed in few studies to date, the sensitivity of this method is unfortunately not completely known (Fuhrmann et al. 2010; Marker et al. 2010; Nimmerjahn et al. 2005). On the
other hand, 2PLSM has several benefits with regard to identifying microglial activation, such as improved anatomical resolution, the ability to compose 3D-stacks and the possibility to follow changes in the same cell over time. However, immunohistochemistry has the advantage of being able to detect the expression of surface markers of microglial activation that could be more sensitive (e.g. Iba1). Microglial motility or turnover rate (TOR) of processes is an incompletely understood behavior that microglia display in living brain tissue. It is thought to represent physiological surveillance of the surrounding environment but may also be associated with trauma from the cranial window itself (Fuhrmann et al. 2010; Nimmerjahn et al. 2005). Hence the decreased TOR we observed in late HE needs to be interpreted cautiously until further studies shed light on this phenomenon. Regarding the mouse model of azoxymethane induced HE, it is well characterized both in our study and previous work. It also has a phenotypic and biochemical profile that is comparable to common forms of HE seen in humans. However, this chemically induced disease model presents some issues regarding possible confounding effects of the drug on the CNS directly. In summary, we believe there are several important questions that remain unanswered for future study including: Is real-time 2PLSM morphometric imaging of microglia an accurate and sensitive measure of activation? What is the function of microglial surveillance behavior in living brains and to what extent is the high turnover rate we observe an artifact of the surgical preparation? Does chronic low-grade hyperammonemia cause microglial activation, e.g. through prolonged reactive oxygen stress, and would inhibition of this improve clinically relevant outcomes in HE (Agusti et al. 2011; Cauli et al. 2007)?

**Ammonia – a ubiquitous building block and deadly toxin.** Ammonia is known to be acutely neurotoxic in humans, and is thought to exert its toxic effects on the brain by causing astrocyte swelling and dysfunction (Brusilow et al. 2010; Cagnon and Braissant 2007). Astrocytes are thought to be most extremely sensitive to ammonia toxicity because of their privileged role as the only cell in the CNS able to detoxify ammonia via the enzyme GS (Martinez-Hernandez et al. 1977). Our first goal was therefore to characterize the extent of astrocyte involvement in ammonia toxicity and image for the first time in vivo the volume changes associated with this condition. We chose to address these questions in the Otcspf-ash model of hyperammonemia with no liver failure, which allowed us to study the CNS effects of ammonia in isolation (cf.
hepatic encephalopathy). Furthermore, following a detailed characterization of the symptomatology we chose to focus on the pathology in the cerebral cortex. This was because electrophysiology findings (myoclonic seizures) led us to suspect this as a major target of the ammonia toxicity. To our great surprise, doses of ammonia sufficient to trigger significant symptoms such as ataxia and seizures did not induce any astrocyte swelling in vivo. Additionally, deleting the main route of water influx into astrocytes, AQP4, had no effect on disease outcome in isolated ammonia toxicity, contrary to contemporary hypotheses (Rama Rao et al. 2010). Our data are therefore consistent with the previously discussed much tighter astrocyte volume regulation in vivo than for instance in vitro. Since the brain edema reported in ammonia toxicity could also be due to water accumulation in other compartments we measured overall brain water content. We found that moderate ammonia doses did not cause any overall brain edema in the acute setting (Brusilow et al. 2010). To ensure our volume assay was sufficiently sensitive, we then administered higher doses of ammonia and were able to replicate the previously described ammonia-induced astrocyte swelling and brain edema. The presence of symptoms with doses of ammonia insufficient to cause swelling led us to conclude that astrocyte swelling is not prerequisite for ammonia neurotoxicity.

Given our negative findings with regards to astrocyte swelling, we next wanted to explore alternative molecular mechanisms for the toxicity of ammonia. First, we used 2PLSM to look for signs of astrocyte dysfunction and chose to examine calcium signaling, which as discussed previously is linked to key homeostatic functions. Consistent with our initial hypothesis that ammonia is selectively toxic to astrocytes, we found a marked increase and desynchronization of astrocyte calcium signals following ammonia administration. Astrocyte calcium signals have recently been shown to be critical for buffering of $[K^+]_o$ via the NKA in both cerebrum and cerebellum (Wang et al. 2012a; Wang et al. 2012b). Additionally, several studies from kidney, bee retina, acute brain slice and astrocyte cultures have indicated that ammonia may directly interfere with potassium homeostasis (Alger and Nicoll 1983; Brookes and Turner 1993; Marcaggi et al. 2004; Stephan et al. 2012; Sugimoto et al. 1997). We therefore hypothesized that ammonia sequestered into astrocytes for GS detoxification might selectively impair potassium homeostasis in these cells causing an increase in $[K^+]_o$. Using $K^+$ ISMs we were able to demonstrate the $[K^+]_o$ increase in vivo (Alger and Nicoll 1983). However, the mechanism for the ammonia induced
[\text{K}^+]_o$ increase was still unknown, as it likely was not be mediated by the swelling-related mechanisms proposed in the previous studies. Using 	extit{in situ} assays we demonstrated that the physical similarities of ammonium ($\text{NH}_4^+$) and potassium ($\text{K}^+$) ions cause them to directly compete for transport across astrocyte membranes. This fundamental biochemical aspect of ammonia might explain why toxicity is observed in bacteria, to fish and ultimately humans (Marcaggi et al. 2004).

To further explore the link between a failure of astrocyte potassium buffering and neurological impairment, we proceeded to correlate the kinetics of the $[\text{K}^+]_o$ increase with symptom onset and severity. Consistent with our previous hypothesis, we found that $[\text{K}^+]_o$ increased robustly prior to symptom onset 	extit{in vivo}, and that the magnitude of the potassium increase correlated closely with encephalopathy grade. Seminal previous studies between 1970-80 showed that neurons exposed to excess ammonia rapidly develop impaired post-synaptic inhibition (Aickin et al. 1982; Alger and Nicoll 1983; Lux 1971; Lux and Loracher 1970; Lux et al. 1970; Lux and Schubert 1969; Meyer and Lux 1974; Raabe and Gunnit 1975; Raabe 1981). To explore this hypothesis 	extit{in vivo}, we used paired-pulse whisker stimulation to show that ammonia toxicity is associated with a failure of cortical inhibitory transmission. Additionally, using 	extit{in situ} electrophysiology we were able to show that the failure of inhibitory transmission was due to excess extracellular $\text{NH}_4^+$ and $\text{K}^+$ driving chloride influx via NKCC1 and causing a depolarizing shift in the $\text{Cl}^-$-based GABA equilibrium potential ($E_{\text{GABA}}$) of pyramidal neurons. NKCC1 can be selectively inhibited by the clinically used diuretic bumetanide, which we found significantly reduced the severity of the ammonia phenotype and increased survival following lethal ammonia injections. Bumetanide has also recently been shown to improve clinical outcomes in HE, though the authors suggested this occurred due to an amelioration of astrocyte swelling (Jayakumar et al. 2008; Jayakumar et al. 2011b). Moreover, recent studies of neonatal and febrile seizures have revealed an important role of potassium and NKCC1 mediated $E_{\text{GABA}}$ depolarization that can be treated with bumetanide (Dzhala et al. 2005; Koyama et al. 2012).

The molecular pathway delineated above led us to suspect that potassium alone might be sufficient to replicate many of the neurotoxic effects of ammonia. Since potassium is largely impermeable to the BBB (Hansen et al. 1977), we developed a model whereby either potassium or ammonia was superfused directly onto the cerebral cortex. Interestingly, we found that increasing $[\text{K}^+]_o$ alone was
sufficient to depolarize $E_{\text{GABA}}$ and trigger myoclonic seizures. This observation is supported by recent studies showing that impaired potassium buffering in reactive astrocytes can mediate seizures in mesial temporal lobe epilepsy, neonatal and febrile seizures (Dzhala et al. 2005; Heuser et al. 2012; Koyama et al. 2012).

In conclusion, we arrived at a novel molecular mechanism for ammonia and potassium neurotoxicity and isolated a molecular target with clear translational applications. We were able to describe how acute hyperammonemia causes a rapid increase in basal $[K^+]_o$, leading to myoclonic seizures. A major limitation of our study was the short timescale of hyperammonemia. Congenital hyperammonemia in children often leads to acute increases in plasma ammonia, though this frequently occurs on top of a low-grade encephalopathy and cognitive impairment (Cagnon and Braissant 2007; Lichter-Konecki et al. 2008). There has been limited experimentation regarding how chronic hyperammonemia might affect learning and memory in young animals. Additionally, it would be interesting to test whether NKCC1 antagonist bumetanide might improve any cognitive phenotype. Finally as ours and other recent studies have highlighted the link between impaired astrocytic $[K^+]_o$ homeostasis, NKCC1 and seizures, further in vivo experiments are required to address whether this causal pathway might be involved in other types of seizure disorders, e.g. post-traumatic and hypoglycemic seizures (Dzhala et al. 2005; Haj-Yasein et al. 2011a; Heuser et al. 2012; Koyama et al. 2012).
10. CONCLUSIONS

In summary, exploiting the strengths of 2PLSM in vivo imaging we chose to examine several key aspects of glial function and dysfunction in the context of water and ion homeostasis. Our results demonstrate that glial cells perform homeostatic and signaling roles that are essential for effective brain function. Additionally, we found that early breakdown of these glial mechanisms was a hallmark of neurological dysfunction across the broad range of conditions examined in our studies. Our data thus illustrate that therapies targeting glial cells have the potential to create a paradigm change in the current clinical approach to treating neurological disorders.

I. AQP4 is critical for calcium signaling evoked by swelling of astrocytes in response to hyponatremic brain edema. AQP4 thus increases astrocyte sensitivity to small osmotic changes and may therefore mediate volume related signaling.

II. AQP4 deletion selectively worsens microwatershed hypoxia in cortical spreading depression, without affecting overall oxygenation or blood flow. This can be explained by either a role of AQP4 in O$_2$ transport or AQP4 facilitating energy-efficient potassium homeostasis.

III. Several commonly used general anesthetics with nominally different molecular mechanisms selectively suppress astrocyte calcium signaling, prior to having a detectable effect on neurons. These observations raise the important question of whether anesthetics may exert some of their sedative actions via astrocytes, and not just neurons.

IV. The paravascular space formed between astrocyte endfeet and the vasculature represents a novel lymphatic-like route for lipid transport and glial signaling in the brain.

V. Microglial activation coincides with the onset of brain edema in the late stages of hepatic encephalopathy, which may increase mortality in this condition. Neurotoxic levels of ammonia alone were insufficient to activate microglia.

VI. Neurotoxic levels of ammonia selectively short-circuit astrocyte potassium buffering, and secondarily impairs neuronal inhibitory activity by decreasing inward NKCC1-dependent GABA$_A$-currents. Pharmacological inhibition with the clinically used diuretic bumetanide reverses this phenotype, improving clinically relevant end-points such as seizures and encephalopathy.
11. REFERENCES


Mathiisen TM, Lehre KP, Danbolt NC, Ottersen OP. 2010. The perivascular astroglial sheath provides a complete covering of the brain microvessels: an electron microscopic 3D reconstruction. Glia 58(9):1094-103.


In vivo NADH fluorescence imaging indicates effect of aquaporin-4 deletion on oxygen microdistribution in cortical spreading depression

Alexander Stanley Thrane\textsuperscript{1,2,3*}, Takahiro Takano\textsuperscript{1*}, Vinita Rangroo Thrane\textsuperscript{1,2,3*}, Fushun Wang\textsuperscript{1}, Weiguo Peng\textsuperscript{1}, Ole Petter Ottersen\textsuperscript{2}, Maiken Nedergaard\textsuperscript{1}, Erlend A. Nagelhus\textsuperscript{1,2,3,4}

\textsuperscript{1}Division of Glial Disease and Therapeutics, Center for Translational Neuromedicine, University of Rochester Medical Center, Rochester, New York 14642.

\textsuperscript{2}Centre for Molecular Biology and Neuroscience, Letten Centre, Institute of Basic Medical Sciences, University of Oslo, 0317 Oslo, Norway.

\textsuperscript{3}Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslo, 0318 Oslo, Norway.

\textsuperscript{4}Department of Neurology, Oslo University Hospital, 0027 Oslo, Norway

* These authors contributed equally to this work

**Correspondence:** Maiken Nedergaard, MD PhD, Center for Translational Neuromedicine, 601 Elmwood Avenue, Rochester, New York 14642, USA. E-mail: nedergaard@urmc.rochester.edu Phone: (585) 273-2868. **Funding:** This work was supported by the US National Institutes of Health (NS075177 and NS078304 to M.N.), Research Council of Norway (NevroNor, and FUGE grants), Letten Foundation, and Fulbright Foundation. **Disclosure:** The authors declare no conflict of interest. **Running headline:** Aquaporin-4 effects oxygenation in spreading depression.
Abstract

Using in vivo two-photon imaging we show that mice deficient in aquaporin-4 (AQP4) display increased fluorescence of nicotinamide adenine dinucleotide (NADH) when subjected to cortical spreading depression (CSD). The increased NADH signal, a proxy of tissue hypoxia, was restricted to micro-watershed areas remote from the vasculature. Aqp4 deletion had no effects on the hyperemia response, but slowed \([K^+]_o\) recovery. These observations suggest that K⁺ uptake is suppressed in Aqp4⁻/⁻ mice as a consequence of decreased oxygen delivery to tissue located furthest away from the vascular source of oxygen, although increased oxygen consumption may also contribute to our observations.

Key words

AQP4, astrocytes, glia, NADH, metabolic.
**Introduction**

Aquaporin-4 (AQP4) is the principal brain water channel and is concentrated in astrocytic endfoot membranes at the brain-blood and brain-liquor interfaces.\(^1\) It is surprising that our understanding of the physiological roles of AQP4 has evolved so slowly given its abundance in brain. Although AQP4 is engaged in interstitial fluid dynamics under physiological conditions,\(^2,\,3\) several lines of work show that animals must be subjected to severe stress for a clear *Aqp4*\(^{-/-}\) phenotype to become apparent. The role of AQP4 in mediating water exchange across the blood-brain interface was for instance initially demonstrated in models of brain edema that entail pronounced osmotic stress.\(^4\)

Here we used cortical spreading depression (CSD) as a model of severe metabolic stress to resolve whether oxygenation of brain neuropil depends on the presence of AQP4. Drawing on experience from studies of brain edema, we hypothesized that severe stress would be needed to disclose a link between AQP4 expression and tissue oxygenation.\(^4\) CSD is a slowly spreading wave of depressed neuronal activity associated with a massive buildup of extracellular concentration of K\(^+\) ions ([K\(^+\)]\(_o\)), thought to occur during migraine headaches. The recovery of [K\(^+\)]\(_o\) involves several mechanisms, including inward rectifying K\(^+\)-channels, (Na\(^+\))-K\(^+\)-Cl\(^-\) cotransporters and the Na\(^+\),K\(^+\)-ATPase.\(^5-\,7\)

Two-photon imaging of nicotinamide adenine dinucleotide (NADH) fluorescence can be used to provide high-resolution maps of tissue redox state *in vivo*. Increased NADH signal is a sensitive non-linear proxy of tissue hypoxia.\(^8\) Our analysis shows that *Aqp4* deletion leads to a more pronounced oxygen deficit in microwatershed areas and a
protracted \([K^+]\) recovery. The most parsimonious explanation of these observations is that removal of AQP4 reduces oxygen supply and hence slows K\(^+\) re-uptake.

Materials and Methods

**Mouse preparation.**\(Aqp4^{-/-}\) and \(Aqp4^{+/+}\) mice of either sex were generated as previously described and anesthetized using intraperitoneal urethane (1 g/kg) and \(\alpha\)-chloralose (50 mg/kg).\(^9\) The mice were prepared for *in vivo* 2-photon imaging as previously described.\(^7\) CSD was evoked by either pressure injecting 1M KCl through a micropipette or surface application of 1M KCl (5 \(\mu\)l) through a small secondary craniotomy. Fixation of mice, preparation of tissue slices and immunohistochemistry were performed as described previously.\(^9\) All animal experiments were conducted in accordance with the ARRIVE guidelines and approved by the Animal Care and Use Committee of the University of Rochester.

**In vivo recordings.** A Mai Tai laser (SpectraPhysics) attached to a confocal scanning system (Fluoview 300, Olympus) and an upright microscope (IX51W) with a 20X objective (0.95 NA, Olympus) was used. We performed combined imaging of NADH and intravascular fluorescein isothiocyanate (FITC)-dextran (2000 kDa, 5%, i.v.).\(^7\) NADH was excited at 740 nm and emission was detected using a 460 nm filter (50 nm bandwidth), whilst FITC-dextran emission was detected using a 515 nm filter (50 nm bandwidth). The images were taken every 3 s at 50-150 \(\mu\)m depth. Images were filtered and converted to percent changes from baseline using ImageJ software (NIH) as described previously.\(^7\) The NADH fluorescence changes during CSD reveal a
characteristic biphasic response. This response has a complex geometry, and perivascular “cylinders” of low NADH signal can be seen whose size depends both on their vascular oxygen content and diameter. We therefore calculated the change in signal intensity of individual pixels normalized to values in a baseline image (ΔF/F₀), before the onset of CSD. By convention the regions where pixel values became more negative (ΔF/F₀ < 0) and positive (ΔF/F₀ > 0) during the CSD wave were defined as “Dip” and “Overshoot”, respectively. Direct current (DC) potentials and [K⁺]₀ were recorded using glass microelectrodes and tissue pO₂ (tpO₂) was measured using a Clark-type polarographic oxygen microelectrode (OX-4, Unisense) as outlined before. Cerebral blood flow was assessed using a fiberoptic laser Doppler probe (PF5010, Perimed) and connected to an infrared laser Doppler flowmeter. All signals were digitized (Digidata 1332A, Axon Instruments) and analyzed (pClamp 10.2, Axon Instruments).

Results

Deletion of Aqp4 increases microwatershed NADH fluorescence during CSD

We measured tissue NADH fluorescence, cerebral blood flow, tissue oxygen tension (tpO₂), local field potentials (LFP), and [K⁺]₀ in living wild type and Aqp4-/- mice following induction of CSD (Figure 1A). Immunofluorescence confirmed high perivascular AQP4 expression in wild type mice and confirmed the efficacy of the gene knockout strategy (Figure 1B). The total and perivascular dip NADH responses in Aqp4-/- animals did not differ from that in wild type during CSD (Figure 1C,D). However, the overshoot region of the NADH response was greater in the Aqp4-/- animals than in wild types almost from the onset of CSD, and became significantly higher ~ 2 min after onset.
(Total neuropil: wild type 14.36 ± 4.02% vs. Aqp4<sup>−/−</sup> 19.61 ± 6.21%. Dip: wild type 17.33 ± 3.43% vs. Aqp4<sup>−/−</sup> 23.23 ± 4.78%. Overshoot: wild type 17.09 ± 3.71% vs. Aqp4<sup>−/−</sup> 39.48 ± 6.43%, all peak values, p<0.05 for 145 to 250 s post-CSD onset) (Figure 1E,F). The rising phase of NADH fluorescence overshoot lasted 187.50 ± 36.54 s in wild type and 133.33 ± 49.09 s in Aqp4<sup>−/−</sup> animals, and was not significantly different (data not shown). Thus, our data suggest that Aqp4 deletion selectively impairs tissue oxygenation in areas furthest away from the vasculature.

**Deletion of Aqp4 does not influence hyperemia and vascular oxygen supply in CSD**

Cerebral blood flow is critical for maintaining adequate tissue oxygenation. Due to the strong AQP4 expression around blood vessels, we tested whether Aqp4 deletion influenced the vascular response to CSD. Neither the amplitude nor the duration of the hyperemia phase differed between wild type and Aqp4<sup>−/−</sup> animals (Peak: wild type 164.50 ± 4.57% vs. Aqp4<sup>−/−</sup> 162.57 ± 7.54%. Duration: wild type 174.50 ± 11.56 s vs. Aqp4<sup>−/−</sup> 178.06 ± 6.09 s) (Figure 2A-C). Additionally, Aqp4 deletion did not affect overall tissue oxygen supply, which we assessed using oxygen sensitive microelectrodes that integrate tpO2 from a ~268-524 μm<sup>3</sup> volume encompassing both NADH dip and overshoot regions (Baseline: wild type 38.60 ± 3.14 mmHg vs. Aqp4<sup>−/−</sup> 45.98 ± 4.88 mmHg. CSD: wild type 9.14 ± 2.05 mmHg vs. Aqp4<sup>−/−</sup> 11.53 ± 3.03 mmHg. (Figure 2D). The kinetics of these tpO2 recordings was not significantly different (Figure 2E,F) (ΔtpO2: wild type -29.46 ± 4.98 vs. Aqp4<sup>−/−</sup> -34.45 ± 3.13. Declining slope: wild type -2.79 ± 1.22 mmHg/s vs. Aqp4<sup>−/−</sup> -3.44 ± 0.74 mmHg/s. Recovery slope: wild type +0.67 ± 0.38 mmHg/s vs. Aqp4<sup>−/−</sup> +0.58 ± 0.12 mmHg/s). Finally, when we used tpO2 and blood flow recordings to
approximate the cerebral metabolic rate of oxygen ($\Delta\text{CMRO}_2$) this was not significantly different between the two genotypes during CSD (wild type $281.50 \pm 21.62$ $\mu$mol/100g/min vs. $\text{Aqp4}^{-/-}$ $292.50 \pm 23.40$ $\mu$mol/100g/min, data not shown). However, this calculation uses equivalent coefficients for oxygen diffusion through brain in both genotypes, which may be an incorrect assumption if AQP4 alters gas diffusion. Taken together, we found no evidence that deleting $\text{Aqp4}$ altered hyperemia or overall oxygen supply during CSD.

Deletion of $\text{Aqp4}$ delays $[\text{K}^+]_o$ recovery in CSD

The amplitude of the DC potential shift, which is dependent on $[\text{K}^+]_o$, was significantly lower in $\text{Aqp4}^{-/-}$ than in wild type mice (Amplitude: wild type $-18.71 \pm 2.11$ mV vs. $\text{Aqp4}^{-/-}$ $-12.80 \pm 1.16$ mV) (Figure 2G,H). In line with these data and the finding that $\text{Aqp4}$ deletion increases basal ECS volume, $^{11}$ the amplitude of the $[\text{K}^+]_o$ increase was significantly lower in $\text{Aqp4}^{-/-}$ animals (Amplitude: wild type $75.54 \pm 1.86$ mM vs. $\text{Aqp4}^{-/-}$ $64.49 \pm 1.73$ mM) (Figure 2I,J). The rising phase of $[\text{K}^+]_o$ in CSD lasted $30.53 \pm 1.76$ s in wild type and $31.61 \pm 4.75$ s in $\text{Aqp4}^{-/-}$ animals, not significantly different (Figure 2K). However, $\text{Aqp4}^{-/-}$ mice showed a slower $[\text{K}^+]_o$ recovery compared to wild types (Recovery rate: wild type $1.79 \pm 0.12$ mM/s vs. $\text{Aqp4}^{-/-}$ $1.27 \pm 0.08$ mM/s. Duration of $[\text{K}^+]_o$ elevation: wild type $130.32 \pm 5.42$ s vs. $\text{Aqp4}^{-/-}$ $153.86 \pm 7.54$ s) (Figure 2L,M), suggesting that the capacity for $[\text{K}^+]_o$ clearance is reduced by $\text{Aqp4}$ deletion.
Discussion

Our study provides the first line of evidence that AQP4 impacts oxygenation of brain tissue. Using CSD as a model of severe metabolic stress, we show that Aqp4 deletion increases NADH fluorescence in areas furthest away from cerebral microvessels. NADH fluorescence is a sensitive indicator of tissue hypoxia with a $p_{50}$ of 3.4 mmHg, and our data thus demonstrate that Aqp4 deletion enhances the already critical microwatershed hypoxia seen in CSD. Measurements with laser Doppler flowmetry show that this impaired oxygenation was not due to inadequate blood supply, as Aqp4-/- and wild type mice had a comparable hyperemia response. Moreover, oxygen sensitive microelectrodes showed that the observed NADH changes did not reflect overall differences in tissue oxygenation, but were spatially restricted to microwatershed regions.

The observed increase of microwatershed hypoxia in Aqp4-/- mice can be explained by either enhanced oxygen consumption or reduced oxygen diffusion. Aqp4 deletion has previously been shown to impair $[K^+]_o$ clearance during CSD, seizures and neuronal stimulation. AQP4 can impact $[K^+]_o$ clearance in several ways, including regulating extracellular space volume, dissipating osmotic gradients arising from ion transport and enhancing interstitial bulk flow. Aqp4 deletion might therefore increase microwatershed hypoxia by making perivascular $[K^+]_o$ homeostasis less efficient and consume excess oxygen. However, this hypothesis would imply that Aqp4-/- mice have a larger perivascular NADH signal dip and a higher overall oxygen uptake, neither of which we found in our study. Additionally, the hypothesis would predict that $[K^+]_o$ increases in the Aqp4-/- mice prior to the observed NADH changes, whereas our data indicate the opposite.
The alternative hypothesis entails *Aqp4* deletion impairing oxygen diffusion across perivascular endfoot membranes. Experimental analyses in oocytes and modeling studies have suggested that AQP4 might serve as a gas channel.\(^{13, 14}\) Wang & Tajkhorshid suggested that the central pore of the AQP4 tetramer could conduct NO and O\(_2\).\(^{13}\) However, the membrane permeability for gasses likely varies significantly depending on the type of gas studied (O\(_2\), CO\(_2\), NO), lipid composition of the membrane (e.g. endfoot vs. oocyte), and macromolecular organization of transmembrane proteins (e.g. AQP4 tetramers). Aquaporin-facilitated gas transport is therefore an unresolved topic, where several studies have presented evidence for and against the hypothesis.\(^{13-15}\) If oxygen diffusion were rate limiting in our study we would hypothesize that microwatershed hypoxia would be increased and involve a larger area, which the NADH imaging supports. We might also expect that inadequate oxygenation precedes and potentially causes the slowed \([K^+]_o\) clearance seen in *Aqp4*\(^{-/-}\) mice, and our data show a tendency towards this. Finally, NADH is an indirect and non-linear indicator of tissue hypoxia that can be influenced by factors unrelated to oxygenation (e.g. cell swelling, hypoglycemia). As we were unable to detect an overall difference in tissue oxygenation using microelectrodes, our data therefore does not directly show that mitochondrial oxygen uptake is inadequate or rate limiting in the *Aqp4*\(^{-/-}\) mice.

In conclusion, our data suggest that *Aqp4* deletion in CSD impairs the oxygenation of areas remote from brain microvessels. These observations are consistent with the hypothesis that AQP4 facilitates oxygen diffusion, but due to methodological limitations we cannot conclusively differentiate this from the alternative explanation that
AQP4 deletion increases metabolic demand. Our study thus provides the first evidence to suggest that AQP4 is involved in facilitating oxygen diffusion in vivo.
References


Figure legends. “In vivo NADH fluorescence imaging…” Thrane AS, Takano T, Rangroo Thrane V, Wang F, Peng W, Ottersen OP, Nedergaard M and Nagelhus EA

Figure 1. Deletion of Aqp4 increased NADH fluorescence in microwatershed areas during CSD. (A) Experimental setup. Following induction of CSD in living Aqp4−/− and wild type (WT) mice, we measured changes in NADH fluorescence with 2PLSM, cerebral blood flow (CBF) with laser Doppler flowmetry (LDF), extracellular concentration of K⁺ ([K⁺]₀) with K⁺-ion-sensitive microelectrodes (ISM), DC potential, and tissue partial pressure of oxygen (tpO2) (not illustrated). (B) Immunofluorescence micrographs from WT and Aqp4−/− mice illustrating AQP4 expression in cerebral cortex. AQP4 (green), GFAP (red) and DAPI (blue). (C) Endogenous NAD⁺ and its reduced counterpart NADH are key coenzymes in glycolysis, the citric acid cycle, and the mitochondrial respiratory chain. Since only NADH is fluorescent (and not NAD⁺), two-photon NADH imaging offers maps of tissue redox state that can be used as a proxy of tissue oxygenation. (D) Left: NADH fluorescence images of cerebral cortex in WT (75 μm depth) and Aqp4−/− (105 μm depth) mice. Green is FITC-dextran labeled blood vessels. NADH fluorescence is largely uniform, except where NADH is made less visible by the presence of large pial vessels at the surface of the brain. Right: Representative false color images of change in NADH fluorescence (ΔF/F₀) from baseline intensity, during the early (CSD wave) and late phase of CSD (hypoxic phase), and after recovery. In the early phase of CSD, when DC potential dropped, cortical tissue showed a complex pattern of NADH decrease (dip, shown in green) and increase (overshoot, shown in red/orange), (8). At a later stage, when DC potential had normalized, all regions showed
increased NADH fluorescence (hypoxic phase), before gradually returning to baseline level. Scale bar represents 50 μm. (E) Running average traces (ΔF/F₀) for the biphasic NADH response during CSD, showing whole field (“total”), dip and overshoot in WT and Aqp4⁻/⁻ mice. Duration of DC shift is indicated. *P < 0.05, n = 5 animals in each group, unpaired t test. (F) Bar graph representing the peak change in NADH fluorescence in WT and Aqp4⁻/⁻ mice. P = 0.394 (total), 0.329 (dip) and 0.00762 (overshoot), n = 5 animals in each group, unpaired t test. Data are shown as mean ± SEM.

Figure 2. Deletion of Aqp4 did not affect vascular oxygen supply but delayed extracellular K⁺ clearance in CSD. (A) Representative laser Doppler recordings (black) and a running average of these recordings (red) demonstrating the hyperemic response during CSD in Aqp4⁻/⁻ and WT mice. (B, C) Bar graphs summarizing the effect of Aqp4 deletion on peak amplitude and duration of the CSD hyperemic response. P = 0.876 (peak), 0.794 (duration), n = 22 (WT) and 41 (Aqp4⁻/⁻) stimulations from 7 (WT) and 12 (Aqp4⁻/⁻) animals, unpaired t test. (D) Line graph showing mean cortical tpO₂ before (basal) and during CSD in WT and Aqp4⁻/⁻ mice, measured using oxygen sensitive microelectrodes. P = 0.264 (base), 0.555 (trough), n = 6 (WT) and 8 (Aqp4⁻/⁻) animals, unpaired t test. (E, F) Bar graphs showing mean cortical tpO₂ slope decline and recovery. P = 0.641 (decline), P = 0.818 (recovery), n = 6 (WT) and 8 (Aqp4⁻/⁻) animals, unpaired t test. (G, H) Representative traces and bar graphs summarizing the effects of Aqp4 deletion on amplitude of the DC-shift. *P = 0.0223, n = 6 (WT) and 8 (Aqp4⁻/⁻) animals, unpaired t test. (I) Running averages of extracellular concentration of K⁺([K⁺]₀) during CSD for WT (black) and Aqp4⁻/⁻ mice (red), acquired using K⁺-ion-sensitive-
microelectrodes (ISM). Inset: $K^+$-ISM calibration curve. $n = 7$ (WT) and 12 ($Aqp4^{-/-}$).

![Image](image1)

Bar graphs summarizing the effect of $Aqp4$ deletion on peak $[K^+]_o$, time to peak, $[K^+]_o$ recovery rate, and duration of $[K^+]_o$ elevation in CSD. $[K^+]_o$ peak is reduced and $[K^+]_o$ recovery is delayed in $Aqp4^{-/-}$ mice. $^* P = 0.0459$ (duration), $^{**} P < 0.001$ (peak and recovery rate), $P = 0.855$ (time to peak), $n =$ 22 (WT) and 41 ($Aqp4^{-/-}$) CSD responses from 7 (WT) and 12 ($Aqp4^{-/-}$) animals, unpaired $t$ test. Data are shown as mean ± SEM.
Fig. 1

A. Diagram showing LDF, LFP, CBF, and ISM with WT or Aqp4−/−. [K+]o, DC, and CBF. NADH and NAD+ reduction and oxidation with e- and O2.

B. Images of AQP4, GFAP, and DAPI in WT and Aqp4−/− mice during hypoxic phase.

C. Diagram showing NADH, NAD+, and O2 with glucose and NADPH oxidation reduction.

D. Greyscale images showing baseline, CSD wave, hypoxic phase, and recovery for WT and Aqp4−/−.

E. Graph showing DC shift for WT and Aqp4−/− during total, Dip, and overshoot.

F. Bar graph showing peak ΔF% for WT and Aqp4−/− during total, Dip, and overshoot with significance markers.

Legend:
- WT
- Aqp4−/−
Fig. 2

(A) Hyperemia duration (s) for WT and Aqp4-/-. 
(B) Hyperemia peak (%) for WT and Aqp4-/-. 
(C) tpO2 (mmHg) for WT and Aqp4-/. 
(D) tpO2 decline (mmHg s^-1) for WT and Aqp4-/. 
(E) tpO2 recovery (mmHg s^-1) for WT and Aqp4-/. 
(F) Basal CSD for WT and Aqp4-/. 
(G) DC potential for WT and Aqp4-/. 
(H) DC amplitude (mV) for WT and Aqp4-/. 
(I) [K+]o peak (mM) for WT and Aqp4-/. 
(J) Time to [K+]o peak (s) for WT and Aqp4-. 
(K) [K+]o recovery rate (mM s^-1) for WT and Aqp4-/. 
(L) [K+]o recovery rate (mM s^-1) for WT and Aqp4-/.
Paravascular microcirculation facilitates rapid lipid transport and astrocyte signaling in the brain

Vinita Rangroo Thrane\textsuperscript{1,2,3}†*, Alexander S. Thrane\textsuperscript{1,2,3}†, Benjamin A. Plog, Meenakshisundaram Thiyagarajan\textsuperscript{1}, Jeffrey J. Iliff\textsuperscript{3}, Rashid Deane\textsuperscript{1}, Erlend A. Nagelhus\textsuperscript{2,3}, Maiken Nedergaard\textsuperscript{1}

Key words: lipophilic, glia, endfoot, cerebrospinal fluid, calcium

\textsuperscript{1}Division of Glia Disease and Therapeutics, Center for Translational Neuromedicine, Department of Neurosurgery, University of Rochester Medical Center, Rochester, New York 14642.

\textsuperscript{2}Letten Institute of Basic Medical Sciences, University of Oslo, 0317 Oslo, Norway.

\textsuperscript{3}Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslo, 0318 Oslo, Norway.

†These authors contributed equally to the paper

Correspondence: Vinita Rangroo Thrane, MD, Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslo, P.O. Box 1137 Blindern, N-0318 Oslo, Norway. E-mail: vrangroo@gmail.com. Phone: +47 999126007.

Acknowledgements: We thank Jeffrey Rothstein and Ole Petter Ottersen for the transgenic animals, and Georg A. Gundersen for the electron micrograph. This work was supported by the US National Institutes of Health (NS075177 and NS078304 to M.N., and F31NS073390 to N.A.S.), Research Council of Norway (NevroNor, and FUGE grants), Letten Foundation, and Fulbright Foundation. Disclosure: The authors declare no conflict of interest.
Abstract

The paravascular circulation of cerebrospinal fluid (CSF) may serve as a lymphatic system in the brain. Using *in vivo* two-photon imaging we demonstrate that the paravascular space facilitates selective movement of small lipophilic molecules and rapid glial calcium signaling in the brain. Depressurizing the paravascular system leads to unselective lipid diffusion, intracellular lipid accumulation and pathological signaling in astrocytes.
The brain, unlike other organs, lacks a separate lymphatic system to clear interstitial fluid, transport lipids and facilitate diffusion of signaling molecules. The extracellular space is narrow and highly tortuous in neuropil, and is incompatible with rapid fluid and solute movement\textsuperscript{1, 2}. Hydrophilic tracers have recently been shown to circulate through the brain in cerebrospinal fluid (CSF) via the paravascular space (PVS)\textsuperscript{3}. This anatomical space is completely ensheathed by astrocyte endfeet and is well-positioned to serve as a highway for glial-glial and glial-vascular communication\textsuperscript{2}. However, the role of the PVS in lipid transport and signal transduction has not been investigated \textit{in vivo}. Two related questions therefore remain unanswered: can the PVS facilitate rapid lipid transport and might the PVS act as a separate compartment for astrocyte signaling?

To outline the CSF microcirculation, tracers were infused via the cisterna magna (Fig. 1a). Both the fixable lipophilic tracer Texas red hydrazide (TXR, 0.621 kDa) and the hydrophilic tracer tetramethylrhodamine (TMR, 3 kDa) moved rapidly through the brain along cerebral blood vessels (tracer penetration: TXR 12.57 ± 4.41 and TMR 38.71 ± 7.70% brain area at 30 min). Surprisingly, lipophilic tracers of small molecular weight showed as limited parenchymal penetration as large hydrophilic tracers (fluorescein isothiocyanate dextran, FITC, 2000 kDa) in cortical grey matter (tracer penetration 15.56 ± 2.81% brain area) (Fig. 1b)\textsuperscript{3}.

We used \textit{in vivo} two-photon laser scanning microscopy (2PLSM) to further explore the highly selective paravascular movement of lipophilic tracers. This restricted movement is unexpected as biologically relevant lipid molecules, such as prostaglandins, cholesterol and palmitic acid, are small (< 1 kDa) and cell permeable \textsuperscript{4-8}. We demonstrated that the movement of small (< 1 kDa) lipophilic tracers was highly selective to the PVS (palmitic acid, rhod-2, TXR, sulforhodamine SR101 and
Oregon green BAPTA-1 OGB) (Fig. 2a, Supplementary Fig. 1a). Intra-arterial Texas red dextran or FITC were used to morphologically distinguish cortical surface arteries and veins as well as penetrating arterioles and venules (Supplementary Fig. 1a). Cross-sectional intensity projections of penetrating arterioles confirmed paravascular tracer selectivity (Fig. 2b). By analyzing regions of interest representing the PVS and the surrounding tissue (Fig. 2c), we showed that the lipophilic tracers were rapidly cleared via the PVS without gaining access to the surrounding tissue (normalized tracer fluorescence ratio of PVS to surround at 60 min: OGB 3.36 ± 0.79, SR101 3.50 ± 0.88, rhod-2 4.21 ± 1.35) (Fig. 2d). Deletion of the astrocyte water channel aquaporin-4 has recently been shown to slow the circulation of hydrophilic tracers in CSF, but did not affect lipophilic tracer movement (PVS to surround ratio in Aqp4−/− at 60 min: 4.83 ± 1.42) 3.

We next examined whether lipophilic tracers enter and exit the brain via similar arterio-venous paravascular routes as hydrophilic molecules3. Using NG2-DsRed mice that have fluorescently labeled vascular smooth muscle in arterioles, we showed that the biologically relevant tracer palmitic acid entered via a para-arterial route (Fig. 2e). Moreover, using 2PLSM imaging we showed that lipophilic tracer (rhod-2) moved sequentially in the PVS surrounding surface arteries, penetrating arterioles, capillaries and venules following cisterna magna infusion (normalized fluorescence of rhod-2 to eGFP expressed under the astrocyte specific Glut1 promoter: 30 min: arteriole 1.90 ± 0.38, capillary 0.45 ± 0.247, venule 0.23 ± 0.172; 60 min: arteriole 2.34 ± 0.44, capillary 0.94 ± 0.21, venule 0.44 ± 0.25; 90 min: arteriole 1.74 ± 0.32, capillary 0.72 ± 0.27, venule 1.33 ± 0.34) (Fig. 2f, g). These observations indicate that lipophilic molecules enter the brain via para-arterial and exit via para-venous routes.
To investigate the consequences of disrupting the paravascular microcirculation, we temporarily depressurized the PVS by puncturing the cisterna magna (CMP) (Fig 3a). We took advantage of astrocyte specific calcium indicators (such as rhod-2), which are lipophilic tracers that become concentrated inside cells due to their acetoxymethyl group\(^\text{9, 10}\). This improved the sensitivity for detecting parenchymal influx. CMP accelerated intracellular accumulation of lipophilic tracer rhod-2 when applied to the cortical surface or injected intraparenchymally (eGFP normalized fluorescence of rhod-2 astrocyte labeling intensity at 30 min for sham control: 1.54 ± 0.36 vs. CMP: 4.01 ± 0.57) (Fig. 3b, c). Conversely, \(\text{Aqp4}^-\) deletion, which slows paravascular water movement, did not enhance cellular tracer uptake (\(\text{Aqp4}^-\) control at 30 min: 1.56 ± 0.27) (Fig. 3d). Thus, an intact PVS restricts lipid diffusion and cellular uptake.

To investigate the role of the PVS as a signaling compartment, we compared spontaneous astrocyte calcium activity in the cortex of awake mice subjected to CMP or sham surgery. Interestingly, depressurizing the PVS caused increased frequency and decreased synchronization of calcium signaling (ctrl 2.21 ± 0.19 vs. CMP 3.08 ± 0.29 mHz cell\(^{-1}\); cell-cell correlation: ctrl 0.69 ± 0.03 vs. CMP 0.60 ± 0.03) (Fig. 3e-g)\(^\text{10}\). Other aspects of astrocyte signaling were not affected (amplitude: ctrl 39.08 ± 2.10% vs. CMP 39.98 ± 2.18%; duration: ctrl 21.29 ± 1.29 s vs. CMP 24.74 ± 1.62 s; P(active over 15 min): ctrl 75.83 ± 4.20% vs. CMP 7981.05 ± 4.18%) (Supplementary Fig. 1b-d). Astrocyte calcium activity has been shown to propagate along blood vessels and the waves are largely ATP mediated\(^\text{11-13}\). We therefore inserted a microelectrode into the PVS \textit{in situ} and stimulated calcium transients by injecting ATP. The rapid movement of agonist in the PVS stimulated a brisk calcium wave spreading outwards from the blood vessel, which propagated faster and over a
larger area than when ATP was injected intraparenchymally (wave propagation: parenchyma $4.47 \pm 0.56$ vs. PVS $8.89 \pm 1.22 \, \mu m \, s^{-1}$; wave diameter: parenchyma $142.86 \pm 12.50$ vs. PVS $315.81 \pm 51.42 \, \mu m$) (Fig. 3h).

To summarize, we show that the brain has a distinct paravascular compartment for lipid transport and glial signaling within the narrow confines of the neuropil. Lipid transport follows the arterio-venous circulation and is highly selective to the PVS. Compromising paravascular transport causes increased intracellular lipid accumulation and abnormal astrocyte calcium signaling. We speculate that lipid transport in the brain may be spatially restricted due to the high concentration of astrocyte secreted lipoproteins in CSF. Interestingly, lipoprotein mutations are the largest known risk factor for developing Alzheimer disease\textsuperscript{14, 15}. Ours and previous data therefore suggest that the paravascular compartment may represent a lymphatic equivalent in the brain that resorbs interstitial fluid, selectively transports small lipid molecules and can act as a signaling highway for coordinated astrocyte communication.
Figure legends

Figure 1 Rapid paravascular movement of lipophilic tracers. (a) Experimental design for studying tracer (red) movement in paravascular space via cisterna magna. Inset: electron micrograph of penetrating arteriole (PA) with surrounding paravascular space (PVS). Scale bar represents 2.5 μm. (b) Epifluorescence montages illustrate distribution of Texas red hydrazide (TXR), fluorescein isothiocyanate dextran (FITC) and tetramethylrhodamine dextran (TMR). Top insets display auto-thresholded images. Scale bar represents 200 μm. (c) Quantification of brain parenchymal penetration. **P < 0.01, n = 6 animals for all groups, Mann-Whitney U. Data are shown as mean ± SEM.

Figure 2 Lipophilic tracers selectively enter and exit brain via paravascular space surrounding arterioles and venules. (a) Left: in vivo two-photon image of rhod-2 circulation via the paravascular space in Glit1-eGFP mouse. White circles indicate penetrating arterioles. Surface artery (SA). Scale bar represents 100 μm. Right: high magnification images of the paravascular space surrounding penetrating arteriole at serial depths. (b) Cross sectional intensity traces illustrating the paravascular space (rhod-2, red) and intravascular space (Texas red dextran) around a penetrating arteriole (PA). Endfoot (EF). Scale bar represents 7.5 (top) and 5 (bottom) μm. (c) Region of interest (left) and analysis of tracer intensity (right) in the paravascular space and surrounding parenchyma. Scale bar represents 10 μm. n = 24 arterioles from 7 animals, paired t test. (d) Ratio of lipophilic tracer fluorescence in paravascular space to surrounding parenchyma at 60 min. Sulforhodamine (SR101), Oregon green BAPTA (OGB). n = 11 (OGB), 15 (SR101), 24 (rhod-2) and 12 (Aqp4⁻/⁻ rhod-2) arterioles from 16 animals (total), unpaired t test. (e) Immunofluorescence
micrographs from NG2-DsRed mouse show entry of palmitic acid lipid along the paravascular space. Antibody against lectin outlines vascular endothelium. White arrows indicate arterioles. Scale bar represents 100 μm. (f, g) Representative images and quantification of rhod-2 tracer in the paravascular space surrounding an arteriole, a capillary and venule. Scale bars represent 7.5 μm. n = 24 (arterioles), 14 (capillaries) and 12 (venules) from 7 animals, paired t test. ***P < 0.001. Data are shown as mean ± SEM.

**Figure 3** Depressurizing the paravascular space impairs lipid transport and astrocyte signaling. (a) Cisterna magna puncture (CMP) temporarily depressurizes the paravascular space. Lipophilic tracer was applied to cortical surface or injected into parenchyma. (b, c) Two-photon images and quantification of lipid tracer labeling in eGFP expressing cortical astrocytes (circled) following sham control and cisterna magna puncture (CMP). Scale bars represent 75 μm. n = 45 cells from 5 animals for both groups, unpaired t test. (d) Normalized rhod-2 astrocyte labeling intensity. n = 45 (Ctrl), 32 (Aqp4−/−) and 45 (CMP) cells from 14 animals (total), one-way ANOVA. (e) Representative traces of spontaneous calcium activity from cortical astrocytes in awake mice. Synchronized (red) and individual (green) transients. (f, g) CMP increases frequency and reduces synchronization of astrocyte calcium signals. n = 60 (ctrl) and 52 (CMP) cells from 10 animals (total), unpaired t test. (h, i) ATP injection (visualized with FITC-dextran) into the paravascular space stimulates rapid and widespread astrocyte calcium wave spreading outwards from the blood vessel. n = 16 (intraparenchymal, IP) and 9 (paravascular space, PVS) slices from 11 animals (total), unpaired t test. Scale bar represents 40 μm. *P < 0.05, **P < 0.01, ***P < 0.001. Data are shown as mean ± SEM.
Paravascular microcirculation facilitates rapid lipid transport and astrocyte signaling in the brain

Vinita Rangroo Thrane\textsuperscript{1,2,3\dagger\ast}, Alexander S. Thrane\textsuperscript{1,2,3\dagger}, Benjamin A. Plog, Meenakshisundaram Thiyagarajan\textsuperscript{1}, Jeffrey J. Iliff\textsuperscript{1}, Rashid Deane\textsuperscript{1}, Erlend A. Nagelhus\textsuperscript{2,3}, Maiken Nedergaard\textsuperscript{1}

Supplementary Figure 1 (a) In vivo two-photon image of the cortical vascular tree outlined using Texas red dextran. Collapsed z-stack from 0 - 200 μm, surface arteries (SA), surface veins (SV), penetrating arterioles (PA), penetrating venules (PV). Scale bar represents 100 μm. (b-d) Cisterna magna puncture (CMP) causes no alteration in amplitude (n = 54 ctrl and 49 CMP cells from 6 and 5 animals, respectively), duration (n = 55 ctrl and 49 CMP cells from 6 and 5 animals, respectively) and percent of active cells (n = 60 ctrl and 52 CMP cells from 6 and 5 animals, respectively) in astrocyte calcium signaling. Unpaired t test. Data are shown as mean ± SEM.
Supplemental Figure 1
Materials and Methods

Animals. *Glt-1*-eGFP, NG2-DsRed and *Aqp4*° mice were generated as outlined previously, and mice of either sex from 6-12 weeks used in conjunction with C57BL/6J wild-types (Jackson Laboratories) were used for experiments. All animals, except those used for awake imaging, were anesthetized with ketamine (0.12 mg g⁻¹) and xylazine (0.01 mg g⁻¹) intraperitoneally (i.p.). All animal experiments were approved by the Animal Care and Use Committee of the University of Rochester.

Tracer preparation and intracisternal infusion. The hydrophilic tracers fluorescein isothiocyanate (FITC) dextran (0.5%, 2000 kDa) and tetramethylrhodamine (TMR) dextran (0.5%, 3 kDa) and the lipophilic, cell-permeant tracers palmitic acid (BODIPY® FL C₁₆ 1 mg ml⁻¹, 0.474 kDa, Molecular Probes), Texas red hydrazide (0.4-2 mM, 0.621 kDa), sulforhodamine SR101 acid chloride (0.2 mM, 0.607 kDa), rhod-2 AM (acetoxymethyl ester) (0.45-4.5 mM, 1.124 kDa) and Oregon-green BAPTA-1 OGB AM (0.5 mM, 1.258 kDa, acquired from Invitrogen and Sigma-Aldrich) were constituted in artificial cerebrospinal fluid (aCSF). These tracers were chosen because of their small size (comparable to endogenous lipids), relevance to *in vivo* imaging (e.g. as calcium indicators) and ability to cross cell membranes, such as the endfoot membrane that encases the PVS. The mice were secured in a stereotaxic frame, and a 30G needle was inserted into the cisterna magna. Tracer dissolved in aCSF was delivered at a rate of 2 μL min⁻¹ over 5 minutes with a syringe pump (Harvard Apparatus). The dyes were used at higher concentrations to allow the approximate dilution factor of 1:5 when 10 μL was infused into the total mouse CSF volume of 40 μL. The cisterna magna was punctured...
with a 30G needle to drain the CSF and depressurize the PVS. In sham control animals the cisterna magna was exposed without puncturing it.

**Ex vivo imaging.** Mouse preparation was modified from published protocols. The animals were perfused transcardially with 4% paraformaldehyde in 0.1M phosphate buffered saline (pH 7.4) and post-fixed overnight. 100 μm vibratome brain sections were then cut and mounted on slides using PROLONG anti-fade gold with DAPI (Invitrogen). Epifluorescence multi-channel whole-brain montages were collected using a virtual slice module (Microlucida Software, Microbrightfield). Exposure and gain levels were maintained constant throughout the study. The percentage of brain tracer penetration was calculated using the area fraction function in ImageJ (NIH) on consistently thresholded images, as described previously. For EM experiments 0.1% glutaraldehyde was added to the perfusate/fixation solution and the ultra-thin Lowicryl sections were prepared as outlined previously. Images were obtained 125 μm below the surface in the barrel cortex.

**In vivo imaging.** Anesthetized animals were intubated and artificially ventilated with a small animal ventilator (CWE), their temperature was maintained using a heating pad, and blood gasses were collected via a femoral arterial cannula to ensure physiological hemodynamic parameters. To visualize the cerebral vasculature FITC or Texas red dextran (Invitrogen) were administered intra-arterially. A steel frame was secured to the skull using dental cement, and a 2 mm craniotomy was opened over the somatosensory cortex with particular care being taken not to puncture the dura mater. To stabilize
imaging, the craniotomy was then sealed with agarose (1.5%, type III-A, Sigma) and a coverslip. A Mai Tai laser (SpectraPhysics) attached to a confocal scanning system (Fluoview 300, Olympus) and an upright microscope (IX51W) were used. Tracers and eGFP were excited at 850 - 890 nm and emission was collected at 575 - 645 nm using a 20x (0.95NA) lens. 512x512 pixel frames were collected from the pial surface to 200 μm depth at 20 μm z-steps. Superficial arteries and veins were distinguished based on morphology (e.g. arteries pass more superficially, and have fewer branches near the surface). Tracer movement was analyzed as outlined previously by defining doughnut shaped ROIs around penetrating arterioles.

**Awake calcium imaging.** Animal preparation was performed as described by the authors previously. Briefly, mice were anesthetized with isoflurane (1.0 - 1.5%), head-restrained with a steel mini-frame, and habituated to imaging through training sessions. The craniotomy was made as outlined above and rhod-2 (2 mM, Invitrogen) was loaded onto exposed cortex before applying the coverslip. Calcium signaling was imaged 75 - 125 μm depth and dual channel (rhod-2 and eGFP) frames were collected at 0.2 or 1 Hz. Calcium transients were analysed using previously described custom-made software (MatLab Inc.) and Image J (NIH).1, 3

**In situ calcium imaging.** Acute cortical slices were prepared from P10-20 mice as described previously. Briefly, 400 um acute cortical slices were incubated with rhod-2 (2 mM) for 20 min, before being transferred to a recording chamber where they were imaged and analyzed as outlined before.
Statistical analyses. All analysis was performed using IBM SPSS Statistics 19 and all tests were two-tailed where significance was achieved at $\alpha = 0.05$ level (for details see supporting information). Wherever necessary a Bonferroni correction for multiple testing was done.

Ammonia compromises astrocyte potassium buffering and impairs neuronal inhibition without causing swelling in vivo

Vinita Rangroo Thrane¹²³†*, Alexander S. Thrane¹²³†, Fushun Wang¹, Maria L. Cotrina¹, Nathan A. Smith¹, Michael Chen¹, Ning Kang¹, Takumi Fujita¹, Erlend A. Nagelhus²³, Maiken Nedergaard¹

Key words: ammonia, astrocyte, potassium, seizure, bumetanide

¹Division of Glial Disease and Therapeutics, Center for Translational Neuromedicine, Department of Neurosurgery, University of Rochester Medical Center, Rochester, New York 14642.

²Center for Molecular Biology and Neuroscience, Department of Anatomy, Institute of Basic Medical Sciences, University of Oslo, 0317 Oslo, Norway.

³Center for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslo, 0318 Oslo, Norway.

†These authors contributed equally to the paper

*To whom correspondence should be addressed:

Vinita R. Thrane, MD, Center for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslo, P.O. Box 1137 Blindern, N-0318 Oslo, Norway.

E-mail: vrangroo@gmail.com

Phone: +47 999126007
**One sentence summary**

Ammonia impairs neural inhibition by compromising astrocyte potassium buffering, and inhibiting Na+-K+-2Cl- cotransporter 1 (NKCC1) can effectively block this neurotoxic process.

**Abstract**

Ammonia is a ubiquitous waste product that accumulates in numerous metabolic disorders, causing neurological dysfunction ranging from learning impairment, to tremor, ataxia, seizures and coma. The brain is particularly vulnerable to ammonia as it readily crosses the blood-brain barrier and rapidly saturates its only removal pathway, glutamine synthetase, located in astrocytes. Although ammonia is believed to exert its neurotoxic effects through astrocyte swelling, here we show that swelling is only a terminal feature of ammonia toxicity *in vivo*. Instead, our data indicate that ammonia rapidly compromises astrocyte potassium buffering, leading to an increase in extracellular potassium. The potassium overload in turn increases Na⁺-K⁺-2Cl⁻ cotransporter isoform 1 (NKCC1) activity and depolarizes the neuronal GABA reversal potential, thus impairing cortical inhibitory networks and causing severe neurological impairment. Inhibiting NKCC1 with the clinically used diuretic, bumetanide, potently treats the ammonia-induced neurological dysfunction. These data identify failure of potassium buffering in astrocytes as a central mechanism in ammonia neurotoxicity, and suggest that bumetanide may constitute a novel therapeutic option for disorders of ammonia handling.
Ammonia is a waste product of cellular metabolism that is constantly generated throughout the body. Existing as 99% NH₄⁺ and 1% NH₃ at physiological pH, ammonia is thus able to cross the blood-brain barrier by diffusing in its gas phase (NH₃) (1). If allowed to accumulate, ammonia causes brain dysfunction ranging from mild cognitive impairment, to seizures, coma and death (2).

Ammonia homeostasis is particularly important in the brain, as an equimolar amount of ammonia is simultaneously released with glutamate during neuronal firing (Fig. 1A) (3). Brain ammonia is almost exclusively detoxified by condensation with glutamate to form glutamine, a reaction catalyzed by glutamine synthetase (GS) with a rapid half-life of less than 3 s (4). GS has a higher affinity for ammonia than glutamate, suggesting that the removal of ammonia is prioritized over an excitotoxic neurotransmitter (5).

The current literature points to astrocytes as the primary target of ammonia toxicity, as they are the only cell type in the brain that express GS (6). Histological preparations from animals exposed to elevated ammonia in the context of liver failure display astrocyte pathology in the form of swelling (7). However, it remains unclear whether astrocyte swelling contributes to the initial deterioration of neurological functions characteristic of acute ammonia toxicity (8).

In order to elucidate the mechanisms responsible for ammonia toxicity in the brain, we use the Otc<sup>xpf-ash</sup> mouse model. These mice have an X-linked mutation in the gene encoding ornithine transcarbamylase (Otc), a urea cycle enzyme essential for liver detoxification of
ammonia. \textit{Otc}\textsuperscript{spf-ash} mice are prone to developing rapid rises in plasma ammonia leading to severe neurological dysfunction and coma (9). Clinically relevant ammonia neurotoxicity can be studied in the absence of hepatic complications using the \textit{Otc}\textsuperscript{spf-ash} mouse model. Ammonia neurotoxicity in the context of acute liver failure, on the other hand, is associated with numerous ammonia-independent changes (e.g. neuroinflammation) that alter the neurological phenotype (8). \textit{Otc}\textsuperscript{spf-ash} mice thus provide an optimal model to study the direct effects of ammonia on the brain.

In this study we used \textit{in vivo} optical imaging and electrophysiology in awake behaving \textit{Otc}\textsuperscript{spf-ash} mice and found that astrocyte swelling is only observed during the terminal stages of ammonia neurotoxicity. The earlier stages are, instead, characterized by a failure of astrocyte potassium buffering. The consequent increase in extracellular potassium ([K\textsuperscript{+}]\textsubscript{o}) drives a Na\textsuperscript{+}-K\textsuperscript{+}-2Cl\textsuperscript{-} cotransporter isoform 1 (NKCC1)-dependent depolarizing shift in the neuronal \(\gamma\)-aminobutyric acid (GABA) reversal potential (\(E_{\text{GABA}}\)). GABA, the main inhibitory transmitter in the brain, principally exerts its rapid hyperpolarizing (inhibitory) action via anion-permeable GABA\(_{A}\) receptors (10). The depolarized \(E_{\text{GABA}}\) in ammonia neurotoxicity thus leads to a rapid impairment of neuronal inhibition. Bumetanide is a specific inhibitor of NKCC1 that is routinely used in clinical practice to treat fluid retention, with a favorable side-effect profile (11). In our awake mouse model, we found that inhibiting NKCC1 with bumetanide restored inhibitory transmission and protected the mice from ammonia-related neurological dysfunction.

Results

The \textit{Otc}\textsuperscript{spf-ash} mouse model is characterized by acute ammonia neurotoxicity
To characterize the effects of ammonia on brain function, we subjected awake adult male Otc<sup>ash</sup> mice to an acute systemic ammonia load (NH<sub>4</sub>Cl or NH<sub>4</sub>Ac, 7.5 mmol kg<sup>-1</sup> i.p.). Shortly after the injection, the mice developed a stereotypical sequence of neurological impairments, including decreased spontaneous movement, hypersensitivity to sound (hyperacusis), imbalance, tremor, ataxia, seizures, and in severe cases coma followed by death (Fig. 1A) (12).

The neurological phenotype in our model of OTC deficiency was accompanied by a brisk increase in the extracellular ammonia concentration ([NH<sub>4</sub>]<sup>+</sup>) in plasma (from 0.32 ± 0.7 to 4.21 ± 0.59 mM) and brain (from 0.54 ± 0.18 to 4.83 ± 0.52 mM) (Fig. 1B,C, Fig. S1A). The excess ammonia, in turn, caused an accumulation of glutamine in the brain via enzymatic trapping in astrocytes by GS (9.25 ± 0.34 μmol g<sup>-1</sup>) (Fig. 1D, Fig. S1B) (1, 6). Similar to children born with OTC deficiency, the Otc<sup>ash</sup> mice also had a baseline excess of both ammonia (plasma 0.32 ± 0.073 mM, brain 0.54 ± 0.19 mM) and glutamine (7.58 ± 0.52 μmol g<sup>-1</sup>), and displayed some milder features of ammonia neurotoxicity, such as impaired learning (Fig. 1B-E, Fig. S1C, D) (2, 9, 13).

Next, we examined whether our disease model was characterized by any global hemodynamic changes, as this can occur in very severe ammonia toxicity (2). Cerebral perfusion pressure (CPP), cerebral blood flow (CBF), and intracranial pressure (ICP) were, however, all unchanged following the acute ammonia challenge (Fig. 1F). Finally, we employed several behavioral measures to track the progression and severity of ammonia neurotoxicity in a clinically relevant fashion. Using automated video tracking we found that spontaneous mouse movement decreased sensitively and early following the ammonia challenge (13.69 ± 1.48 vs. 0.42 ± 0.22 m min<sup>-1</sup>) (Fig. 1H). We also developed a sensory-motor phenotype score that
allowed us to both track the onset of specific phenotypes (e.g. ataxia) and also grade their severity (0.53 ± 0.28 vs. 9.00 ± 0.46 out of 11) (Fig. 1H, Fig. S1E) (9, 14).

**Acute ammonia exposure causes a robust seizure phenotype**

In addition to cognitive, sensory, and motor impairment, children with OTC deficiency typically also develop seizures during episodes of transient increases in ammonia (2, 12). We used cortical, subcortical and muscle electrodes in awake mice to further explore this phenotype (Fig. 2A) (8). Around weaning *Otc*^opf-ash^ mice occasionally developed spontaneous myoclonuses, which are brief (< 2 s) involuntary jerk-like movements that can be caused by seizure activity in either the cortex or subcortical structures (15). However, these events were scarce and too variable to allow careful study. We therefore used the aforementioned acute ammonia challenge to precipitate a more robust seizure phenotype. The intermediate doses (7.5 mmol kg\(^{-1}\)) employed in most of our study caused numerous myoclonic events (ME), whilst a lethal dose (10 mmol kg\(^{-1}\)) of ammonia also induced longer lasting generalized tonic-clonic seizures (Fig. 2B).

We proceed to examine the ME in more detail, and found several lines of evidence indicated that these events were a form of centrally generated seizures. Firstly, we found that the myoclonic electroencephalogram (EEG) discharges consistently preceded the electromyogram (EMG) discharges by 19.42 ± 4.78 s, indicating that these events originated in the brain (Fig. 2C). Secondly, we were able to detect 3-9 Hz poly-spike and wave (SWD) discharges typical of myoclonic epilepsy using EEG and the associated myoclonic jerks using video-analysis and EMG (Fig. S2A-C and Video 1) (16, 17). Finally, we found that the frequency of ME closely correlated with overall disease severity (assessed by the aforementioned phenotype score), which both showed similar dose-response curve (Fig. 2D). Importantly, both overall phenotype and ME
were entirely masked by anesthesia, emphasizing the need for recordings in awake animals in our study.

Direct cortical application of ammonia reproduces the disease phenotype

Next, we wanted to examine the anatomical origin of the ammonia-induced seizures. To do this we generated a new model where we applied ammonia (10 mM) directly on the cortex of awake mice. We found that the resultant cortical ammonia elevation was sufficient to reproduce the disease phenotype of systemic ammonia toxicity (Fig. 2E, F). The lower ME frequency in this compared to the systemic model likely relates to small area of cortex (1.5 mm cranial window) being exposed to ammonia. To define how deep into the brain the locally applied ammonia permeated we used NH$_4^+$ ion-sensitive microelectrodes (ISM). We found that the ammonia diffusion was surprisingly restricted, affecting mainly the superficial cortex (Fig. 2E). Seen in the context of previously radio-isotope studies, this observation most likely relates to the rapid metabolic trapping of ammonia in astrocytes by the enzyme GS (I). Consistent with this idea, when we inhibited GS with L-methionine sulfoximine (MSO, 1.5 mM) the cortical [NH$_4^+$]$_o$ gradient was reduced. It is therefore likely that cortical astrocytes take up most of the excess [NH$_4^+$]$_o$ in our model of focal ammonia toxicity. The importance of astrocyte ammonia sequestration is further illustrated by the increased ME frequencies we recorded when MSO was co-administered with ammonia (MSO 1.06 ± 0.26 vs. NH$_4$Cl 2.66 ± 0.14 vs. NH$_4$Cl + MSO 3.29 ± 0.19) (Fig. 2F). Astrocyte uptake of excess [NH$_4^+$]$_o$ in the cortex thus appears to play a critical role in generating the neurological dysfunction seen in ammonia neurotoxicity.

Using both our systemic and cortical disease models, we proceeded to explore whether ammonia-related ME arise in the cortex or thalamus. Recent studies in humans and rodents have
suggested that several generalized seizure types, such as SWD (including ME and absence seizures) and tonic-clonic, may primarily originate in the cortex and secondarily invade the thalamus (18-20). To establish the origin of ammonia-induced seizures, we placed extracellular electrodes in the cortex and thalamus of awake mice. The dual recordings showed that ammonia-induced SWD in the cortex preceded those in the thalamus by 7.87 ± 2.15 ms when ammonia was administered systemically, and 8.26 ± 2.11 ms when ammonia was applied cortically (Fig. 2G) (21). In conclusion, several lines of evidence suggest cortical ammonia toxicity may be sufficient and necessary for ME generation, which in turn correlated closely with overall disease severity.

Cortical ammonia exposure causes rapid disinhibition of neuronal firing

Different and often inconsistent neuronal effects of ammonia have been described in the context of different disease models (in vitro, in situ and in vivo) and different time courses (acute, subacute and chronic) (22). Similar to previous 1H-NMR studies, we found no net change in the levels of neurotransmitters glutamate and GABA that could explain the neurotoxicity of ammonia (Table S1) (13, 23). In one of the few previous in vivo studies Lux et al. showed that inhibitory GABAergic neurotransmission is impaired when cats receive an acute ammonia challenge. However, this study looked primarily at spinal motor neurons and did not actually measure seizure activity. To extend these observations into a more clinically relevant analysis, we examined the effect of ammonia superfusion on cortical inhibitory networks in awake animals using paired-pulse whisker stimulation. This method has previously been used to study the maturation of inhibitory networks (24). The whisker stimulation paradigm we employed elicits two successive field excitatory post-synaptic potentials (fEPSP). The amplitude of the
second fEPSP is normally smaller than the first one, owing to activation of cortical inhibitory networks that suppress the second fEPSP. This is quantified by a paired-pulse ratio (PPR) of less than one. Ammonia superfusion, however, increased the PPR from 0.64 ± 0.13 in the control setting to 1.56 ± 0.24 (paired-pulse facilitation), which recovered to 0.61 ± 0.15 upon washout (Fig. 2H, I). For the first time we therefore demonstrate that ammonia causes a significant disinhibition of excitatory neuronal firing in the cortex and thereby provide a direct link to cortical seizure generation.

**Astrocyte swelling is only a terminal feature of acute ammonia neurotoxicity**

We next asked what role astrocytes might play in ammonia neurotoxicity. Much of recent literature has suggested ammonia-induced astrocyte swelling and brain edema are an important cause of the neurological impairment seen in ammonia neurotoxicity (7, 25-27). However, astrocyte swelling has to our knowledge never been demonstrated in vivo. We used two-photon laser scanning microscopy (2PLSM) in awake Otcopf-ash mice expressing eGFP in astrocytes under the Glt-1 promoter to examine real-time volume changes following an acute ammonia challenge (Fig. 3A). We found that ammonia caused no significant astrocyte swelling in vivo, but rather a transient yet significant shrinkage of 5.04 ± 0.85% (Fig. 3B). In addition, cortical slices acutely exposed to ammonia (10 mM) failed to show astrocyte swelling unless concentrations high enough to cause cell lysis (50 mM) were applied (Fig. 3C).

To further investigate the role of astrocyte swelling, we examined mice deficient in aquaporin-4 (AQP4) water channels. AQP4 is the major influx pathway for water into astrocytes and knocking out this protein reduces astrocyte swelling (28). AQP4 has also been shown to be upregulated in ammonia neurotoxicity (29). However, when injected with ammonia, Agp4-/- mice
displayed no improvement in the severity of phenotype or ME frequency (Fig. S3A, B). Finally, to determine whether global brain swelling is necessarily associated with all levels of ammonia neurotoxicity, we measured brain water content in \(Otc^{opf-ash}\) and WT mice following different doses of ammonia. We found that 5-7.5 mmol kg\(^{-1}\) of ammonia did not cause brain edema despite causing the previously illustrated significant neurological phenotype (Fig 3D, Fig. S3C). Swelling was only observed with a lethal ammonia dose of 10 mmol kg\(^{-1}\), consistent with data from patients with fatal ammonia toxicity (30). Taken together, our results indicate that astrocyte swelling is not a critical event in acute ammonia neurotoxicity. Moreover, the data demonstrate that the \(Otc^{opf-ash}\) model used in our study is not associated with significant edema, even though the mice exhibit all the clinical and biochemical signs of ammonia neurotoxicity.

**Astrocytes calcium signaling: an early sign of impaired glia-neuronal crosstalk in ammonia neurotoxicity**

Having not yet found any sign of astrocyte dysfunction, despite strong evidence suggesting astrocytes bear the brunt of the ammonia load, we proceeded to explore astrocyte signaling. Since astrocytes are electrically silent, we used 2PLSM to image intracellular calcium transients in cortical astrocytes of \(Otc^{opf-ash}\) mice loaded with calcium indicator rhod-2. The indicator selectively loaded astrocytes, as shown by co-localization with eGFP expressed in astrocytes as described above. To allow direct correlation of imaging to clinical phenotype these animals were again awake (Fig. 3F, Fig. S3D). Astrocyte calcium signaling is believed to modulate a range of functions including cerebral blood flow, synaptic activity and extracellular ion homeostasis (31-33). However, most data has been collected from anesthetized mice or in situ preparations, and the role of spontaneous calcium transients in awake behaving mice is not well characterized (34).
We recorded several distinct patterns of spontaneous calcium transients during control conditions (Fig. 3F). The most striking observation in awake mice was a higher frequency of spontaneous calcium transients compared to anesthetized animals (Table S2, Video 2). The predominant pattern of signaling in awake mice was synchronous bursts, whereas anesthetized animals largely displayed individual calcium transients. This observation is consistent with the only other study that explored calcium activity in the awake cortex, which concluded that the synchronous bursting exhibited a delayed and variable correlation with neuronal activity (34).

We next examined astrocyte calcium transients in awake Otc<sup>pyf-ash</sup> mice receiving a systemic ammonia challenge. Following the ammonia administration the mice experienced a prolonged increase in overall calcium transient frequency from 2.67 ± 0.36 to 9.03 ± 1.16 Hz cell<sup>−1</sup> 10<sup>−3</sup> (Fig. 3E, F). The increase in calcium signaling preceded the onset of ME by 1.58 ± 0.37 min. Surprisingly, however, calcium transient frequency decreased when ME frequency peaked (Fig. 3E, F). Additionally, individual ME showed a weak temporal correlation of 0.15 ± 0.10 with calcium transients (Fig. 3G, Fig. S3E). Moreover, the ammonia challenge also caused a pathological desynchronization of cortical calcium transients, with a reduced cell-cell (∆F/F<sub>0</sub>) correlation from 0.65 ± 0.06 to 0.26 ± 0.08 compared to baseline (Fig. 3H, Video 3). Finally, both ammonia and saline injection triggered a brief burst of transients one minute after administration, likely due to animal arousal (35). Taken together, these observations indicate astrocytes signaling distress early in ammonia neurotoxicity, and perhaps experience an overall failure of signaling during the most severe clinical stage of the disorder. The decreased and desynchronized signaling when ME activity is peaking could represent pathological neuron-to-glia signaling evoked by excessive neuronal firing (32).
Astrocytes overloaded with ammonia fail to buffer potassium

Using awake intact mouse models we have so far shown that acute ammonia toxicity is associated with 1) severe neurological impairment, 2) neuronal disinhibition and 3) astrocyte distress and/or dysfunction, but not swelling. We therefore proceeded to examine the link between astrocyte and neuronal dysfunction. Extracellular potassium homeostasis ([K⁺]o) is a vital function of astrocytes with important implications for neuronal function (36-41). Previous *in situ* and *in vitro* studies have also indicated that ammonia may compromise astrocyte potassium buffering (42, 43). Using NH₄⁺ and K⁺-ISM electrodes in awake mice we found that both systemically (7.5 mmol kg⁻¹) and cortically (10 mM) applied ammonia directly impaired potassium homeostasis in the cortex (Fig. 4A-C). Systemic administration caused a 1.93 ± 0.19 mM [K⁺]o increase in the Otc⁢pf⁻ash mice (subtracted for NH₄⁺ interference), above a resting level of 3.91 ± 0.27 mM (Fig. 4B) (44). Direct cortical administration caused a 2.24 ± 0.17 mM increase in [K⁺]o, which recovered to a level slightly below baseline upon washout as the neurological manifestations including ME subsided (Fig. 4C, Fig. S4C). More importantly, this [K⁺]o increase preceded ME onset by 4.91 ± 0.35 min and 2.875 ± 0.201 min in the systemic and cortical models, respectively (Fig. S4A-C). Additionally, the [K⁺]o increase we observed showed a strong correlation with ME frequency (Fig. 4D). Similar observations could be reproduced in wild-type mice, indicating that the is not an artifact of the Otc⁢pf⁻ash strain (Fig. S4D).

Next, we wanted to assess the role of astrocyte ammonia sequestration (via GS) in the potassium accumulation. Reduced activity of GS in gliotic brain tissue has previously been implicated in the initiation of temporal lobe epilepsy (45). Similarly, we found that administering MSO prior to the ammonia challenge exacerbated both the [NH₄⁺]o and the [K⁺]o increase (Fig. S4DE, F). This observation may reflect that decreasing the influx of ammonia into astrocytes
with MSO increases the overall cation load (NH$_4^+$ or K$^+$) on neurons, as less NH$_4^+$ is trapped in glutamine. Finally, ammonia is also known to exert pH effects in brain (46). We therefore used H$^+$ ISMs and found an extracellular alkalization following ammonia injection. However, this effect was mild, delayed and correlated poorly with clinical phenotype (Fig. S4G). Thus, we confirmed that astrocytes play a key role in enzymatic ammonia removal, and show that ammonia neurotoxicity causes a profound cortical [K$^+$]$_o$ increase that precedes and correlates strongly disease severity.

**Potassium replicates the neuronal impairment in ammonia toxicity**

Our data indicate that ammonia-related neurological changes are preceded by an increase in cortical [K$^+$]$_o$. We therefore superfused KCl (12.5 mM) across the cortex of awake mice to explore whether increased [K$^+$]$_o$ is sufficient by itself to replicate the adverse effects of ammonia (Fig. 4A). Strikingly, when [K$^+$]$_o$ was increased by 2.37 ± 0.03 mM using KCl superfusion, the mice developed ME similar to our ammonia superfusion model (Fig. 4E, F). With higher doses (20 mM) they would also develop tonic-clonic seizures (Fig. 4F). We subsequently proceeded to explore whether potassium-related seizures were also associated with disinhibition of neuronal firing. Using the paired-pulse paradigm we described above, we demonstrated that KCl superfusion caused a disinhibition similar to ammonia with a mean PPR of 1.48 ± 0.22, which recovered to 0.63 ± 0.14 after washout (Fig. 4G). In conclusion, for the first time in vivo we show that increasing [K$^+$]$_o$ alone is sufficient to generate neuronal disinhibition, seizures, and thus replicate the neuronal impairment seen in ammonia toxicity. These observations were entirely dependent on using awake intact animals, as the clinical phenotype was masked by anesthesia.
Ammonia competes with potassium for uptake in astrocytes

We subsequently used a combination of in vitro assays to determine the mechanism of the ammonia-induced [K⁺]₀ increase. Interestingly, previous radioisotope studies revealed that almost immediately following an acute ammonia load, 4x as much ¹⁵N-labelled ammonia is fixed in glutamine than exists as the free ionized form NH₄⁺ (I). Given that glutamine is only formed in astrocytes (via GS), this observation means that >4x as much ammonia crosses astrocyte membranes than any other cell type (including neurons). Previous studies have used this insight to focus principally on the toxic effects of excess ammonia and/or glutamine in the astrocyte cytosol (25). However, the >4x higher flux of ammonia across astrocyte membranes provides perhaps the most bioenergetically challenging load, and this is often overlooked.

To explain how the excess ammonia load on astrocyte membranes could lead to decreased K⁺ uptake we hypothesized that ammonia would either indirectly impair (pump failure) or directly compete (pump overactivity) for uptake with K⁺. Because the gradients driving astrocyte uptake of potassium inevitably all depend on Na⁺-K⁺-ATPase (NKA) activity, we chose to focus on this transporter as a proof of principle. NKA-mediated potassium clearance, but not clearance via K⁺-channels or (Na⁺)-K⁺-Cl⁻ cotransporters, is for instance known to be most important during epileptic activity (47). Surprisingly, when NH₄Cl was substituted KCl in a cell-free NKA assay, we found that NH₄Cl alone was able to maintain normal NKA activity, indicating that K⁺ can be substituted by NH₄⁺ without an effect on ATPase function (Fig. 4I). This observation is further supported by previous studies in kidney showing that NH₄⁺ can replace K⁺ as a substrate for the renal NKA (48, 49). Notably, NH₄⁺ and K⁺ ions have a similar
hydrated radius and charge, and can also permeate potassium channels with similar efficacy (3, 50).

Given that both $K^+$ and $NH_4^+$ ions can bind to the Na$^+$-K$^+$-ATPase, we would predict that Na$^+$-K$^+$-ATPase activity is increased during ammonia toxicity, as there is more overall substrate ([NH4$^+$]$_o$ and [K$^+$]$_o$) available for transport. Interestingly, increased Na$^+$-K$^+$-ATPase activity has been shown in both congenital and acquired ammonia disorders (51). Indeed, the transient shrinkage of ammonia-exposed astrocytes shown above is consistent with increased activity of the Na$^+$-K$^+$-ATPase, which exports 3 Na$^+$ and imports 2 K$^+$ ions. Furthermore, we would predict that ammonia decreases potassium uptake in a dose-dependent fashion. Consistent with this hypothesis we found that biologically relevant ammonia concentrations (0.5-10 mM) inhibited NKA-dependent (ouabain-sensitive) potassium analogue rubidium ($^{86}$Rb$^+$) uptake in cultured astrocytes in a dose-dependent fashion (Fig. 4H). In contrast, neuronal $^{86}$Rb$^+$ uptake was more inconsistently reduced, compatible with the hypothesis that neurons play a less prominent role in potassium buffering than astrocytes (Fig. S4H) (37). Combined, our observations indicate that $NH_4^+$ short circuits the astrocytic K$^+$ buffering, causing the sustained increase in [K$^+$]$_o$ observed in vivo (Fig. 4J).

**Ammonia depolarizes $E_{GABA}$ in cortical neurons**

We next wanted to explore the link between impaired astrocyte potassium buffering and neuronal disinhibition by using neuronal patch clamping in cortical slices perfused with ammonia. Adding 7 mM ammonia to the perfusate reproduced the increase in [NH4$^+$]$_o$ and [K$^+$]$_o$ observed in vivo (3.67 ± 0.53 mM and 1.88 ± 0.13 mM respectively) (Fig. 5A).
The inhibitory action of GABA is dependent on a hyperpolarized $E_{GABA}$ (10). Using whole-cell patch clamping of pyramidal neurons with ramp voltage and GABA application we found that ammonia depolarized $E_{GABA}$ by $12.33 \pm 3.66$ mV (Fig. 5B). This effect was GABA$_A$-receptor dependent as bicuculline, a GABA$_A$-receptor antagonist, completely blocked the GABA-induced current (Fig. S5A, B). Similar to previous studies using moderate ammonia concentrations, we found no consistent change in neuronal resting membrane potential or input resistance (22, 52).

Because $E_{GABA}$ is heavily dependent on chloride transporters, we next tested the diuretic bumetanide, a highly specific NKCC1 inhibitor used in clinical practice to treat heart failure (11). In our study, bumetanide (5 $\mu$M) pre-incubation successfully prevented the depolarizing effect of ammonia on $E_{GABA}$ (Fig. 5B). Using immunohistochemistry we found that NKCC1 is present in cortex (Fig 5C), confirming previous studies indicating NKCC1 expression in adult brain, although at lower levels than in developing tissue (53-55). We observed no obvious differences in the expression pattern of NKCC1 between wild-type and $Otc^{opf-ash}$ mice throughout the cortex. Interestingly, chronic low elevations of ammonia similar to the resting levels seen in our $Otc^{opf-ash}$ mice have been shown to increase NKCC1 activity up to 3 fold, perhaps explaining some of the baseline learning deficit in these mice (56). On the basis of these observations, we hypothesize that elevated $[K^+]_o$ and $[NH_4^+]_o$ overactivate neuronal NKCC1, leading to an intracellular accumulation of chloride that depolarizes $E_{GABA}$ (Fig. 5D). Supporting this conclusion, previous in vivo, in situ and in vitro work has shown that neurons exposed to elevated ammonia levels have significantly increased intracellular chloride content (52, 57, 58).

**NKCC1 inhibition improves clinically relevant features of ammonia neurotoxicity**
To test the validity of our in situ model we returned to awake animals, and asked whether blocking NKCC1 with bumetanide reducing disinhibition in vivo (Fig. 6A). Using the previously described paired-pulse paradigm, we found that adding bumetanide to the superfusate significantly improved disinhibition following cortical application of both ammonia and potassium (Fig. 6B-C, Fig. S6A). With ammonia application PPR increased maximally to 0.88 ± 0.15 when bumetanide was co-administered, and recovered to a control level of 0.59 ± 0.17 after washout of both ammonia and bumetanide. Similarly, when potassium alone was co-applied with bumetanide the mean PPR only increased to 0.92 ± 0.18. Taken together, these data indicate that bumetanide effectively treats the neuronal dysfunction seen in ammonia neurotoxicity.

Next, we wanted to investigate whether this improvement of neuronal function translated into a clinically relevant improvement in disease phenotype. Employing the same phenotype measures outline in Figure 1 we demonstrated that NKCC1 inhibition increases spontaneous mouse movement, reduces the sensory-motor phenotype score, decreases ME frequency and increases survival following an ammonia overdose (Fig. 6E-H). Spontaneous movement increased from 0.42 ± 0.22 to 3.17 ± 0.46 m min⁻¹ and phenotype score was reduced from 9.00 ± 0.46 to 6.00 ± 0.72 (Fig. 6E, F). ME frequency was reduced from 0.78 ± 0.05 to 0.13 ± 0.03 (with cortical KCl), 1.02 ± 0.07 to 0.10 ± 0.02 (with cortical NH₄Cl) and 2.66 ± 0.14 to 0.32 ± 0.02 ME min⁻¹ (with systemic NH₄Cl) (Fig. 6G). Survival over a 45 min period after ammonia overdose (10 mmol kg⁻¹) increased by a factor of 3.87 (hazard rate ratio 0.26, 95% confidence interval 0.08 to 0.87). These clinically relevant improvements were observed both when bumetanide was administered systemically (i.p., 30 mg kg⁻¹) and cortically (5 μM), indicating that the drug exerts its beneficial action principally in the cortex. Moreover, the therapeutic effect
of bumetanide could not be attributed to a normalization of $[K^+]_o$, $[NH_4^+]_o$ or brain amino acids, which were unaltered by the treatment (Fig. 6I, J, Table S1 and Table S3).

These *in vivo* data demonstrate that an elevation of ammonia in the cortex is sufficient to induce NKCC1-dependent and bumetanide-sensitive neuronal impairment, supporting the model developed from the *in situ* data (see Fig. 4g).

**Discussion**

Ammonia neurotoxicity is an almost universal phenomenon that occurs in all animals from fish to humans, and has previously been extensively studied *in vitro, in situ*, and using biochemical or histological methods. This work has produced important clues as to the cellular mechanisms underlying ammonia neurotoxicity, but the continued lack of treatment illustrates clearly that the overall picture is still incomplete. What we have tried to do in our study is to test and extend individual *ex vivo* observations using *in vivo* models, where we can continuously correlate experimental observations with clinical phenotype. In this way we attempted to piece together a more complete picture of what cellular and subcellular changes are necessary and sufficient to produce the neurological dysfunction seen in acute ammonia neurotoxicity (e.g. elevated $[K^+]_o$), and which are not (e.g. astrocyte swelling). All anesthetics tested in our study masked the ammonia-induced neurological phenotype and disrupted normal astrocyte signaling. Thus, the use of awake animals in our *in vivo* models was critical to identify the pathological chain of events involving both astrocytes and neurons that leads to ammonia neurotoxicity.

First, we chose a childhood disorder, X-linked OTC deficiency, and used this to develop a clean mouse model of acute ammonia neurotoxicity that was unconfounded by hemodynamic or hepatic complications (9). Using behavioral and biochemical methods we show that this
model replicates all the pathognomic features of ammonia neurotoxicity. This relatively rare disorder thus represents an important opportunity to try and understand the larger phenomenon of ammonia toxic effects on neural tissue.

Second, using paired-pulse whisker stimulation in awake mice we show that an acute ammonia challenge causes disinhibition of neuronal firing and consequently ME similar to those observed in children with OTC deficiency (2). Additionally, we provide evidence suggesting that these ME originate in the cortex, likely due to the rapid influx of ammonia into cortical astrocytes driven by the enzyme GS. Finally, we show that the neurological phenotype in ammonia neurotoxicity can be reproduced using a novel model where we apply ammonia directly to cortex of awake mice.

Third, due to the putatively four times larger ammonia-load on astrocyte membranes than all other cell type, we next asked how astrocytes contribute to or cause the neuronal dysfunction. Extensive ex vivo literature suggests that ammonia causes brisk astrocyte swelling (7, 25-27). To our surprise, however, we found that ammonia does not cause astrocyte swelling, but instead produces novel changes in astrocyte calcium signaling. We suggest that the signaling changes represent astrocytic responses to neuronal hyperexcitability, astrocyte distress and/or dysfunction of astrocytes early in the disease process. To our knowledge this is the first examination of astrocyte volume and signaling changes in vivo during ammonia neurotoxicity.

Fourth, we proceeded to explore whether dysfunctional astrocyte signaling was indicative of impaired astrocyte potassium uptake, as the two are closely linked (36). Using our awake mouse models of systemic and direct cortical ammonia neurotoxicity we observed that a ~2 mM $[\text{K}^+]_o$ increase preceded symptom onset. Notably, the magnitude of the $[\text{K}^+]_o$ increase correlated closely with disease severity. We were also able to reproduce the neural and clinical features of
ammonia neurotoxicity by cortical application of potassium alone. We thus provide the first direct link between potassium and neural dysfunction, including seizures, in ammonia intoxication.

Fifth, we demonstrate that NH$_4^+$ can compete with K$^+$ ions for active uptake on astrocyte membranes. This competition short circuits the astrocytic Na$^+$-K$^+$-ATPase pump with severe consequences, including compromised [K$^+$]$_o$ buffering and seizures. A similar competition has been shown in kidney and retina, suggesting that an accumulation of ammonia may act as a universal hazard that can disrupt potassium homeostasis in any organ and almost any animal (3, 48).

Finally, we show that there is currently no effective way (e.g. MSO) of protecting astrocytes from ammonia without increasing the ammonia-load on neurons. Instead, we find that inhibiting the downstream effects of ammonia and potassium on neurons is the most effective therapeutic strategy. These downstream effects appear to depend most critically on a potassium-driven depolarizing shift in $E_{\text{GABA}}$ that impairs neural inhibition. We show that inhibiting the chloride importer NKCC1 with the clinically used diuretic bumetanide not only rescues the shift in $E_{\text{GABA}}$, but also improves all aspects of the neurological phenotype.

ME are characterized by generalized SWD on the EEG (16). SWD are observed in a group of seizure disorders, including childhood absence seizures, which have recently been shown to involve early cortical activation (18). This led to the hypothesis that SWD originate from a focus in the cortex, before recruiting the thalamus leading to generalized seizures. Notably, during SWD, injection of lidocaine into the cortex to locally inhibit neuronal firing is able to suppress all seizure activity in the brain (19). In our study, two lines of evidence suggest that the ME we observed during ammonia neurotoxicity are cortical in origin. First, we recorded
SWD in the cortex ~8 ms prior to the thalamus. Second, direct application of ammonia or potassium on the cortex replicated the SWD activity seen in systemic ammonia toxicity. Taken together, these data suggest that an impairment of potassium homeostasis in the cortex is sufficient to generate ME in our model.

In our study we find that ammonia- and potassium-induced neurological impairment is preceded by a depolarizing shift in neuronal $E_{GABA}$. A similar shift in $E_{GABA}$ has been shown in resected hippocampi from patients with temporal lobe epilepsy (59). Interestingly, administration of the astrocyte toxin fluoroacetate or insulin-induced hypoglycemia also depolarize $E_{GABA}$ (60).

In adults, the inhibitory action of GABA is dependent on a hyperpolarized $E_{GABA}$. In early development, however, cortical neurons have a depolarized $E_{GABA}$ due to the high activity of NKCC1, which causes an intracellular accumulation of chloride (61). Early studies using radiolabelled $^{36}$Cl$^-$ and intracellular electrodes found a similar chloride accumulation during acute ammonia exposure, although the mechanism was not known (52, 57). Later in development, decreased activity of NKCC1 and increased activity of K$^+$-Cl$^-$ cotransporter isoform 2 (KCC2), cause a developmental switch in $E_{GABA}$ making it hyperpolarized (62).

Inhibition of NKCC1 has therefore been suggested as a therapy for seizures in early development (neonates) (53). Moreover, KCC2 expression is reduced following nerve injury in adults, depolarizing $E_{GABA}$, causing inappropriate neuronal firing and neuropathic pain (63). In our model, increased $[\text{NH}_4^+]_o$ and $[\text{K}^+]_o$ drive an NKCC1-dependent depolarizing shift in $E_{GABA}$, resembling early development. Using awake behaving adult mice, we demonstrate that this depolarizing shift is followed by a severe impairment of cortical inhibitory neurotransmission and seizures.
The FDA-approved diuretic bumetanide considerably improved clinically relevant behavioral measures in our awake models of ammonia- and potassium-induced neurotoxicity. During childhood an accumulation of ammonia is most frequently caused by enzyme deficiencies such as the Otc mutation explored in our study. These devastating conditions have attracted limited research focus, and consequently the disease mechanisms are incompletely understood (7, 29). Few mechanism-specific therapies have been developed for acute ammonia neurotoxicity, and bumetanide may bridge the gap in ammonia-related translational research, providing a safe, effective and mechanism-targeted therapeutic option. Our results provide clear impetus for the initiation of clinical trials investigating the therapeutic potential of bumetanide in ammonia neurotoxicity.

Materials and Methods

Rodent breeding and behavioral studies

All animal experiments were approved by the Animal Care and Use Committee of the University of Rochester. Otc<sup>spf-ash</sup> B6C3-F1 mice were bred as described previously, and males from 8-12 weeks were used (9). Otc<sup>spf-ash</sup> mice were crossed with Glt-1-eGFP mice for imaging experiments. C57BL/6J mouse and Wistar rat pups were obtained from Jackson Laboratories. To analyze cognitive abilities in OTC mice, two commercial conditioning chambers (H10-11M-TC, Coulbourn Instruments) were adapted for contextual fear conditioning. Over the course of 4 days, mice were trained via a tone/shock protocol and trained to fear contextual and auditory cues. Better trained mice exhibited higher freezing percentages in the precesense of auditory or contextual cues (64, 65). Automated movement analysis was performed using AnyMaze™
software analysis of CCD-camera recordings in a standard mouse cage. We developed a sensory-motor phenotype score to quantify the severity of ammonia neurotoxicity based on two previous studies (9, 14). Each animal gets scored every 15 minutes based on the severity of the following phenotypes: hyperacusis (0-2), imbalance (0-3), ataxia / tremor (0-3) and level of consciousness (0-3). A maximum score of 11 represents deep coma (no corneal reflex) whilst 0 represents normal wakefulness.

**Animal preparation for awake in vivo recordings**

Mouse preparation was modified from published protocols (8, 34). Briefly, mice were anesthetized using isoflurane (1.5% mixed with 1-2 L/min O₂), head restrained with a custom-made mini-frame, habituated over 2 days, a 1.5 mm craniotomy was then opened over the somatosensory cortex, and the mice were allowed 60 min recovery prior to conducting the experiments. Body temperature was maintained with a heating pad. For systemic drug treatment, a polyethylene intraperitoneal (i.p.) catheter was surgically implanted to deliver drugs accurately and with minimal manipulation. For cortical drug application artificial cerebrospinal fluid (aCSF) was perfused across the cortex of awake mice at a rate of 2 mL/min, into a custom-made well with ~200 μL volume, through tubing with ~100 μL volume, meaning the entire volume bathing the brain was exchanged every ~9 s. The aCSF solution contained (in mM) 126 NaCl, 2.5 KCl, 1.25 NaH₂PO₄, 2 MgCl₂, 2 CaCl₂, 10 glucose, and 26 NaHCO₃, pH 7.4. For imaging, calcium indicator rhod-2 AM (Invitrogen, 2 mM) was loaded onto exposed cortex for 45 min before applying agarose (1.5%, type III-A, Sigma) and a coverslip (28).

**Biochemical and hemodynamic analysis**
Plasma ammonia analysis was performed on blood samples collected using 50 μL heparinized tubes from the femoral artery. A L-glutamate dehydrogenase based kit (Sigma) was used for the quantification of ammonia in plasma. For ¹H-NMR mouse forebrains were extracted, frozen, homogenized and lyophilized before being reconstituted with D₂O as described previously (23). ¹H-NMR spectra were acquired at 25°C using a 600 mHz Varian UnityINOVA spectrometer (7200 Hz spectral width, 32K data points, 64 signals averaged for each spectrum). For hemodynamic recordings an intracranial pressure probe (Millar) was inserted through a small 0.5 mm craniotomy over the somatosensory cortex. Cerebral blood flow was assessed using a fiberoptic laser Doppler probe (PF5010, Perimed) and connected to an infrared laser doppler flowmeter. Blood pressure was monitored through the femoral artery cannula (SYS-BP1, WPI), and cerebral perfusion pressure was deduced by subtracting ICP from blood pressure. All signals were digitized (Digidata 1332A, Axon Instruments) and analyzed (pClamp 10.2). Brain water content was assessed using wet-to-dry ratios (WDR) of brain weight as described previously (66).

**Electrophysiological recordings**

*In vivo* recordings were obtained from layer II somatosensory cortex. *In situ* recordings were obtained from layer II in coronal cortical slices prepared from P21-30 mice. ISMs of K⁺ and NH4⁺ were pulled from double-barreled pipette glass (PB150-6, WPI) with a tip of 1-3 μm. The pipettes were silanized (coated) with dimethylsilane I (Fluka, Sigma) and filled with either K⁺ ionophore I cocktail B (Fluka, selectivity coefficient -1.8 log(K⁺/NH₄⁺)) or NH₄⁺ ionophore I cocktail B (Fluka, -0.9 log(NH₄⁺/K⁺)). All ISMs were calibrated before and after each experiment (a < 5% difference was acceptable) using standard solutions and the calibration data were fitted to the Nikolsky equation to determine electrode slope and interference (44). Whole-
cell patch-clamp recordings were performed as described previously (67). Electroencephalogram (EEG) signals were externally filtered at 6 Hz (Filter Butterworth Model by Encore, Axopatch 200B by Axon Instruments), bandpass filtered at 1-100 Hz and digitized (Digidata 1440A by Axon Instruments). Ion-sensitive microelectrode (ISM) signals were amplified (FD223a by WPI), externally filtered and digitized as above, and reference field potential traces were subtracted. In selected experiments, wireless electromyogram (EMG) and electroencephalogram (EEG) electrodes were implanted (DSI Physiotel®), and an extracellular microelectrode was placed in the thalamus (ventrobasal complex). Recordings were analyzed offline using pClamp 10.2. Myoclonic events (ME) were defined on the EEG as single or multiple 3-9 Hz polyspike and wave discharges (SWD) of 0.2-2 s duration associated with myoclonic jerks determined by video recording, EMG or direct observation. Whisker stimulation was delivered using a picospritzer III (Parken Instrumentation) and Master 8 (A.M.P.I.). Stimuli consisted of paired 50 μs air pulses with an inter-stimulus interval of 150 ms, and paired-pulse ratio (PPR) was calculated as previously described (24). NH₄Cl/NH₄Ac solutions were pH (7.4) and osmolarity adjusted.

**Two-photon laser scanning microscopy**

A Mai Tai laser (SpectrPhysics) attached to a confocal scanning system (Fluoview 300, Olympus) and an upright microscope (IX51W) was used. *In vivo* volume changes and calcium activity were imaged in cortex 100 μm below the pial surface, using a 60x (1.1NA) and a 20x (0.95NA) lens, respectively. For *in vivo* volumetry we collected xyzt image series (z-step 1.5 μm, every 5 min) with acquisition time <20 seconds and laser power <40 mW. For *in vivo* calcium imaging we collected dual channel (rhod-2 and eGFP) frames at 0.2 or 1 Hz. A low sampling
rate and <20 mW laser were used to avoid photodamage. A calcium transient was defined as an event where the relative ratio between the rhod-2 and eGFP signal intensities ($\Delta F/F_0$) was >2 standard deviations ($\sigma$) from baseline. Beginning and end were defined as $\Delta F/F_0$ >0.5 $\sigma$ and <0.5 $\sigma$ respectively. Amplitude was taken as the peak $\Delta F/F_0$ in this interval. For *in situ* volumetric imaging acute cortical slices were loaded with texas red hydrazide (1.5 µM, a fixable sulforhodamine 101 derivative) in aCSF for 50 minutes. Volume and calcium recordings were analyzed using previously described custom-made software (MatLab Inc.) (28).

**Cell culture assays**

Cultured neocortical astrocytes were prepared from P1-2 mouse and rat pups as previously described (36, 68). For $^{86}$Rb$^+$ experiments the cultures were incubated for 10 min ± ouabain (1 mM). The potassium analogue $^{86}$Rb$^+$ was then added to each well plate for 15 min (1 µCi, Perkin Elmer). The reaction was stopped by placing the cells on ice and washed with ice-cold aCSF. The cells were lysed and $^{86}$Rb$^+$ uptake quantified by liquid scintillation counting (Beckman Coulter). For Na$^+$-K$^+$-ATPase activity, astrocyte cultures were utilized as previously described, and enzyme activity was quantified using the malachite green reaction (Sigma) and analyzed using spectrophotometry (69).

**Immunohistochemistry**

Mice were anesthesized and perfused transcardially with 4% paraformaldehyde, and the brains were post-fixed overnight. Serial 16 µm sagittal cryostat sections were cut after overnight cryoprotection in 30% sucrose. Sections were incubated with goat anti-NKCC1 primary antibody (1:200, Sta. Cruz Biotechnology) overnight at 4°C, followed by incubation with an Alexa-488
donkey anti-goat secondary antibody (1:500, Invitrogen). Vectashield containing DAPI (Vector) was used for mounting. Images were taken with a 10x lens in a BX53 Olympus system microscope attached to a DP72 Olympus digital camera.

**Statistical analysis**

All analysis was performed using IBM SPSS Statistics 19 and all tests were two-tailed where significance was achieved at $\alpha = 0.05$ level. Where $n \geq 10$ for normally distributed data, the unpaired $t$ test or ANOVA were used for independent samples, and paired $t$ test for paired samples. Where $n < 10$ non-parametric tests including Mann-Whitney $U$ and Kruskall-Wallis were used for independent samples, and Wilcoxon signed ranks test for paired samples. Overdose survival was compared using Cox regression model (controlling for the confounding effect of mouse weight).

**Supplementary Materials**

Materials and methods

Fig. S1. Behavioral and biochemical characterization of acute ammonia neurotoxicity.

Fig. S2. Myoclonic phenotype associated with ammonia intoxication.

Fig. S3. Deletion of astrocyte water channel aquaporin 4 (AQP4) is not protective in acute ammonia toxicity.

Fig. S4. Ammonia impairs cortical potassium buffering.

Fig. S5. GABA-currents recorded during ramp voltage are entirely GABA$_A$-receptor dependent.

Fig. S6. Bumetanide treats potassium-induced neural disinhibition.

Table S1. Biochemical changes during acute ammonia neurotoxicity.
Table S2. Astrocyte calcium signaling during acute ammonia neurotoxicity in awake mice.

Table S3. Bumetanide treatment does not affect cortical ammonia or potassium concentrations.

Movie S1. Myoclonic phenotype induced by 7.5 mmol kg$^{-1}$ ammonia injection in an $Otc^{opf-ash}$ mice.

Movie S2. Spontaneous calcium transients in cortical astrocytes prior to 7.5 mmol kg$^{-1}$ ammonia injection (control).

Movie S3. Calcium transients in cortical astrocytes after 7.5 mmol kg$^{-1}$ ammonia injection.
References

15. J. F. Russell et al., Familial cortical myoclonus with a mutation in NOL3.


Acknowledgements: We thank S. Kennedy for help with $^1$H-NMR experiments, L. K. Bekar for his much appreciated comments and help with electrophysiology, J. Chang for designing MatLab software, D. Wang for helpful advice and for EEG analysis, J. M. Wilson (University of Pennsylvania) for providing the $Otc^{epf-ash}$ mice and J. D. Rothstein (Johns Hopkins University) for providing $Glt-1$-eGFP BAC transgenic mice. Funding: This work was supported by the US National Institutes of Health (grants P01NS050315 and R01NS056188 to M.N., and F31NS073390 to N.A.S.), Research Council of Norway (STORFORSK, NevroNor, and FUGE grants), Nordic Center of Excellence Program, Letten Foundation and Fulbright Foundation.

**Figure legends**

**Fig. 1.** Acute ammonia neurotoxicity is characterized by severe neurological impairment and pathognomic biochemical changes. (A) Otc^{spf-ash} mice deficient in the liver enzyme ornithine transcarbamylase (OTC) are unable to metabolize ammonia to urea and excrete it via the kidney. Following an acute systemic ammonia load the Otc^{spf-ash} mice therefore accumulate ammonia in the brain, where it is only metabolized in astrocytes via the amination of glutamate (Glu) to glutamine (Gln) catalyzed by glutamine synthetase (GS). Ammonia neurotoxicity progresses through stages characterized by stereotypical neurological features (e.g. ataxia). (B) Ammonia levels in blood plasma and (C) brain before and after 7.5 mmol kg^{-1} NH_{4}Cl. ***P < 0.001, n = 7 for each group, Mann-Whitney U test. (D) Brain [glutamine] measured by 1H-NMR 30 minutes after saline (ctrl) or ammonia. *P = 0.015, n = 6 for each group, Kruskall-Wallis test. (E) Baseline deficit in spatial learning in Otc^{spf-ash} mice shown using fear chamber conditioning. *P = 0.014, n = 5 for each group, Mann-Whitney U test. (F) No significant change in global hemodynamic parameters in our model of acute ammonia neurotoxicity (cerebral perfusion pressure: CPP, cerebral bloodflow: CBF and intracranial pressure: ICP). (G) Left panel, diagram illustrating automated video movement analysis. Right panel, decreased spontaneous mouse movement is an early feature of ammonia neurotoxicity. ***P < 0.001, n = 8 (NH_{4}Cl) and 5 (Ctrl), Mann-Whitney U test. (H) Left panel, diagrams illustrating elements of the sensory-motor phenotype score we developed to follow disease severity after the ammonia load. Right panel, phenotype score increases sensitively after the ammonia load (7.5 mmol kg^{-1}) in Otc^{spf-ash} mice, followed by a slow recovery. ***P < 0.001, n = 8 (NH_{4}Cl) and 5 (Ctrl), Mann-Whitney U test. Data are shown as mean ± SEM.
Fig. 2. Ammonia potently triggers seizure activity by causing an impairment of neural inhibition (disinhibition). (A) Double-barreled ion-sensitive microelectrodes (ISM), electroencephalogram (EEG) and electromyogram (EMG) electrodes were used to record seizure activity during acute ammonia neurotoxicity in awake mice. The ammonia was either applied systemically (7.5 mmol kg⁻¹) or cortically (10 mM), and EEG electrodes were placed in both cortex (Ctx) and thalamus (Tha). (B) Acute ammonia administration triggers tonic-clonic seizures and myoclonic events (ME). (C) ME are associated with polyspike and wave discharges (SWD) on EEG that are occasionally followed by a delayed EMG discharge. n = 10. (D) ME and behavioral phenotypes worsen with increasing doses of ammonia, but are suppressed when animals are anesthetized (pooled data for ketamine, isoflurane, urethane). *P < 0.01, n = 6 for each group, Kruskall-Wallis test. (E) [NH₄⁺]₀ at different depths in the brain during direct cortical application of ammonia. The ammonia gradient in the brain dissipates when glutamine synthetase is inhibited with 1.5 mM MSO. Depth 0 μm represents ISM in the solution. *P = 0.019, **P < 0.01, n = 5 for each depth, Mann-Whitney U test. (F) Inhibiting GS with MSO (0.83 mmol kg⁻¹ i.p.) induces ME in awake mice. The ME phenotype was exacerbated when ammonia is co-administered. *P = 0.00022, n = 7 (MSO), 22 (NH₄Cl) and 7 (NH₄Cl + MSO), Kruskall-Wallis test. (G) Extracellular recordings demonstrate that SWD in the cortex (Ctx) precede those in the thalamus (Tha). n = 478 events, 6 mice. (H) 10 consecutive sweeps of field excitatory postsynaptic potentials (fEPSP) elicited by paired-pulse whisker stimulation before, during, and after cortical NH₄Cl application (10 mM, red box). (I) The paired-pulse ratio (PPR) increases during ammonia superfusion, indicating an impairment of cortical inhibitory networks. *P < 0.001, n = 10, paired t test. Data are shown as mean ± SEM.
Fig. 3. Astrocyte ammonia toxicity is associated with impaired calcium signaling, but not swelling in vivo. (A) Two-photon laser scanning microscopy (2PLSM) was performed following a systemic ammonia load (7.5 mmol kg\(^{-1}\)) in awake Otc\(^{spf-ash}\) mice expressing eGFP under the \(Glt-1\) promoter. (B) 3D real-time volume analysis using xyzt scans of eGFP expressing astrocytes during ammonia neurotoxicity reveals no astrocyte swelling, only transient shrinkage. Representative images are shown below. Red outline represents volume at time 0. Scale bar represents 5 \(\mu\)m. ***\(P < 0.001, n = 12\) for each group, unpaired \(t\) test. (C) Equivalent volume analysis of texas red hydrazide (TxR) loaded astrocytes in cortical slices. Left panel, texas red selectively labels astrocytes expressing eGFP under the \(Glt-1\) promoter. Scale bar represents 10 \(\mu\)m. Right panel, 10 mM NH\(_4\)Cl is not associated with acute astrocyte swelling, which was only observed in conjunction with cell lysis when 50 mM NH\(_4\)Cl was applied. **\(P = 0.0019\) (50 mM NH\(_4\)Cl vs. Ctrl), \(n = 13\) (Control), \(12\) (10 mM), \(10\) (50 mM), unpaired \(t\) test. (D) Brain water content is not increased 30 min after mild to moderate ammonia intoxication, but is elevated when a lethal dose is administered. **\(P = 0.0025\), n.s. = not significant, \(n = 7\) (0 mmol kg\(^{-1}\)), \(5\) (5 mmol kg\(^{-1}\)), \(6\) (7.5 mmol kg\(^{-1}\)), \(5\) (10 mmol kg\(^{-1}\)), Mann-Whitney \(U\) test. (E) Left panel, representative image showing eGFP expressing astrocytes loaded with calcium indicator rhod-2 imaged 100 \(\mu\)m below the pial surface using 2PLSM. Scale bar represents 30 \(\mu\)m. Right panel, corresponding rhod-2 intensity traces showing calcium transients. (F) Increased calcium activity is an early sign of ammonia neurotoxicity, but calcium activity paradoxically decreases during the period with peak ME frequency, before increasing again. Red box indicates time of i.p. injection. Heat bar indicates mean ME frequency per minute. ***\(P < 0.0001, n = 52\) (ammonia) and 62 (control) cells sampled from 12 animals, unpaired \(t\) test with Bonferroni correction. (G)
Representative calcium ($\Delta F/F_0$) and corresponding EEG trace demonstrate a weak temporal correlation between individual ME and calcium transients (coefficient < 0.3). (H) Ammonia injection desynchronizes calcium transients, as assessed by Pearson correlation of $\Delta F/F_0$. *$P < 0.0001$, $n = 52$ (ammonia) and 62 (control) cells, paired $t$ test. Data are shown as mean ± SEM.

Fig. 4. Ammonia compromises astrocyte potassium buffering by competing with potassium for uptake. (A) Double-barreled ISM were used to record $[\text{NH}_4^+]_o$, $[\text{K}^+]_o$ and electroencephalogram (EEG) from layer II cortex of awake mice either receiving 7.5 mmol kg$^{-1}$ i.p. or 10 mM cortical NH$_4$Cl. The calibration curves for NH$_4^+$ and K$^+$ ISMs are shown. (B) Representative NH$_4^+$ (top panel) and K$^+$ (bottom panel) ISM traces following i.p. injection (red box) of either ammonia (NH$_4$Cl) or saline (Ctrl). Vertical red lines indicate individual ME. (C) Representative ISM trace (top panel) and scatterplot (bottom panel) showing an increase in $[\text{K}^+]_o$ during cortical application of ammonia (red box) in an awake mouse. Red lines indicate individual ME. Red arrow indicates mean onset of ME. $[\text{K}^+]_o$ increases prior to seizure onset. *$P < 0.001$, $n = 10$ (ammonia) and 7 (control), Mann-Whitney $U$ test. (D) Linear regression showing that seizure frequency correlates strongly with $[\text{K}^+]_o$ concentrations recorded during ammonia neurotoxicity. $n = 8$ (NH$_4$Cl i.p.) and 10 (cortical NH$_4$Cl application, Ctx). (E) Representative K$^+$ ISM trace (top panel) during direct potassium application to the cortex of an awake mouse. KCl application (red box) causes multiple ME (red lines). Line graph (bottom panel) showing that cortical application of 12.5 mM KCl replicates the cortical $[\text{K}^+]_o$ increase seen following 10 mM NH$_4$Cl application at different depths in the brain. $n = 5$ for each depth. (F) Representative traces illustrating tonic-clonic (top) and ME (bottom) induced by direct cortical application of KCl in awake mice. Seizure discharges are detect in the cortex (Ctx) prior to the thalamus (Tha) and
muscle (EMG). (G) 10 consecutive sweeps of fEPSP elicited by paired-pulse whisker stimulation before, during, and after cortical KCl application (12.5 mM, red box). \( *P = 0.028, n = 6 \), Wilcoxon signed ranks test. (H) NH\(_4\)Cl (15 mM) can substitute KCl (15 mM) as a substrate for the Na\(^+\)-K\(^+\)-ATPase in a cell-free assay of astrocyte cultures. n.s. = not significant, \( P = 0.49 \), \( n = 4 \) for each group, Mann-Whitney U test. (I) Na\(^+\)-K\(^+\)-ATPase-dependent (ouabain-sensitive) uptake of potassium analogue rubidium (\(^{86}\)Rb\(^+\)) in cultured astrocytes, normalized to vehicle. \( *P < 0.0001, n = 23 \) (0 mM), 17 (0.5 mM), 16 (2 mM), 10 (5 mM), 10 (10 mM), one-way analysis of variance (ANOVA). (J) Diagram illustrating how excess ammonia would anatomically (via end-feet, e.f.) and enzymatically (via glutamine synthetase, GS) be drawn into astrocytes and trapped as glutamine (Gln). This cation influx compromises the ability of astrocytes to buffer potassium generated by normal neuronal firing. Data are shown as mean ± SEM.

**Fig. 5.** Excess ammonia and potassium cause a depolarization of the neuronal GABA reversal potential (\( E_{\text{GABA}} \)). (A) Top panel, cortical slices from WT mice (>P21) were superfused with 7 mM NH\(_4\)Cl. Bottom panel, representative ISM recordings for [NH\(_4^+\)]\(_o\) and [K\(^+\)]\(_o\) illustrating similar ionic changes observed in vivo. (B) Mean \( \Delta[\text{ion}]_o \) recorded following ammonia superfusion. [NH\(_4^+\)]\(_o\) (\( n = 9 \)) and [K\(^+\)]\(_o\) (\( n = 18 \)). (C) Representative traces show that ammonia reduces the chloride current induced by ramp voltage with application of GABA. (D) Ammonia causes a right shift of the I-V curve. NKCC1 antagonist bumetanide (BUM) reverses this effect. (E) Bumetanide prevents the ammonia-induced depolarization of \( E_{\text{GABA}} \). **\( P = 0.0034, n = 11 \) (control), 11 (NH\(_4\)Cl), 7 (BUM), 7 (NH\(_4\)Cl + BUM), Wilcoxon signed ranks test. (F) Immunofluorescence micrograph of adult Otc\(^{ash}\) and wild-type mouse cortex labeled with primary antibody against NKCC1 and DAPI-stained nuclei. Scale bar represents 100 \( \mu\)m. Inset
shows NKCC1 labeling in choroid plexus (positive control). Scale bar represents 250 μm. (G) Diagram showing the proposed mechanism for ammonia neurotoxicity. NH₄⁺ competes with K⁺ ions for active uptake, impairing astrocyte potassium buffering. This leads to an increase in [K⁺]ₒ, overactivating neuronal NKCC1, which depolarizes E₇₅GABA rendering GABAergic (inhibitory) neurotransmission less effective. Na⁺-K⁺-ATPase (NKA), glutamate (Glu), glutamine synthetase (GS), glutamine (Gln), Na⁺-K⁺-2Cl⁻cotransporter isoform 1 (NKCC1), GABAA receptor (GABAA-R), K⁺-Cl⁻ cotransporter isoform 2 (KCC2), bumetanide (BUM), membrane potential (Vₑ), GABA reversal potential (E₇₅GABA). Data are shown as mean ± SEM.

**Fig. 6.** NKCC1 inhibition with bumetanide (BUM) potently treats the electrophysiological and clinical features of ammonia neurotoxicity. (A) Awake mice were treated with either systemic NH₄Cl (7.5 mmol kg⁻¹), cortical NH₄Cl (10 mM), or cortical KCl (12.5 mM) ± bumetanide (30 mg kg⁻¹ i.p. or 5 μM cortically), while electrophysiological and behavioral changes were recorded. (B) 10 consecutive sweeps of field excitatory post-synaptic potentials (fEPSP) elicited by paired-pulse whisker stimulation before, during, and after cortical application of NH₄Cl with (blue box). (C) The facilitating (increased) paired-pulse ratio (PPR) induced by NH₄Cl cortical application (blue box) is reversed by bumetanide. ***P < 0.001, n = 10 for both groups, unpaired t test. (D) The PPR facilitation seen following KCl cortical application (blue box) is similarly reduced by bumetanide. **P = 0.0022, n = 6 (KCl) and 5 (KCl + BUM), Mann-Whitney U test. (E) Bumetanide improves spontaneous mouse movement after a systemic NH₄Cl load (blue box) in Otc<sup>spf-ash</sup> mice. **P < 0.01, n = 8 (NH₄Cl) and 7 (NH₄Cl + BUM), Mann-Whitney U test. (F) Following a systemic NH₄Cl load in Otc<sup>spf-ash</sup> mice sensory-motor phenotype score is reduced by bumetanide treatment. **P < 0.01, n = 8 (NH₄Cl) and 7 (NH₄Cl + BUM), Mann-Whitney U test.
(G) Frequency of MEs induced by ammonia and/or potassium is reduced by bumetanide treatment. ***$P < 0.001$, **$P < 0.01$, $n = 10$ (systemic NH$_4$Cl), 10 (cortical NH$_4$Cl) and 6 (cortical KCl). Mann-Whitney $U$ test. (H) Cox regression analysis of $Otc^{spf-ash}$ mouse survival time after a NH$_4$Cl overdose (10 mmol kg$^{-1}$). *$P = 0.021$, $n = 9$ (NH$_4$Cl) and 10 (NH$_4$Cl + bumetanide). (I) Increase in cortical $[K^+]_o$ following a systemic NH$_4$Cl load in $Otc^{spf-ash}$ mice is unchanged by bumetanide. (J) Increase in cortical $[K^+]_o$ following a cortical NH$_4$Cl is unchanged by bumetanide. Data are shown as mean ± SEM.
Fig. 4.

![Figure 4](image)

**A**

- $K^+ / NH_4^+$ ISM

- Normal inhibition

- Reduced inhibition

**B**

- $\Delta [K_+^+]$ in mM

- $\Delta [GABA]$ in mM

- $\Delta V_m$ in mV

**C**

- $\Delta [GABA]$ in mM

- $\Delta V_m$ in mV

- $\Delta [K_+^+]$ in mM

**D**

- $\Delta [K_+^+]$ in mM

- $\Delta [GABA]$ in mM

- $\Delta V_m$ in mV

Fig. 5.

**A**

- $K^+ / NH_4^+$ ISM

- Normal inhibition

- Reduced inhibition

**B**

- $\Delta [K_+^+]$ in mM

- $\Delta [GABA]$ in mM

- $\Delta V_m$ in mV

**C**

- $\Delta [K_+^+]$ in mM

- $\Delta [GABA]$ in mM

- $\Delta V_m$ in mV

**D**

- $\Delta [K_+^+]$ in mM

- $\Delta [GABA]$ in mM

- $\Delta V_m$ in mV

Fig. 6.

**A**

- $K^+ / NH_4^+$ ISM

- Normal inhibition

- Reduced inhibition

**B**

- $\Delta [K_+^+]$ in mM

- $\Delta [GABA]$ in mM

- $\Delta V_m$ in mV

**C**

- $\Delta [K_+^+]$ in mM

- $\Delta [GABA]$ in mM

- $\Delta V_m$ in mV

**D**

- $\Delta [K_+^+]$ in mM

- $\Delta [GABA]$ in mM

- $\Delta V_m$ in mV

**E**

- $\Delta [K_+^+]$ in mM

- $\Delta [GABA]$ in mM

- $\Delta V_m$ in mV

**F**

- $\Delta [K_+^+]$ in mM

- $\Delta [GABA]$ in mM

- $\Delta V_m$ in mV

**G**

- $\Delta [K_+^+]$ in mM

- $\Delta [GABA]$ in mM

- $\Delta V_m$ in mV

**H**

- $\Delta [K_+^+]$ in mM

- $\Delta [GABA]$ in mM

- $\Delta V_m$ in mV

**I**

- $\Delta [K_+^+]$ in mM

- $\Delta [GABA]$ in mM

- $\Delta V_m$ in mV

**J**

- $\Delta [K_+^+]$ in mM

- $\Delta [GABA]$ in mM

- $\Delta V_m$ in mV
Supplementary Materials


Materials and Methods

Animal preparation

Otc<sup>sf-ash</sup> mice and wild-type littermates were generated as outlined by Wilson et al. (1). Apa<sup>4−/−</sup> mice and wild-type littermates were generated as described previously (2). Mice subjected to studies were males from 8 to 12 weeks of age. Mice were anesthetized with isoflurane (1.5% mixed with 1-2 L/min O<sub>2</sub>) via nose cone. A custom-made mini-frame was secured to the skull. The animals were habituated to the head-restraint for 3-4 hours, in multiple sessions over 2 days. The mice were then re-anesthetized and a craniotomy was opened, 1.5 mm in diameter, 3 mm lateral and 1.5 mm posterior to the bregma with the dura carefully removed. The latter procedure lasted <20 minutes. Animals were then head-restrained, placed in a behavioral tube and moved to the set-up located in a dark quiet room, where they were allowed to recover from the anesthetic for 60 minutes prior to commencing recordings. The short surgery time and multiple recovery periods were used to minimize the effects of isoflurane on cortical electrical activity.

Sensory-motor phenotype score

We developed composite sensory-motor phenotype score based on two previous studies (1, 3). Mouse movement and seizure activity were omitted from this score, because we wanted to represent these manifestations independently and more quantitatively. The score thus consisted of 4 elements:
hyperacusis, imbalance, ataxia/tremor and level of consciousness. Each animal was scored after the first 5 min and then every 15 min as they progressed through the stereotypical stages of ammonia neurotoxicity. Hyperacusis was score from 0 if the mouse did not display a startle response to 30-60 dB sound, 1 if the mouse responded to only 60 dB and 2 if it responded to 30 dB as well. Imbalance was scored using a ledge test, and the mice were given 0 if the balanced on the ledge and let themselves down in a controlled fashion, 1 if they loose their footing whilst walking on the ledge, 2 if it does not effectively walk on or let itself down from the ledge, and 3 if it is unable to walk, get down, or just falls off. Ataxia/tremor was scored using a gait test, where the mouse is encouraged to walk for a short distance. The mouse gets 0 if it walks effectively, 1 if it has a slight tremor, 2 if it has a broad based gait or severe tremor, 3 if it drags its abdomen on the ground or is unable to walk. Consciousness was scored as either 0 for awake, 1 loss of scatter reflex, 2 loss of righting reflex (LORR), 3 loss of corneal reflex.

**Ion sensitive microelectrode (ISM) fabrication**

ISMs of K⁺, NH₄⁺ and H⁺ were made from double-barreled pipette glass (PB150-6, WPI) and pulled to a tip of 1-3 μm. The pipettes were silanized (coated) with dimethylsilane I (Fluka, Sigma). The ionophore used for K⁺ was Fluka 60398 (potassium ionophore I cocktail B), for NH₄⁺ was Fluka 09882 (ammonium ionophore I cocktail B) and for H⁺/pH was Fluka 95291 (hydrogen ionophore I cocktail A) all obtained from Sigma. The K⁺ ionophore has a selectivity coefficient relative to NH₄⁺ of -1.8 log(K⁺/NH₄⁺), and the NH₄⁺ ionophore has a selectivity coefficient relative to K⁺ of -0.9 log(NH₄⁺/K⁺). The backfill solutions for the K⁺, NH₄⁺ and H⁺ ISMs were 0.15 M KCl, 0.5 M NH₄Cl and phosphate-buffered saline (PBS) with a pH of 7.4 respectively. The reference barrels were used to record the DC potentials and were filled with 0.15 M NaCl. In selected experiments, single barrel
electrodes were also used in combination with single reference electrodes. $K^+$ and $NH_4^+$ ISM traces were subtracted for interference by calculating the mV response to the increase of the other ion in calibration solutions. All ISMs were calibrated before and after each experiment. $K^+$ calibrations were done in 150 mM NaCl that contained doubling steps of $K^+$ over a range of concentrations appropriate for the experiment, usually from 3-48 mM. $NH_4^+$ calibrations were carried out in 150 mM NaCl and aCSF from 0.1-10 mM to determine the sensitivity during the *in vivo* environment. $H^+$ calibrations were carried out in phosphate buffers from pH 5 to 9, where >90% had a response time of 1-5 seconds and a 51-59 mV response to 1 pH unit change. Calibration data were fitted to the Nikolsky equation to determine electrode slope and interference (4). In all experiments, recordings were used only if the post-experiment calibration did not differ >5% from the pre-experiment calibration.

**Two-photon laser scanning microscopy (2PLSM)**

Normal calcium signaling was easily abolished if the astrocytes were loaded too long with calcium indicator, the craniotomy diameter was too large and with laser or mechanical injury. We therefore tested each animal for optimal loading by performing whisker stimulation, to verify a physiological calcium response (5).

**$^1$H-NMR spectroscopy**

Mice were anesthetized using 1.5% isoflurane and decapitated. Forebrains (whole brain minus cerebellum/brainstem) were quickly extracted, frozen in liquid nitrogen, and homogenized in 7.5 mL 12% PCA at 0°C using a micro-sonicator. The homogenate was centrifuged at 25,000G for 15 minutes, and the supernatants were neutralized to pH 7.0 with KOH over an ice bath. A further 15-
minute centrifugation (25,000G) separated the resultant KClO₄, and the supernatant was lyophilized
before being reconstituted with 0.65 ml D₂O. ¹H-NMR spectra were acquired using a 600 mHz
Varian UnityINOVA spectrometer equipped with a triple-axis gradient HCN probe (standard room
temperature). Signals were acquired following a 90° pulse with a spectral width of 7200 Hz and 32K
data points. The time between pulses was 15 seconds and 64 signals were averaged for each
spectrum. The sample temperature was 25°C. Integrals of the relevant peaks were converted to
µmol/gram wet-weight and normalized NAA (methyl) to increase inter-sample consistency.

In situ electrophysiology
Coronal cortical slices were prepared from P21-30 mice as described previously (6). This age was
chosen as in younger pups the GABA reversal potential can be depolarizing (excitatory) (7). Whole-
cell patch-clamp recordings were done using electrodes with 3-5 MΩ resistance, and an intracellular
solution containing 135 mM K-methylsulfate, 10 mM KCl, 10 mM hepes, 5 mM NaCl, 2.5 mM Mg-
ATP, 0.3 mM Na-GTP (pH 7.3), containing Alexa Fluor® 350 (Invitrogen). Signals were low-pass
filtered at 2 kHz and digitized at 10 kHz using Axopatch MultiClamp 700A and Digidata 1320A
(Axon Instruments).
Fig. S1. Behavioral and biochemical characterization of acute ammonia neurotoxicity. (A) Cortical $[\text{NH}_4^+]_o$ increase in NH$_4$Cl and NH$_4$Ac injected mice. $P = 0.88$, $n = 7$ (NH$_4$Cl) and 5 (NH$_4$Ac), Mann-Whitney $U$ test. (B) Representative $^1$H-NMR spectra 30 minutes after injection with saline or ammonia in Otc$^{sph-ash}$ mice. ppm (parts per million), aspartate (Asp), glutamine (Gln), glutamate (Glu), $\gamma$-aminobutyric acid (GABA), glutamine + glutamate (Glx), N-acetylaspartic acid (NAA), N-acetylaspartylglutamate (NAAG), alanine (Ala), lactate (Lac). (C) Otc$^{sph-ash}$ and WT mouse freezing behavior upon being placed in the fear chamber where they receive a shock through 4 days of training. (D) Otc$^{sph-ash}$ and WT mouse freezing behavior upon hearing the noise associated with shock treatment through 4 days of training. (E) Ammonium chloride (NH$_4$Cl) and ammonium acetate (NH$_4$Ac) induce a similar phenotype in Otc$^{sph-ash}$ mice (7.5 mmol kg$^{-1}$ i.p.). Data are shown as mean ± SEM.

Fig. S2. Seizure phenotype associated with ammonia intoxication. (A) Representative EEG and EMG trace showing myoclonic seizures in an Otc$^{sph-ash}$ mouse following 7.5 mmol kg$^{-1}$ NH$_4$Cl. (B) Myoclonic seizure frequency in Otc$^{sph-ash}$ and WT littermates following 7.5 mmol kg$^{-1}$ ammonia injection. ***$P < 0.001$, $n = 22$ (Otc$^{sph-ash}$) and 10 (WT), unpaired $t$ test. (C) Seizure frequency following 7.5 mmol kg$^{-1}$ NH$_4$Cl and NH$_4$Ac intraperitoneally (i.p.). $P = 0.83$, $n = 22$ (NH$_4$Cl) and 5 (NH$_4$Ac), Mann-Whitney $U$ test. Data are shown as mean ± SEM.

Fig. S3. Deletion of astrocyte water channel aquaporin 4 (AQP4) is not protective in acute ammonia toxicity. (A) Seizure frequency and phenotype score in wild-type (WT) and Aqp4$^{-/-}$ mice injected with 7.5 mmol kg$^{-1}$ NH$_4$Cl i.p. $P = 0.829$ (seizures), $P = 0.357$ (encephalopathy), $n = 10$ (ctrl) and 9 (Aqp4$^{-/-}$).
Cortical $[\text{NH}_4^+]_o$ in WT and $Aqp4^{-/-}$ mice before and after ammonia injection. $P = 0.94$, $n = 6$ for each group, Mann-Whitney $U$ test. (C) Brain water content measured by wet-to-dry ratios in control and ammonia injected WT and $Aqp4^{-/-}$ mice. Ammonia injection does not cause increased brain water content. $Aqp4^{-/-}$ mice have increased brain water content in the control setting as we have described previously (8). $P = 0.59$ (WT), $P = 0.69$ ($Aqp4^{-/-}$), $n = 10$ (WT ctrl), 5 (WT NH$_4$Cl), 5 ($Aqp4^{-/-}$ ctrl) and 5 ($Aqp4^{-/-}$ NH$_4$Cl), Mann-Whitney $U$ test. (D) For awake calcium imaging change in rhod-2 fluorescence ($\Delta F/F_0$) was normalized to eGFP to reduce movement artifacts. Calcium transients were defined as $\Delta F/F_0 > 2$ standard deviations ($\sigma$) from baseline. (E) Pearson correlation of astrocyte calcium transients (cell) and ECoG seizure recordings. $n = 52$ cells.

Data are shown as mean ± SEM.

**Fig. S4.** Ammonia impairs cortical potassium buffering. (A) Scatterplot of $[\text{NH}_4^+]_o$ increase following ammonia (7.5 mmol kg$^{-1}$) or saline administration (red box). $n = 7$ for each group. Red arrow indicates mean onset of seizures. (B) Scatterplot of $[\text{K}^+]_o$ increase following ammonia (7.5 mmol kg$^{-1}$) or saline administration (red box). $n = 10$ (ammonia) and 7 (control). (C) Scatterplot of $[\text{NH}_4^+]_o$ increase following cortical application of ammonia (10 mM, red box). $n = 4$. (D) $[\text{K}^+]_o$ increase following ammonia injection in $Otc^{ypf-ash}$ and WT littermates. ***$P < 0.001$, $n = 10$ ($Otc^{ypf-ash}$) and 5 (WT), Mann-Whitney $U$ test. (E) Glutamine synthetase inhibition further compromises potassium buffering by preventing ammonia removal in astrocytes. $[\text{NH}_4^+]_o$ increase following ammonia ± L-methionine sulfoximine (MSO) (0.83 mmol kg$^{-1}$, administered 3 h before the ammonia) i.p. in $Otc^{ypf-ash}$ mice. *$P = 0.0043$, **$P = 0.048$, $n = 6$ (Ctrl), 6 (MSO), 7 (NH$_4$Cl) and 5 (NH$_4$Cl + MSO), Mann-Whitney $U$ test. (F) $[\text{K}^+]_o$ increase following ammonia injection and/or MSO in $Otc^{ypf-ash}$ mice. *$P = 0.0016$, **$P = 0.013$, $n = 9$ (Ctrl), 6 (MSO), 10 (NH$_4$Cl) and 5 (NH$_4$Cl + MSO), Mann-Whitney $U$
test. (G) Ammonia-induced pH effects are mild and delayed. Linear regression of seizure frequency on $\text{pH}_o$. $Otc^{spl-ash}$ mice show a mild extracellular brain alkalinization and peripheral (blood) acidosis, following 7.5 mmol kg$^{-1}$ ammonia i.p. Both pH changes correlate weakly with seizure frequency. (H) Ammonia causes a variable reduction in the potassium uptake of neurons. Na$^+$-K$^+$-ATPase-dependent (ouabain-sensitive) uptake of potassium analogue $^{86}\text{Rb}^+$ in cultured neurons, normalized to vehicle (0 mM NH$_4$Cl). *$P<0.0001$, $n = 20$ (0 mM), $n = 4$ (0.5 mM), $n = 4$ (2 mM), $n = 16$ (5 mM), $n = 4$ (10 mM), Kruskall-Wallis test. Data are shown as mean ± SEM.

**Fig. S5.** GABA-currents recorded during ramp voltage are entirely GABA$_A$-receptor dependent. (A) Representative traces show that bicuculline blocks the current induced by ramp voltage after GABA application. (B) I-V curve shows that bicuculline blocks all GABA-induced current.

**Fig. S6.** Bumetanide treats potassium-induced neural disinhibition. (A) 10 consecutive sweeps following paired-pulse whisker stimulation shows KCl superfusion (12.5 mM, blue box) no longer evokes a facilitating sensory response (disinhibition) when co-administered with bumetanide (BUM, 5 μM).

**Table S1.** Biochemical changes during acute ammonia neurotoxicity. $^1$H-NMR was used to determine amino acid concentrations (μmol g$^{-1}$ wet weight) 30 minutes after saline (Ctrl) or ammonia administration (7.5 mmol kg$^{-1}$ i.p.). Data are shown as mean ± SEM.

<table>
<thead>
<tr>
<th>Genotype: Exposure:</th>
<th>WT Ctrl</th>
<th>WT BUM</th>
<th>WT NH$_4$ Ctrl</th>
<th>$Otc^{spl-ash}$ Ctrl</th>
<th>$Otc^{spl-ash}$ BUM NH$_4$</th>
<th>$Otc^{spl-ash}$ NH$_4$</th>
<th>$Otc^{spl-ash}$ BUM NH$_4$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glutamate</td>
<td>14.29 ± 0.19</td>
<td>14.38 ± 0.22</td>
<td>12.49 ± 0.15</td>
<td>14.67 ± 0.68</td>
<td>14.27 ± 0.23</td>
<td>13.24 ± 0.33</td>
<td>12.51 ± 0.37</td>
</tr>
</tbody>
</table>
Table S2. Astrocyte calcium signaling during acute ammonia neurotoxicity in awake mice. Data from analysis of 2PLSM xyt series, where calcium indicator rhod-2 was used to detect astrocyte calcium transients 100 μm below the pial surface. Data are shown as mean ± SEM.

<table>
<thead>
<tr>
<th>Glutamine</th>
<th>4.85 ± 0.47</th>
<th>4.52 ± 0.18</th>
<th>8.69 ± 0.33</th>
<th>7.58 ± 0.52</th>
<th>8.70 ± 1.54</th>
<th>9.25 ± 0.34</th>
<th>11.44 ± 0.46</th>
</tr>
</thead>
<tbody>
<tr>
<td>GABA</td>
<td>2.00 ± 0.13</td>
<td>2.55 ± 0.05</td>
<td>2.19 ± 0.12</td>
<td>2.53 ± 0.12</td>
<td>2.39 ± 0.13</td>
<td>2.46 ± 0.13</td>
<td>2.23 ± 0.08</td>
</tr>
</tbody>
</table>

**Table S3.** Bumetanide treatment does not affect cortical ammonia or potassium concentrations. NH₄⁺ and K⁺ ISMs recordings from cortex of awake Otc<sup>opf-ash</sup> mice. Data are shown as mean ± SEM.

<table>
<thead>
<tr>
<th>CORTICAL SUPERFUSION</th>
<th>[NH₄⁺]₀ (mM)</th>
<th>n (animals)</th>
<th>P value Mann-Whitney U test</th>
<th>Δ[K⁺]₀ (mM)</th>
<th>n (animals)</th>
<th>P value Mann-Whitney U test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>0.45 ± 0.17</td>
<td>6</td>
<td></td>
<td>0.0058 ± 0.01</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>BUM</td>
<td>0.52 ± 0.11</td>
<td>6</td>
<td>0.59</td>
<td>0.0025 ± 0.01</td>
<td>8</td>
<td>0.94</td>
</tr>
<tr>
<td>NH₄Cl</td>
<td>5.82 ± 0.18</td>
<td>6</td>
<td>0.87</td>
<td>2.24 ± 0.17</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>NH₄Cl + BUM</td>
<td>5.78 ± 0.13</td>
<td>6</td>
<td>0.39</td>
<td>2.17 ± 0.12</td>
<td>9</td>
<td>0.66</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>INTRAPERITONEAL INJECTION</th>
<th>[NH₄⁺]₀ (mM)</th>
<th>n (animals)</th>
<th>P value Mann-Whitney U test</th>
<th>Δ[K⁺]₀ (mM)</th>
<th>n (animals)</th>
<th>P value Mann-Whitney U test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>0.48 ± 0.12</td>
<td>6</td>
<td>0.015 ± 0.025</td>
<td></td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>BUM</td>
<td>0.42 ± 0.16</td>
<td>6</td>
<td>0.0073 ± 0.015</td>
<td></td>
<td>6</td>
<td>0.53</td>
</tr>
<tr>
<td>NH₄Cl</td>
<td>4.83 ± 0.52</td>
<td>7</td>
<td>1.93 ± 0.19</td>
<td>10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------------</td>
<td>-------------</td>
<td>---</td>
<td>-------------</td>
<td>---</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NH₄Cl + BUM</td>
<td>4.70 ± 0.32</td>
<td>6</td>
<td>0.83</td>
<td>1.97 ± 0.17</td>
<td>6</td>
<td>0.92</td>
</tr>
</tbody>
</table>

**Supplementary Movies**

**Movie S1.** Seizure phenotype induced by 7.5 mmol kg⁻¹ ammonia injection in an Otc<sup>spf-ash</sup> mice.

**Movie S2.** Spontaneous calcium transients in cortical astrocytes prior to 7.5 mmol kg⁻¹ ammonia injection (control).

**Movie S3.** Calcium transients in cortical astrocytes after 7.5 mmol kg⁻¹ ammonia injection.

**Supplementary References**


**Fig. S1.**

**Fig. S2.**

**Fig. S3.**

**Fig. S4.**
Fig. S5.

Fig. S6.
References